{
    "paper_id": "xml_output_cochrane\\Bergman_et_al-2019-Cochrane_Database_of_Systematic_Reviews",
    "header": {
        "generated_with": "S2ORC 1.0.0",
        "date_generated": "2024-04-05T17:20:07.191146Z"
    },
    "title": "Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males",
    "authors": [
        {
            "first": "Hanna",
            "middle": [],
            "last": "Bergman",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Brian",
            "middle": [
                "S"
            ],
            "last": "Buckley",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Gemma",
            "middle": [],
            "last": "Villanueva",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Jennifer",
            "middle": [],
            "last": "Petkovic",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Chantelle",
            "middle": [],
            "last": "Garritty",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Vittoria",
            "middle": [],
            "last": "Lutje",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Alina",
            "middle": [
                "Ximena"
            ],
            "last": "Riveros-Balta",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Nicola",
            "middle": [],
            "last": "Low",
            "suffix": "",
            "affiliation": {},
            "email": ""
        },
        {
            "first": "Nicholas",
            "middle": [],
            "last": "Henschke",
            "suffix": "",
            "affiliation": {},
            "email": ""
        }
    ],
    "year": "",
    "venue": null,
    "identifiers": {},
    "abstract": "Comparison of di erent human papillomavirus (HPV",
    "pdf_parse": {
        "paper_id": "xml_output_cochrane\\Bergman_et_al-2019-Cochrane_Database_of_Systematic_Reviews",
        "_pdf_hash": "",
        "doi": "10.1002/14651858.cd013479",
        "keywords": [],
        "abstract": [
            {
                "text": "Comparison of di erent human papillomavirus (HPV",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Abstract",
                "sec_num": null
            }
        ],
        "body_text": [
            {
                "text": "Uptake of human papillomavirus (HPV) vaccine remains low in many countries, although the bivalent and quadrivalent HPV vaccines given as a three-dose schedule are e ective in the prevention of precancerous lesions of the cervix in women.Simpler immunisation schedules, such as those with fewer doses, might reduce barriers to vaccination, as may programmes that include males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Background",
                "sec_num": null
            },
            {
                "text": "To evaluate the e icacy, immunogenicity, and harms of di erent dose schedules and di erent types of HPV vaccines in females and males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Objectives",
                "sec_num": null
            },
            {
                "text": "We conducted electronic searches on 27 September 2018 in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) (in the Cochrane Library), and Ovid Embase.We also searched the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov(both 27 September 2018), vaccine manufacturer websites, and checked reference lists from an index of HPV studies and other relevant systematic reviews.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Search methods",
                "sec_num": null
            },
            {
                "text": "We included randomised controlled trials (RCTs) with no language restriction.We considered studies if they enrolled HIV-negative males or females aged 9 to 26 years, or HIV-positive males or females of any age.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selection criteria",
                "sec_num": null
            },
            {
                "text": "Risk with three doses of HPV vaccine",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Anticipated absolute effects ** (95% CI) Clinical and harms outcomes *",
                "sec_num": null
            },
            {
                "text": "Relative effect (95% CI)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk with two doses of HPV vaccine",
                "sec_num": null
            },
            {
                "text": "Certainty of the evidence (GRADE)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2116 of participants (studies)",
                "sec_num": null
            },
            {
                "text": "Two doses were non-inferior to, or had higher GMTs than, three doses for all HPV vaccine genotypes (bivalent, quadrivalent, and nonavalent vaccines), except HPV 45 (where non-inferiority was inconclusive), at short-term follow-up (4 studies, number of participants ranged from 132 to 1833 depending on HPV type and vaccine; see Appendix 5) .",
                "cite_spans": [
                    {
                        "start": 328,
                        "end": 339,
                        "text": "Appendix 5)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Comments",
                "sec_num": null
            },
            {
                "text": "HIGH* Short-term results (follow-up 1 month after final dose)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "MODERATE/",
                "sec_num": null
            },
            {
                "text": "Two doses of bivalent vaccine had inconclusive non-inferiority for GMTs of HPV 16 and HPV 18 compared with three doses at 60-month follow-up (1 study, 93 participants; see Appendix 5) .",
                "cite_spans": [
                    {
                        "start": 172,
                        "end": 183,
                        "text": "Appendix 5)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "MODERATE/",
                "sec_num": null
            },
            {
                "text": "Two doses of quadrivalent vaccine resulted in non-inferior GMTs for HPV 6, HPV 11 and HPV 16 compared with three doses, while results were inconclusive for HPV 18 at 60-month follow-up (1 study, 101 participants; see Appendix 5) .",
                "cite_spans": [
                    {
                        "start": 217,
                        "end": 228,
                        "text": "Appendix 5)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LOW*",
                "sec_num": null
            },
            {
                "text": "Two doses of nonavalent vaccine resulted in non-inferior GMTs for all HPV genotypes measured except HPV 45 and HPV 52 where non-inferiority was inconclusive, compared with three doses, at 36-month follow-up (1 study, 476 to 511 participants depending on HPV type; see Appendix 5) .",
                "cite_spans": [
                    {
                        "start": 268,
                        "end": 279,
                        "text": "Appendix 5)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "LOW* Antibody response (immunogenicity)",
                "sec_num": null
            },
            {
                "text": "Long-term results (follow-up 36 to 60 months)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "High-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High-grade cervical, vulval, and vaginal disease",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.Data for specific local adverse events (pain/swelling/redness at injection site) are presented in the analysis section.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall local/injection site adverse events",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Serious adverse events at up to 5-year follow-up 30 per 1000 31 per 1000 (20 to 49) OR 1.03 (0.64 to 1.66) 2317 (4 RCTs)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "VERY LOW 1,2 Please see Table 1 for a list of events in each RCT.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 30,
                        "end": 31,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "Mortality at up to 5-year follow-up 1 per 1000 0 per 1000 (0 to 9) OR 0.33 (0.01 to 8.19) 1797 (3 RCTs)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "\u2295\u2295\u229d\u229d LOW 1",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "One death was reported in the three-dose group (nonavalent vaccine).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "*Certainty of the evidence (GRADE) for immunogenicity outcomes are presented in detail in Appendix 5.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "**The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "CI: confidence interval; GMT: geometric mean titre; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect 1 Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potential large beneficial e ect and a potential large harmful e ect.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "2 Downgraded one level for indirectness: this outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure.This outcome is considered to provide indirect evidence about vaccine safety.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "\u2295\u229d\u229d\u229d",
                "sec_num": null
            },
            {
                "text": "Risk with two doses of HPV vaccine with shorter interval",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Anticipated absolute effects ** (95% CI) Clinical and harms outcomes *",
                "sec_num": null
            },
            {
                "text": "Relative effect (95% CI)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk with two doses of HPV vaccine with longer interval",
                "sec_num": null
            },
            {
                "text": "\u2116 of participants (studies)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk with two doses of HPV vaccine with longer interval",
                "sec_num": null
            },
            {
                "text": "Longer intervals between the first two doses of bivalent vaccine resulted in higher and non-inferior GMTs for HPV 16 (n = 971) and HPV 18 (n = 986) compared with shorter intervals in 9-to 14-year-old females at short-term follow-up (2 studies; moderate-to high-certainty evidence, see Appendix 6).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Comments",
                "sec_num": null
            },
            {
                "text": "A longer interval between the first two doses of nonavalent vaccine resulted in higher and non-inferior GMTs than a shorter interval for all HPV vaccine genotypes in girls and boys at short-term follow-up (1 study, number of participants ranged from 778 to 815 depending on HPV type; high-certainty evidence, see Appendix 6).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "MODERATE/ HIGH*",
                "sec_num": null
            },
            {
                "text": "HIGH* Short-term results (follow-up one month after final dose)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "MODERATE/ HIGH*",
                "sec_num": null
            },
            {
                "text": "Longer intervals between the first two doses of bivalent vaccine resulted in higher and non-inferior GMTs for HPV 16 (n=817) and HPV 18 (n=794) compared with shorter intervals in 9-to 14-year-old females at 36 months follow-up (1 study; high-certainty evidence, see Appendix 6).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "MODERATE/ HIGH*",
                "sec_num": null
            },
            {
                "text": "Antibody response (geometric mean titre)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "A longer interval between the first two doses of nonavalent vaccine resulted in higher and non-inferior GMTs than a shorter interval for all HPV vaccine genotypes in girls and boys at seven and 36 months follow-up (1 study, number of participants ranged from 236 to 263 depending on HPV type; high-certainty evidence, see Appendix 6).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "Long-term results (follow-up 36 months)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "Invasive cervical, vaginal, vulval, anal, or penile cancer",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "High-grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "Overall local/injection site adverse events",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.Data for specific local adverse events (pain/swelling/redness at injection site) are presented in the analysis section.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "Overall systemic events and general symptoms",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HIGH*",
                "sec_num": null
            },
            {
                "text": "Bivalent vaccine (0 and 2 months)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "Bivalent vaccine (0 and 6 months) OR 1.15 (0.55 to 2.41) No deaths were reported in the trial.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "Bivalent vaccine (0 and 6 months) No deaths were reported in the trial.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "0",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "*Certainty of the evidence (GRADE) for immunogenicity outcomes are presented in detail in Appendix 6.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "**The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "Patient or population: 10-to 26-year-old males Setting: 18 countries in five regions (Africa, Asia-Pacific, Europe, Latin America, North America) Intervention: quadrivalent HPV vaccine, 3 doses at months 0, 2, and 6; or bivalent HPV vaccine, 3 doses at months 0, 1, and 6",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "Comparison: control (vaccine adjuvant-containing placebo), 3 doses at months 0, 2, and 6 or hepatitis B vaccine, 3 doses at months 0, 1, and 6 In a subgroup from Lehtinen 2018, a cluster-RCT, 58/2436 HPV vaccine recipients (2.4%) and 25/1267 control HBV vaccine recipients (2.0%) experienced serious adverse events.This was also considered very low-certainty evidence 2,4 Please see Table 1 for list of events in each RCT.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 389,
                        "end": 390,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "Serious adverse events",
                "sec_num": null
            },
            {
                "text": "Serious adverse events at up to 3-year follow-up Control: 4 per 1000",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Anticipated absolute effects",
                "sec_num": null
            },
            {
                "text": "Quadrivalent vaccine: 3 per 1000 (1 to 7) OR 0.69 (0.29 to 1.66)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Anticipated absolute effects",
                "sec_num": null
            },
            {
                "text": "(2 RCTs) \u2295\u229d\u229d\u229d VERY LOW 2,4 Please see Table 1 for list of events in each RCT.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 44,
                        "end": 45,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "5162",
                "sec_num": null
            },
            {
                "text": "Bivalent vaccine: see comment",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Control: see comment",
                "sec_num": null
            },
            {
                "text": "OR not estimable: see comment",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Control: see comment",
                "sec_num": null
            },
            {
                "text": "(1 RCT) \u2295\u2295\u229d\u229d LOW 5 No events were reported Mortality at up to 3-year follow-up Control: 4 per 1000 Quadrivalent vaccine: 1 per 1000 (0 to 4) OR 0.30 (0.09 to 1.01)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "270",
                "sec_num": null
            },
            {
                "text": "(2 RCTs) \u2295\u2295\u229d\u229d LOW 2 *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: confidence interval; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "5173",
                "sec_num": null
            },
            {
                "text": "Human papillomavirus (HPV) is the most common viral infection of the reproductive tract in women and men (WHO 2017) .Although most HPV infections resolve spontaneously, persistent infections can lead to precancerous lesions and cancer of the cervix, vagina, vulva, anus, penis, and head and neck.HPV-related cancers accounted for an estimated 4.5% of all cancers worldwide in 2012 (de Martel 2017).When stratified by sex, these represent 8.6% of cancers in women and 0.8% of cancers in men, and by development status, 6.7% of all cancers in low-and middle-income countries and 2.8% in high-income countries (de Martel 2017).In 2012, of an estimated 636,000 HPV-related cancers worldwide, 530,000 were cervical cancer, 35,000 anal cancer, 8500 vulval cancer, 13,000 penile cancer, and 37,000 head and neck cancers (de Martel 2017).",
                "cite_spans": [
                    {
                        "start": 105,
                        "end": 115,
                        "text": "(WHO 2017)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "Amongst women with normal cytological findings, the worldwide prevalence of infection with any HPV genotype has been estimated in a meta-analysis to be 11.7%, with higher prevalence in sub-Saharan Africa, Latin America, the Caribbean, south-east Asia and eastern Europe (Bruni 2010).Amongst heterosexual men assessed at baseline in a multicentre trial in 18 countries in Africa, Asia-Pacific, Europe, Latin America and North America, penile infection with any HPV genotype was found in 18.7%, scrotal infection in 13.1%, perianal infection in 7.9% and infection at any site in 21.0%.Prevalence was highest in Africa and lowest in the Asia-Pacific region (Vardas 2011) .Prevalence of HPV infections in general is higher in men with HIV infection, men who have sex with men (MSM), and highest in MSM with HIV infection (Schim van der Loe 2014; Smith 2011).",
                "cite_spans": [
                    {
                        "start": 654,
                        "end": 667,
                        "text": "(Vardas 2011)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "The main types of lesions associated with anogenital HPV infection are anogenital warts (condylomata acuminata) and intraepithelial neoplasia of the cervix (cervical intraepithelial neoplasia, CIN), vulva, vagina, anal canal/perianal area, and penis.Intraepithelial neoplasia is a precursor of some of these cancers, although it can regress at earlier stages and does not progress to invasive cancer in most a ected people.A study that followed up women with inadequately treated CIN3 found that 31.3% (95% CI 22.7 to 42.3) developed invasive cancer a er 30 years (McCredie 2008) .HPV is also associated with squamous cell cancer of the head and neck (HNSCC).Of all head and neck cancers globally in 2012 (534,000), about 7% (37,000) were attributable to HPV, including 29,000 of 96,000 (31%) cases of oropharyngeal cancer (de Martel 2017).The incidence of cancers of the oropharynx has increased over time, more amongst men than women (Gillison 2015) .It is likely that HPV is a main contributor to the increase in men, whilst smoking dominates the rise in women (Gillison 2015) .",
                "cite_spans": [
                    {
                        "start": 564,
                        "end": 579,
                        "text": "(McCredie 2008)",
                        "ref_id": null
                    },
                    {
                        "start": 936,
                        "end": 951,
                        "text": "(Gillison 2015)",
                        "ref_id": null
                    },
                    {
                        "start": 1064,
                        "end": 1079,
                        "text": "(Gillison 2015)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "The International Agency for Research on Cancer classifies HPV genotypes according to oncogenic potential, with HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 , and 59 considered as highrisk genotypes (Bouvard 2009) .HPV 16 and 18 are the most common genotypes in women worldwide and are associated with most cases of invasive cervical cancer; combined, HPV 16, 18, 31, 33, 45, 52 and 58 cause approximately 90% of all HPV-positive squamous cell carcinomas of the cervix (Alemany 2014; Bruni 2010; de Sanjose 2010).HPV 16 and 18 are also the cause of 90% of all anal cancers (Bosch 2002) .HPV 16 is found in around 80% of HPV-related anal squamous cell cancers, in 52% of invasive penile squamous cell carcinoma, and in 90% of penile intraepithelial neoplasia (Krustrup 2009 ; Schim van der Loe 2014).In a meta-analysis, HPV was detected in 22% of HNSCC, with 86.7% of those being attributed to HPV 16, although HPV 6 and 11 were also detected in a minority of cases (Syrj\u00e4nen 2010) .HPV 6 and 11 account for up to 90% of anogenital warts (Greer 1995; Sturegard 2013) .",
                "cite_spans": [
                    {
                        "start": 126,
                        "end": 129,
                        "text": "16,",
                        "ref_id": null
                    },
                    {
                        "start": 130,
                        "end": 133,
                        "text": "18,",
                        "ref_id": null
                    },
                    {
                        "start": 134,
                        "end": 137,
                        "text": "31,",
                        "ref_id": null
                    },
                    {
                        "start": 138,
                        "end": 141,
                        "text": "33,",
                        "ref_id": null
                    },
                    {
                        "start": 142,
                        "end": 145,
                        "text": "35,",
                        "ref_id": null
                    },
                    {
                        "start": 146,
                        "end": 149,
                        "text": "39,",
                        "ref_id": null
                    },
                    {
                        "start": 150,
                        "end": 153,
                        "text": "45,",
                        "ref_id": null
                    },
                    {
                        "start": 154,
                        "end": 157,
                        "text": "51,",
                        "ref_id": null
                    },
                    {
                        "start": 158,
                        "end": 161,
                        "text": "52,",
                        "ref_id": null
                    },
                    {
                        "start": 162,
                        "end": 165,
                        "text": "56,",
                        "ref_id": null
                    },
                    {
                        "start": 166,
                        "end": 168,
                        "text": "58",
                        "ref_id": null
                    },
                    {
                        "start": 211,
                        "end": 225,
                        "text": "(Bouvard 2009)",
                        "ref_id": null
                    },
                    {
                        "start": 364,
                        "end": 371,
                        "text": "HPV 16,",
                        "ref_id": null
                    },
                    {
                        "start": 372,
                        "end": 375,
                        "text": "18,",
                        "ref_id": null
                    },
                    {
                        "start": 376,
                        "end": 379,
                        "text": "31,",
                        "ref_id": null
                    },
                    {
                        "start": 380,
                        "end": 383,
                        "text": "33,",
                        "ref_id": null
                    },
                    {
                        "start": 384,
                        "end": 387,
                        "text": "45,",
                        "ref_id": null
                    },
                    {
                        "start": 388,
                        "end": 390,
                        "text": "52",
                        "ref_id": null
                    },
                    {
                        "start": 585,
                        "end": 597,
                        "text": "(Bosch 2002)",
                        "ref_id": null
                    },
                    {
                        "start": 770,
                        "end": 784,
                        "text": "(Krustrup 2009",
                        "ref_id": null
                    },
                    {
                        "start": 977,
                        "end": 992,
                        "text": "(Syrj\u00e4nen 2010)",
                        "ref_id": null
                    },
                    {
                        "start": 1049,
                        "end": 1061,
                        "text": "(Greer 1995;",
                        "ref_id": null
                    },
                    {
                        "start": 1062,
                        "end": 1077,
                        "text": "Sturegard 2013)",
                        "ref_id": "BIBREF50"
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "Three prophylactic HPV vaccines, given by intramuscular injection, are available.All three vaccines are made by genetic technologies and are non-infectious because they do not contain viral DNA.They are made from purified L1 capsid proteins, which form viruslike particles that resemble the structure of specific genotypes of HPV.Each vaccine is directed against two or more high-risk HPV genotypes.All three vaccines contain L1 proteins of HPV genotypes 16 and 18 (WHO 2017) , because these cause about 70% of cervical cancer globally.The vaccines are commonly known by the number of di erent genotypes that they contain (i.e. the valency, Table 2 ).",
                "cite_spans": [
                    {
                        "start": 465,
                        "end": 475,
                        "text": "(WHO 2017)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [
                    {
                        "start": 647,
                        "end": 648,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "The bivalent vaccine contains L1 proteins of two HPV genotypes; 16 and 18.The quadrivalent vaccine contains L1 proteins of four HPV genotypes; 16 and 18, plus HPV 6 and 11, which cause genital warts.The nonavalent vaccine is the most recent vaccine and contains L1 proteins of nine HPV genotypes; 16, 18, 31, 33, 45, 52 and 58, plus HPV 6 and 11. All three vaccines contain adjuvants (Table 2 ).In addition to the licensed vaccines, as of September 2018, there are three vaccines in stage 2 to 3 development, two bivalent vaccines manufactured by Innovax and Walvax in China, and a quadrivalent vaccine manufactured by the Serum Institute of India (LaMontagne 2017).",
                "cite_spans": [
                    {
                        "start": 297,
                        "end": 300,
                        "text": "16,",
                        "ref_id": null
                    },
                    {
                        "start": 301,
                        "end": 304,
                        "text": "18,",
                        "ref_id": null
                    },
                    {
                        "start": 305,
                        "end": 308,
                        "text": "31,",
                        "ref_id": null
                    },
                    {
                        "start": 309,
                        "end": 312,
                        "text": "33,",
                        "ref_id": null
                    },
                    {
                        "start": 313,
                        "end": 316,
                        "text": "45,",
                        "ref_id": null
                    },
                    {
                        "start": 317,
                        "end": 327,
                        "text": "52 and 58,",
                        "ref_id": null
                    },
                    {
                        "start": 328,
                        "end": 346,
                        "text": "plus HPV 6 and 11.",
                        "ref_id": null
                    }
                ],
                "ref_spans": [
                    {
                        "start": 391,
                        "end": 392,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "To prevent HPV infection, all HPV vaccines are intended to be administered, where possible, before the first exposure to HPV, that is, before onset of sexual activity.All national HPV vaccination programmes involve girls, and some countries have extended their programme to boys.According to most modelling studies, HPV vaccination programmes for preadolescent girls will be coste ective for the prevention of cervical cancer, particularly in settings in which infrastructure for cervical cancer screening is poor (WHO 2017) .HPV vaccination of females gives indirect protection to males.These so-called herd e ects mean that, at the population level, female-only vaccination programmes have resulted in reductions in HPV infections in both men and women (Drolet 2019).However, herd e ects from female-only vaccination do not a ect MSM, who experience a high burden of anal cancer and anogenital warts.Modelling studies also indicate that female-only HPV vaccination, even at high levels of coverage, will not prevent all HPV-related cancers in heterosexual men (Bogaards 2015) .The cost-e ectiveness of vaccinating boys depends on vaccination coverage in girls, the epidemiology of HPV-related disease, and the costs of the vaccine and the programme (WHO 2017).",
                "cite_spans": [
                    {
                        "start": 514,
                        "end": 524,
                        "text": "(WHO 2017)",
                        "ref_id": null
                    },
                    {
                        "start": 1062,
                        "end": 1077,
                        "text": "(Bogaards 2015)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "The uptake of HPV vaccination varies widely between countries that have introduced it as part of their national immunisation programmes.In 2017, across 82 countries coverage rates ranged from 8% to 98% (Brotherton 2018).To date, few countries in Africa and Asia have introduced HPV vaccine.Whilst there is evidence from some low-and middle-income countries (LMICs) that HPV vaccine can be e ectively introduced, countries with challenges have also been reported.For example, Uganda reported coverage of more than 80% for the first dose of a two-dose vaccine schedule, but this was not sustained for the second dose (Brotherton 2018).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "In high-income countries, such as England, Scotland, and Australia, school-based programmes have reached 70% to 80% of girls for",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews all doses.In other high-income countries, such as France, USA, Japan and Denmark, coverage has either not reached, or has fallen below 50%.The reasons for low coverage di er between countries, but include organisation of programme implementation, resistance from healthcare providers, adverse media coverage, and concerns about safety (Gallagher 2018).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "HPV vaccines containing virus-like particles of the L1 protein are prophylactic, meaning that they prevent infection and the development of intraepithelial lesions caused by HPV genotypes that are present in the vaccine (Stanley 2006) .The virus-like particles in the vaccines produce very high levels of antibodies in serum, but the exact mechanisms by which the vaccines prevent HPV infection are not completely understood.The levels of antibodies needed to provide protection against clinical disease caused by HPV (known as the immunological correlate of protection) have not been established because the number of breakthrough infections a er vaccination has been too low.The International Agency for Research on Cancer regards persistent HPV infection with HPV types 16 and 18, measured with standardised and validated tests, as an accurate surrogate marker for the precancerous lesions of the cervix and anus (IARC 2014) .Postlicensure data from national immunisation programmes show reductions in high-grade lesions of the cervix and anus with three-dose regimens of the bivalent and quadrivalent vaccines (Markowitz 2018 ).Since precancer is on the causal pathway to invasive cancer, it is assumed that prevention of precancerous lesions will also be shown to prevent cancer when su icient followup time has accrued in post-licensure studies.Less is known about the prognostic value of persistent HPV infection in the development of vaginal, vulval and oropharyngeal cancers (IARC 2014) .",
                "cite_spans": [
                    {
                        "start": 220,
                        "end": 234,
                        "text": "(Stanley 2006)",
                        "ref_id": "BIBREF47"
                    },
                    {
                        "start": 916,
                        "end": 927,
                        "text": "(IARC 2014)",
                        "ref_id": null
                    },
                    {
                        "start": 1114,
                        "end": 1129,
                        "text": "(Markowitz 2018",
                        "ref_id": null
                    },
                    {
                        "start": 1484,
                        "end": 1495,
                        "text": "(IARC 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "All of the randomised controlled trials (RCTs) that established the e icacy of HPV vaccines in the prevention of high-grade precancerous lesions of the cervix used a three-dose vaccination schedule (Arbyn 2018).Because of low HPV exposure and ethical constraints in conducting research that requires genital examination and specimen collection in adolescent populations (under 15 years of age), randomised e icacy trials of vaccines have typically been first conducted in women aged 15 to 25 or 26 years (Arbyn 2018).Once immunogenicity and harms have been evaluated, non-inferiority of immunological outcomes in 9to 15-year-olds is assessed in non-randomised bridging studies (e.g. Block 2006; Dobson 2013) .The International Agency for Research on Cancer regards bridging studies that demonstrate noninferiority as a su icient endpoint for individuals under 16 years of age (IARC 2014) .",
                "cite_spans": [
                    {
                        "start": 683,
                        "end": 694,
                        "text": "Block 2006;",
                        "ref_id": null
                    },
                    {
                        "start": 695,
                        "end": 707,
                        "text": "Dobson 2013)",
                        "ref_id": null
                    },
                    {
                        "start": 876,
                        "end": 887,
                        "text": "(IARC 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "Vaccine schedules are designed to produce a strong and longlasting antibody response so that, when challenged by exposure to the real pathogen, the immune system prevents infection.A threedose vaccine schedule is typical for inactivated protein vaccines for infants; the second dose is given one or two months a er the first dose and a third dose six months a er the first dose.The first two vaccine doses are called 'prime' doses that generate immune memory via B-lymphocytes produced in the bone marrow (Stanley 2014) .The second dose results in higher levels of antibodies than the first and increases the binding a inity of the antibody to the antigen, in a process that lasts several months.As a result of this process (a inity maturation), B cells with very high levels of a inity, di erentiate in the bone marrow into memory B cells that respond rapidly to produce antibodies on exposure to antigen and longlived plasma cells that continuously produce antibody at low levels.",
                "cite_spans": [
                    {
                        "start": 505,
                        "end": 519,
                        "text": "(Stanley 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "A third vaccine dose given at least four months a er the prime doses 'boosts' these responses maximally to provide long-lasting protection (Stanley 2014) .",
                "cite_spans": [
                    {
                        "start": 139,
                        "end": 153,
                        "text": "(Stanley 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "Simplified HPV vaccination schedules with fewer doses should allow more people to receive the vaccine.Preadolescents and adolescents (age 9 to 15 years) produce stronger antibody responses to virus-like protein HPV vaccines than older adolescents and adults (Block 2006; Dobson 2013) , even a er a single dose (Sankaranarayanan 2016 ).It appears that multiple repeated doses of these vaccines are not required for a inity maturation and that long-lived plasma cells are more important than memory B cells in the immune response (Schiller 2018) .It is thought that structural characteristics of the virus-like particles allow e icient production of the long-lived plasma cells, which continuously produce antigen-specific antibodies, resulting in strong longlasting immune responses with reduced dose schedules (Schiller 2018) .",
                "cite_spans": [
                    {
                        "start": 258,
                        "end": 270,
                        "text": "(Block 2006;",
                        "ref_id": null
                    },
                    {
                        "start": 271,
                        "end": 283,
                        "text": "Dobson 2013)",
                        "ref_id": null
                    },
                    {
                        "start": 310,
                        "end": 332,
                        "text": "(Sankaranarayanan 2016",
                        "ref_id": null
                    },
                    {
                        "start": 528,
                        "end": 543,
                        "text": "(Schiller 2018)",
                        "ref_id": null
                    },
                    {
                        "start": 810,
                        "end": 825,
                        "text": "(Schiller 2018)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "Evidence of the likely e icacy of a two-dose schedule of viruslike particle HPV vaccines in preventing incident vaccine-type HPV infection comes from studies in which data from RCTs were analysed as cohort studies according to the number of doses of HPV vaccine received (Kreimer 2011; Sankaranarayanan 2016) .Kreimer and colleagues conducted a secondary analysis of data from an RCT of the bivalent vaccine amongst 18-to 25-year-old women in Costa Rica (Kreimer 2011) .In that trial, 20% of women did not receive all three doses of the vaccine.Women were grouped according to the number of HPV vaccine doses that they received.The proportions of women with incident HPV 16/18 infection that persisted for 12 months or more was similar amongst women who received one, two and three doses (Kreimer 2011 ).An updated analysis combined data from this Costa Rica vaccine trial and a pivotal trial of the bivalent vaccine, Paavonen 2007 , according to number of doses received a er four years of follow-up (Kreimer 2015) .In the modified total vaccinated cohort, vaccine e icacy against HPV 16/18 incident infection that persisted for 12 months or more was 83.7% (95% CI 35.7 to 97.5%) with two doses, and 92.6% (95% CI 89.2 to 95.1%) with three doses.Sankaranarayanan and colleagues analysed an RCT of the quadrivalent vaccine in 10-to 18-year-olds in India (which was stopped before enrolment was completed) according to the number of HPV vaccine doses received (Sankaranarayanan 2016) .Incidence of HPV 16/18 was 0.8% (95% CI 0.2 to 1.9%, 4/526) amongst participants who received two doses, and 0.4% (95% CI 0.0 to 1.3%, 2/536) amongst those who received three doses (Sankaranarayanan 2016) .Additional data from a systematic review of post-licensure studies in national HPV vaccination programmes, show the receipt of two doses of HPV vaccine was associated with a reduction in the incidence of vaccinetype HPV prevalence, anogenital warts and cervical abnormalities in some, but not all, studies (Markowitz 2018) .",
                "cite_spans": [
                    {
                        "start": 271,
                        "end": 285,
                        "text": "(Kreimer 2011;",
                        "ref_id": null
                    },
                    {
                        "start": 286,
                        "end": 308,
                        "text": "Sankaranarayanan 2016)",
                        "ref_id": null
                    },
                    {
                        "start": 454,
                        "end": 468,
                        "text": "(Kreimer 2011)",
                        "ref_id": null
                    },
                    {
                        "start": 788,
                        "end": 801,
                        "text": "(Kreimer 2011",
                        "ref_id": null
                    },
                    {
                        "start": 918,
                        "end": 931,
                        "text": "Paavonen 2007",
                        "ref_id": null
                    },
                    {
                        "start": 1001,
                        "end": 1015,
                        "text": "(Kreimer 2015)",
                        "ref_id": null
                    },
                    {
                        "start": 1459,
                        "end": 1482,
                        "text": "(Sankaranarayanan 2016)",
                        "ref_id": null
                    },
                    {
                        "start": 1665,
                        "end": 1688,
                        "text": "(Sankaranarayanan 2016)",
                        "ref_id": null
                    },
                    {
                        "start": 1996,
                        "end": 2012,
                        "text": "(Markowitz 2018)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "In practice, HPV vaccination rates in many countries remain low.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "Simpler HPV immunisation schedules have been identified as a potential strategy to increase the coverage of vaccination (Walling 2016) .The World Health Organization (WHO) recommended a two-dose HPV vaccine schedule in 2014, based on a systematic review of studies with immunogenicity as the end-point (D'Addario This review aims to extend the evidence base on the e icacy and harms of HPV vaccines by including and evaluating RCTs of di erent HPV vaccines and di erent dose schedules in adolescent and adult females and males, as well as women and men living with HIV infection.",
                "cite_spans": [
                    {
                        "start": 120,
                        "end": 134,
                        "text": "(Walling 2016)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "While RCTs can identify adverse events that take place during the study period, post-marketing surveillance is needed to continue monitoring harms associated with HPV vaccines in the population, and will be incorporated in future updates of this review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "To evaluate the e icacy, immunogenicity, and harms of di erent dose schedules and di erent types of HPV vaccines in females and males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "O B J E C T I V E S",
                "sec_num": null
            },
            {
                "text": "We included RCTs with no language restrictions.We included unpublished studies, studies in press, and abstracts without a fulltext publication, if they met the inclusion criteria.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of studies",
                "sec_num": null
            },
            {
                "text": "Females or males aged 9 to 26 years, including MSM.For the comparisons among people living with HIV, we included all age groups.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "Prophylactic administration of licensed bivalent (Cervarix, GlaxoSmithKline), quadrivalent (Gardasil, Merck), or nonavalent (Gardasil 9, Merck) HPV vaccines.We excluded studies if they assessed monovalent or plasmid vaccines, or assessed nonprophylactic uses of bivalent, quadrivalent or nonavalent vaccines.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "In addition, we considered for inclusion any trials reporting on the e icacy, immunogenicity, or adverse events in vaccines currently in phase 2 or 3 development.Studies comparing bivalent versus quadrivalent vaccines were excluded, as these will be included in an update of a separate Cochrane Review (Arbyn 2018).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "For males and people living with HIV, we included comparisons of HPV vaccines to placebo containing no adjuvant or only the adjuvant of the HPV vaccine, or another HPV vaccine.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "In this review, we use the term 'control' to refer to comparator products that contain another vaccine or only vaccine adjuvants, regardless of the terminology used in individual study reports.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "We use the term 'placebo' only to refer to comparator products containing no adjuvant or active vaccine.In Characteristics of included studies we have reported full details of the type of comparison group compound.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "The focus of the review was on di erent dose schedules and comparisons between di erent types of HPV vaccine.Where possible we stratified data by participant characteristics of age, gender, and HIV status.Specifically, we aimed to investigate the e icacy, immunogenicity, and harms of:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "\u2022 fewer than three doses of HPV vaccine in females and males;",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "\u2022 di erent intervals between doses in a two-dose schedule in females and males; \u2022 HPV vaccination compared to control for males (a Cochrane Review for females has been published (Arbyn 2018)); \u2022 nonavalent HPV vaccine compared to the other HPV vaccines in females and males; \u2022 HPV vaccination in people living with HIV.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "Unless otherwise stated, primary outcomes were assessed at the longest follow-up time reported by the included studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primary outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 Invasive cervical, vaginal, vulval, anal, or penile cancer",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primary outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 Adverse events related to the vaccines: local adverse events (overall local/injection site adverse events, redness, swelling, pain at the injection site), assessed at the follow-up times reported in the trials (usually up to seven days); overall systemic events and general symptoms assessed at the follow-up times reported in the trials (usually up to 15 days) \u2022 Serious adverse events and mortality: any events that are fatal, life-threatening, or result in hospitalisation and mortality.We collected information from each trial about whether these events were considered to be vaccine-related and the methods of adverse events data monitoring and collection, including mode of data collection, timing, attribution methods, intensity of ascertainment, harms-related monitoring and stopping rules, and reporting based on event frequency (i.e.frequency-based filter), based on the CONSORT statement extension for reporting harms (Ioannidis 2004; Lineberry 2016) .",
                "cite_spans": [
                    {
                        "start": 931,
                        "end": 947,
                        "text": "(Ioannidis 2004;",
                        "ref_id": null
                    },
                    {
                        "start": 948,
                        "end": 963,
                        "text": "Lineberry 2016)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Unless otherwise stated, secondary outcomes were assessed at the longest follow-up time reported by the included studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 Incident infection with vaccine HPV genotypes (HPV 16 and HPV 18 jointly; HPV 6, HPV 11, HPV 16 and HPV 18 jointly; and HPV 31, HPV 33, HPV 45, HPV 52 , and HPV 58 jointly) \u2022 Persistent infection (persisting for at least six months or at least 12 months) with vaccine HPV genotypes \u2022 Immunological outcomes (geometric mean titre (GMT) and seropositivity), assessed at one month following the last dose and at the longest-term follow-up",
                "cite_spans": [
                    {
                        "start": 83,
                        "end": 90,
                        "text": "HPV 11,",
                        "ref_id": null
                    },
                    {
                        "start": 91,
                        "end": 117,
                        "text": "HPV 16 and HPV 18 jointly;",
                        "ref_id": null
                    },
                    {
                        "start": 118,
                        "end": 129,
                        "text": "and HPV 31,",
                        "ref_id": null
                    },
                    {
                        "start": 130,
                        "end": 137,
                        "text": "HPV 33,",
                        "ref_id": null
                    },
                    {
                        "start": 138,
                        "end": 145,
                        "text": "HPV 45,",
                        "ref_id": null
                    },
                    {
                        "start": 146,
                        "end": 152,
                        "text": "HPV 52",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "For the comparisons of dose schedules (i.e.number of doses and longer or shorter interval(s) between doses) we considered immunological outcomes as primary outcomes because these trials were designed to show non-inferiority of immunogenicity.While these trials were not designed to evaluate e icacy or safety of the vaccines, we have included clinical outcomes when reported and comparative estimates of harms associated with the di erent dose schedules.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press and in progress) .",
                "cite_spans": [
                    {
                        "start": 91,
                        "end": 141,
                        "text": "(published, unpublished, in press and in progress)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Search methods for identification of studies",
                "sec_num": null
            },
            {
                "text": "All searches were conducted on 27 September 2018.We searched the following electronic databases: The search terms used are detailed in Appendix 1, Appendix 2, and Appendix 3. We also searched ClinicalTrials.govand the WHO International Clinical Trials Registry Platform (ICTRP) to identify ongoing trials using 'genital warts', 'condyloma', 'anogenital warts', 'venereal warts', 'human papilloma virus vaccine', and 'HPV vaccine' as search terms.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Electronic searches",
                "sec_num": null
            },
            {
                "text": "We searched the reference lists of all included studies, as well as the reference lists of any relevant systematic reviews published within the search dates.We searched vaccine manufacturer web sites for relevant clinical trial reports (GlaxoSmithKline; Merck).In addition, we screened a list of HPV vaccine studies (J\u00f8rgensen 2018a), that was constructed through enquiries to HPV vaccine manufacturers and regulators, as well as searches of trial registers and journal publication databases.For each included study, where available, we identified and screened study governance documents (protocols, trial registration listings and results, manufacturers' clinical study reports) for relevant data and outcomes.We also contacted the vaccine manufacturers through the WHO Initiative for Vaccine Research for any additional, potentially relevant studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "Two experienced systematic reviewers independently screened citations and abstracts of studies identified from the electronic searches for potential inclusion.A third reviewer resolved any disagreements.We obtained full-text reports for all potentially eligible studies.Two independent reviewers determined the eligibility of studies for inclusion in the review from the full reports according to predefined criteria.A third reviewer resolved any disagreements.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selection of studies",
                "sec_num": null
            },
            {
                "text": "For the purpose of the review, we named studies on the basis of the first-named study author and year of publication.Many studies have more than one document associated with them: journal publications (main study reports, reports of long-term follow-up, secondary outcomes and post-hoc analyses), conference abstracts, and study governance documents (protocols, trial registration listings and results, manufacturers' clinical study reports).For each study we grouped these documents together and designated one report as the primary reference for the study; the study name is derived from the name of the first author and year of publication of this particular report.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data extraction and management",
                "sec_num": null
            },
            {
                "text": "In cases where study reports emanate from the same parent study, but are planned or reported, or both, as distinct, discrete studies, we have named and handled these separately.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data extraction and management",
                "sec_num": null
            },
            {
                "text": "Two reviewers carried out data extraction independently using pretested data extraction forms.We resolved any di erences by discussion between the two reviewers and referral to the study reports.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data extraction and management",
                "sec_num": null
            },
            {
                "text": "We cross-checked data for the e icacy outcomes and adverse events between the primary trial publications, trial registries, and clinical study reports.We used the data derived from these sources with the longest follow-up time for the primary analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data extraction and management",
                "sec_num": null
            },
            {
                "text": "Two reviewers independently carried out 'Risk of bias' assessments using the Cochrane 'Risk of bias' tool for all included studies (Higgins 2011b) .We judged the risk of bias for each domain as 'low risk', 'unclear risk' or 'high risk'.We resolved di erences by discussion between the two reviewers and if necessary we referred to a third reviewer for arbitration.",
                "cite_spans": [
                    {
                        "start": 131,
                        "end": 146,
                        "text": "(Higgins 2011b)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We calculated risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes.We calculated rate ratios with 95% CIs for dichotomous clinical outcomes reported as incidence rates.For outcomes with rare events (i.e. an event rate of < 10%), serious adverse events, and deaths, we calculated Mantel-Haenszel odds ratios (OR) for dichotomous outcomes.We assessed the robustness of the primary analysis for very rare events with alternative statistical methods (see Sensitivity analysis).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "For continuous geometric mean titre (GMT) data, we calculated inverse variance (IV) ratios of GMTs with 95% CIs.Initially, we transformed the point estimates as well as the lower and upper bound of the 95% CI of GMT for each group into the logarithmic scale in order to obtain statistically correct standard deviations.Then we calculated the mean di erence of the compared group and back-transformed the results (point estimate and 95% CIs) to the original scale through exponentiation.Non-inferiority margins for immunological outcomes were derived from the individual trials (all trials used 0.5 for the GMT ratio).For GMT ratios non-inferiority is demonstrated if the lower 95% CI is greater than 0.5.If the lower confidence interval was below the non-inferiority margin, but the point estimate was within the margin, we considered the result to be inconclusive (Piaggio 2012).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "For adverse events and e icacy outcomes we carried out a complete-case analysis (the number analysed) and an intentionto-treat analysis when data were available.For immunogenicity outcomes assessed in non-inferiority trials, we favoured data from per-protocol analyses, in which all participants were HPV-seronegative at baseline.We did not pool studies with participants who were HPV-seropositive at baseline with studies with participants who were HPV-seronegative at baseline.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "If a single trial compared two or more vaccine arms (with or without a control arm), we labelled the arms separately in analyses.We grouped suitable multiple treatment arms (e.g.arms that evaluated di erent vaccine lots) and excluded irrelevant trial arms.We did not pool data from cluster RCTs with those from individually randomised studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unit of analysis issues",
                "sec_num": null
            },
            {
                "text": "If data on specific outcomes or population groups were missing, we attempted to contact study authors or data owners to request this data.We did not impute missing outcome data.Where data were missing or losses to follow-up were substantial, we downgraded the certainty of study evidence due to risk of bias according to GRADE criteria (Guyatt 2011a).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Dealing with missing data",
                "sec_num": null
            },
            {
                "text": "We described potential sources of clinical heterogeneity, and downgraded the certainty of the evidence according to GRADE criteria due to inconsistency where appropriate (Guyatt 2011b).When pooling of studies was feasible (i.e. at least two studies included), we inspected forest plots visually for potential outlying studies and variability in the estimated e ects across studies.We assessed statistical heterogeneity using the I 2 statistic.This statistic quantifies the percentage of inconsistency in the treatment e ects across studies beyond simple chance.We regarded heterogeneity as potentially unimportant if the I 2 was 0% to 40%; that values of 30% to 60% might represent moderate heterogeneity; values between 50% to 90% might represent substantial heterogeneity; and that values between 75% to 100% would represent considerable heterogeneity (Higgins 2011a) .Where considerable heterogeneity existed (>75%), we did not pool study data.",
                "cite_spans": [
                    {
                        "start": 854,
                        "end": 869,
                        "text": "(Higgins 2011a)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of heterogeneity",
                "sec_num": null
            },
            {
                "text": "We had planned to use funnel plots to investigate the possible presence of small-study e ects for each outcome.However, we did not produce funnel plots, due to the limited number of studies per outcome (i.e.fewer than 10) (Guyatt 2011c).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of reporting biases",
                "sec_num": null
            },
            {
                "text": "When pooling was considered feasible, we employed a randome ects meta-analysis using the DerSimonian and Laird method (DerSimonian 1986), as it was assumed that e ect size might vary across studies and settings.We used data from the last available follow-up for clinical and adverse event outcomes, with the number of participants (rather than the number of events) used in the analysis.For immunological outcomes, we extracted data from one month a er the last HPV dose and at the longest-term follow-up.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "To assess the harms associated with the HPV vaccine comparisons in this review, we recorded the methods used in each included study to collect adverse event data, and extracted data on common events that we determined a priori as: pain, swelling, redness at the injection site and overall systemic adverse events.For all serious adverse events reported in the included studies, we extracted the number of participants, participants with events and a description of the events.We also extracted information on whether the serious adverse events were considered to be related to the vaccines.We did not conduct statistical hypothesis testing because our protocol did not prespecify hypotheses about di erences in the occurrence of any specific serious adverse event.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "We prepared 'Summary of findings' tables for each comparison for which data were available for the following outcomes that were assessed as critical or important according to GRADE guidelines (Guyatt 2011d):",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "\u2022 for females: high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, or cervical cancer; high-grade vulval and vaginal disease; \u2022 for males: invasive anal or penile cancer, external genital lesions;",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "\u2022 for all populations: anogenital warts, overall local/injection site adverse events, overall systemic events and general symptoms, serious adverse events, deaths; \u2022 for comparisons of dose schedules (i.e.number of doses and longer or shorter interval between doses): immunological outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "We assessed the certainty of evidence in the review through discussion between review authors using the GRADE approach using GRADEpro online so ware (GRADEpro GDT).We assessed only the primary outcomes reported in the 'Summary of findings' tables and appendices using GRADE.We considered the following factors for downgrading: limitations in the study design (risk of bias); inconsistency of results (heterogeneity); indirectness of evidence (applicability); imprecision (few events and wide",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews confidence intervals); and publication bias (Guyatt 2011a).When evidence was downgraded, we detailed the reasons in footnotes of the 'Summary of findings' tables and summarised these in the Quality of the evidence section.Depending on whether evidence was downgraded or not, we rated the certainty of the evidence for each outcome as follows:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "\u2022 high-certainty evidence indicates that we are very confident that the true e ect lies close to that of the estimate of the e ect (evidence was not downgraded); \u2022 moderate-certainty evidence indicates that we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent (evidence was downgraded one step for any of the factors described above); \u2022 low-certainty evidence indicates that our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect (evidence was downgraded two steps for any of the factors described above); \u2022 very low-certainty evidence indicates that we have very little confidence in the e ect estimate: the true e ect is likely to be substantially di erent from the estimate of e ect (evidence was downgraded three steps for any of the factors described above).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We reported relative risks (ORs or RRs) in the E ects of interventions section for all relevant outcomes, but where the evidence was of very low-certainty we reported the number of events in each group only.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We performed subgroup meta-analyses where possible, using vaccine type, gender, and age group (9 to 15 years; 16 to 26 years) as stratifying variables.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Subgroup analysis and investigation of heterogeneity",
                "sec_num": null
            },
            {
                "text": "We carried out one post-hoc sensitivity analysis for outcomes using a Mantel-Haenszel odds ratio where events were very rare (i.e. an event rate of < 1% across both trial arms).We compared the results of the primary analysis calculated with Mantel-Haenzsel methods against those with Peto methods (Bradburn 2007) .We also planned to conduct sensitivity analyses for the primary outcomes according to allocation concealment (high risk of bias, low risk of bias, and unclear risk of bias) for outcomes for which data could not be pooled because of considerable heterogeneity (I 2 > 75%).",
                "cite_spans": [
                    {
                        "start": 297,
                        "end": 312,
                        "text": "(Bradburn 2007)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "Overall, 20 RCTs were included for analysis in this review (Figure 1 ).The characteristics of individual studies and assessment of risk of bias are presented in the Characteristics of included studies section and Figure 2 .",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 67,
                        "end": 68,
                        "text": "1",
                        "ref_id": null
                    },
                    {
                        "start": 220,
                        "end": 221,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "We found 20 RCTs that contained data on vaccine e icacy or harms, or both, and enrolled a total of 31,940 men, women, and children.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Included studies",
                "sec_num": null
            },
            {
                "text": "Ten studies were multi-national and were carried out in two to 18 countries in Africa, Asia, Asia-Pacific, Europe, Latin America, North America, and South America.The other 10 studies were carried out in one country only (USA, including Puerto Rico (3 studies), Finland (2), Canada (1), Denmark (1), Japan (1), Spain (1), South Africa (1)).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Included studies",
                "sec_num": null
            },
            {
                "text": "Owing to di erences in the protocols of the included trials, the maximum age for inclusion was either 25 or 26 years.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Included studies",
                "sec_num": null
            },
            {
                "text": "Four RCTs evaluated the e ects of reduced dose schedules (Dobson 2013; Iversen 2016; Leung 2015; Romanowski 2011) .All these trials were designed as non-inferiority trials of antibody responses.They reported on immunogenicity as the primary outcome and on adverse events.None of these trials collected data on clinical events.These four RCTs evaluated the e ects of two doses of HPV vaccine versus three doses of HPV vaccine in adolescent girls (9 to 15 years).We did not identify any RCTs that evaluated the e icacy or harms of one dose of HPV vaccine.",
                "cite_spans": [
                    {
                        "start": 57,
                        "end": 70,
                        "text": "(Dobson 2013;",
                        "ref_id": null
                    },
                    {
                        "start": 71,
                        "end": 84,
                        "text": "Iversen 2016;",
                        "ref_id": null
                    },
                    {
                        "start": 85,
                        "end": 96,
                        "text": "Leung 2015;",
                        "ref_id": null
                    },
                    {
                        "start": 97,
                        "end": 113,
                        "text": "Romanowski 2011)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "Four RCTs compared di erent intervals between doses.Two RCTs compared a longer interval two-dose schedule with a shorter schedule (0 and 6 months versus 0 and 2 months; or 0 and 12 months versus 0 and 6 months) of bivalent HPV vaccine in 9-to 14-year-old females (Puthanakit 2016; Romanowski 2011).One RCT of nonavalent HPV vaccine compared a two-dose schedule with a longer interval (0 and 12 months) and a shorter interval (0 and 6 months) in 9-to 14-year-old females and males (Iversen 2016).One RCT compared a longer interval three-dose schedule (administered at 0, 2 and 12 months) with a shorter schedule (administered at 0, 2 and 6 months) of quadrivalent HPV vaccine in 18-to 25-year-old males (Lin 2014).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "Two RCTs compared quadrivalent HPV vaccine versus control in 5189 males aged 16 to 26 years (Giuliano 2011; NCT01862874 2018) .",
                "cite_spans": [
                    {
                        "start": 92,
                        "end": 107,
                        "text": "(Giuliano 2011;",
                        "ref_id": "BIBREF54"
                    },
                    {
                        "start": 108,
                        "end": 125,
                        "text": "NCT01862874 2018)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "A subgroup analysis of Giuliano 2011 also reported on the e icacy and harms of the quadrivalent HPV vaccine compared with control vaccine in MSM.Giuliano 2011 reported on clinical, adverse event, and immunogenicity outcomes, and NCT01862874 2018 reported on clinical outcomes and adverse events.One RCT compared bivalent HPV vaccine versus control hepatitis B virus (HBV) vaccine in 270 boys aged 10 to 18 years and reported on immunogenicity and harms (Petaja 2009).In addition, a cluster-RCT investigating both direct and indirect e ects of HPV vaccination of girls and boys (gender-neutral) and girls-only vaccination reported on adverse events in a subgroup of 3703 12-to 15-year-old males vaccinated with the bivalent vaccine or control HBV vaccine (Lehtinen 2018).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "We identified no studies investigating the clinical e icacy of the nonavalent vaccine in males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "Three RCTs compared three doses of nonavalent vaccine with three doses of quadrivalent vaccine: one in 9-to 15-year-old females (Vesikari 2015), one in 16-to 26-year-old females (Joura 2015), and one in males aged 16 to 26 years (van Damme 2016).Joura 2015 reported clinical outcomes for the 16-to 26-year-old population.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "All three studies reported on adverse event and immunogenicity outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of studies",
                "sec_num": null
            },
            {
                "text": "We Cochrane Database of Systematic Reviews participants a er vaccine administration, or field workers visiting or calling participants in their homes); both passive and proactive in nine studies; and in two studies, the details were insu icient for us to categorise as passive or proactive.Time frame (duration of follow-up) was reported for all but three studies; for two studies it was unclear, and one study did not report on adverse events (NCT00941889 2016).Methods to determine the relationship between vaccination and adverse events were reported by 10 studies: attribution was done by study investigators in nine studies and by a study co-ordinator in one study.Where the attribution method was not reported, we assumed this role was performed by study investigators.Fourteen studies (74%) provided definitions for the adverse events outcomes.Withdrawals due to adverse events were reported in 14 (70%) studies, but most studies (95%) did not report on how withdrawals would be handled in the analysis.Only one study reported harms-related monitoring and stopping rules (Hidalgo-Tenorio 2017) .Seventeen studies reported on all adverse events regardless of frequency (i.e. they did not use a frequencybased filter); NCT01862874 2018 used a 5% threshold for other adverse events; it was unclear whether Dobson 2013 used a filter, and one study did not report on adverse events (NCT00941889 2016).",
                "cite_spans": [
                    {
                        "start": 1078,
                        "end": 1100,
                        "text": "(Hidalgo-Tenorio 2017)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Studies including participants living with HIV",
                "sec_num": null
            },
            {
                "text": "The length of follow-up for serious adverse events in the included studies ranged from seven months to five years.Table 1 lists the serious adverse events reported in each study.In all studies, the individual serious events were listed for each study arm.In five of the 20 RCTs, 50 or more serious adverse events were reported (Joura 2015 , Lehtinen 2018; Puthanakit 2016; Romanowski 2011; Wilkin 2018) .Information on whether serious adverse events were considered to be related to the vaccine is reported in the section E ects of interventions.",
                "cite_spans": [
                    {
                        "start": 327,
                        "end": 338,
                        "text": "(Joura 2015",
                        "ref_id": null
                    },
                    {
                        "start": 339,
                        "end": 355,
                        "text": ", Lehtinen 2018;",
                        "ref_id": null
                    },
                    {
                        "start": 356,
                        "end": 372,
                        "text": "Puthanakit 2016;",
                        "ref_id": null
                    },
                    {
                        "start": 373,
                        "end": 389,
                        "text": "Romanowski 2011;",
                        "ref_id": null
                    },
                    {
                        "start": 390,
                        "end": 402,
                        "text": "Wilkin 2018)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [
                    {
                        "start": 120,
                        "end": 121,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "Studies including participants living with HIV",
                "sec_num": null
            },
            {
                "text": "We identified two studies that included both males and females randomised to HPV vaccine and control (Li 2012; Reisinger 2007) .The male population in these studies would qualify for inclusion in our review, but at the time of preparing this review we were not able to access data for males only.We have requested this information from the study investigators and, should these data become available, they will be included in a future update of this review.",
                "cite_spans": [
                    {
                        "start": 101,
                        "end": 110,
                        "text": "(Li 2012;",
                        "ref_id": "BIBREF1"
                    },
                    {
                        "start": 111,
                        "end": 126,
                        "text": "Reisinger 2007)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Studies awaiting classification",
                "sec_num": null
            },
            {
                "text": "Li 2012 and Reisinger 2007 both compared quadrivalent HPV vaccine to vaccine adjuvant-containing control in 9-to 15-yearold males.The studies reported on the comparison of males with females for immunogenicity outcomes and adverse events for males and females as one group.Li 2012 was carried out in China, and Reisinger 2007 was carried out in 10 countries in North America, Latin America, Europe and Asia.See Characteristics of studies awaiting classification for further details.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Studies awaiting classification",
                "sec_num": null
            },
            {
                "text": "We identified 15 potentially relevant ongoing studies that have not been completed, but might be relevant for inclusion in future updates of this review.All studies are RCTs and studies may appear in more than one category of the list below:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing studies",
                "sec_num": null
            },
            {
                "text": "\u2022 eight include healthy females (NCT01735006; NCT02009800; NCT02405520; NCT02562508; NCT02733068; NCT02740777; NCT02834637; NCT03180034);",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing studies",
                "sec_num": null
            },
            {
                "text": "\u2022 four include healthy males and females (NCT01824537; NCT02567955; NCT02710851; NCT02888418); \u2022 one includes HIV-positive MSM (NCT02087384); \u2022 one includes males and females cured of genital warts (NCT03296397); \u2022 one includes females with genital warts (NCT02750202); \u2022 seven are evaluating new vaccines in development in China (NCT01735006; NCT02405520; NCT02562508; NCT02710851; NCT02733068; NCT02740777; NCT02888418); \u2022 four are evaluating the quadrivalent vaccine (NCT02009800; NCT02087384; NCT02750202; NCT03296397); \u2022 one is evaluating the nonavalent vaccine (NCT01824537); and \u2022 three are comparing the bivalent to the nonavalent vaccine (NCT02567955; NCT02834637; NCT03180034).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing studies",
                "sec_num": null
            },
            {
                "text": "In addition to the seven studies ongoing in China, three of these studies are ongoing in Canada, and one study each in Costa Rica, France, the Netherlands, South Africa, and Tanzania.See Characteristics of ongoing studies for further details.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing studies",
                "sec_num": null
            },
            {
                "text": "We excluded 438 full texts.Twenty-two of these were potentially relevant studies, and the reasons for their exclusion are included in the Characteristics of excluded studies table.We excluded six studies because they were not RCTs, and two studies because they included females over 26 years of age.Most of the excluded studies contained no comparison of relevance to the review: seven studies compared HPV-vaccinated to HPV-unvaccinated females, five compared di erent intervals in three-dose schedules in females, one compared three-dose schedules of the bivalent and quadrivalent vaccine in young females, and one evaluated the e ect of a booster dose of HPV vaccine.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Excluded studies",
                "sec_num": null
            },
            {
                "text": "The risk of bias for each included study is detailed in Characteristics of included studies and an overview is presented in Figure 2 . Overall risk of bias for each comparison is discussed in each results section below.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 131,
                        "end": 132,
                        "text": "2",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "We assessed most studies as being at low risk of selection bias, as they reported adequate randomisation sequence generation (15/20 = 75%) and allocation concealment procedures (15/20 = 75%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation",
                "sec_num": null
            },
            {
                "text": "We assessed most included studies (18/20 = 90%) as having a low risk of attrition bias, as they reported withdrawals and provided adequate reasons for dropouts.We assessed one study as having a high risk of attrition bias because only a subgroup of included participants were analysed (Lehtinen 2018).We assessed another study as having a high risk of attrition bias because data for 62.5% (20/32) of the participants enrolled were missing due to early withdrawals from the study (NCT00941889 2016).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data",
                "sec_num": null
            },
            {
                "text": "For the majority of studies (16/20 = 80%) either a study protocol or clinical trial registry entry was available to determine that selective reporting was unlikely; we assessed these studies as having a low risk of reporting bias.We assessed four studies as having a high risk of selective reporting bias; Lehtinen 2018 because most outcomes were not reported separately for boys and girls, indeed, only adverse events were reported separately in boys, but in a selected subset; NCT00941889 2016 because predetermined outcomes, including serious adverse events, were not reported; NCT01031069 2017 because not all outcomes listed in the online trial record were reported in the trial result summary report; and NCT01862874 2018 because HPV disease was not reported as a separate outcome, but were reported as an outcome combined with persistent HPV infection.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selective reporting",
                "sec_num": null
            },
            {
                "text": "All included studies provided a statement of the funding source for the trial.Thirteen studies were funded by the vaccine manufacturers (GSK, Merck or Sanofi Pasteur) and we rated them as having an unclear risk of other bias.Industry sponsored studies are associated with favourable e icacy results and conclusions (Lundh 2017) which may be mediated by factors other than those assessed by the Cochrane 'Risk of bias' tool.We also rated a further two studies as having an unclear risk of other bias because no published report was identified for either (NCT00941889 2016; NCT01031069 2017), and we extracted data from the clinical trials records, which provided insu icient information to establish whether there was a risk of other bias.We assessed the remaining five studies as being at low risk of other bias (Dobson 2013; To 2014; Hidalgo-Tenorio 2017; Levin 2010; Wilkin 2018) .",
                "cite_spans": [
                    {
                        "start": 315,
                        "end": 327,
                        "text": "(Lundh 2017)",
                        "ref_id": null
                    },
                    {
                        "start": 812,
                        "end": 825,
                        "text": "(Dobson 2013;",
                        "ref_id": null
                    },
                    {
                        "start": 826,
                        "end": 834,
                        "text": "To 2014;",
                        "ref_id": null
                    },
                    {
                        "start": 835,
                        "end": 856,
                        "text": "Hidalgo-Tenorio 2017;",
                        "ref_id": null
                    },
                    {
                        "start": 857,
                        "end": 868,
                        "text": "Levin 2010;",
                        "ref_id": null
                    },
                    {
                        "start": 869,
                        "end": 881,
                        "text": "Wilkin 2018)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other potential sources of bias",
                "sec_num": null
            },
            {
                "text": "See: Summary of findings for the main comparison Two doses of HPV vaccine compared with three doses of HPV vaccine in 9-to 15year-old females; Summary of findings 2 Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9-to 14-year-old females and males; Summary of findings 3 Three doses HPV vaccine compared with control in 10-to 26-year-old males; Summary of findings 4 Nonavalent HPV vaccine compared with quadrivalent HPV vaccine in 9-to 26-yearold females and males 1.Two doses of HPV vaccine versus three doses of HPV vaccine in 9-to 15-year-old females or males",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "The results for this comparison are presented in Summary of findings for the main comparison and Appendix 5. We analysed four studies in females that compared two doses (months 0 and 2, or 0 and 6, or 0 and 12) versus three doses (months 0, 1, and 6; or 0, 2, and 6) of HPV vaccine (Dobson 2013; Iversen 2016; Leung 2015; Romanowski 2011), and reported immunogenicity outcomes (seven months to five years) for all vaccine types and adverse event outcomes throughout the study period (one to five years).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "No studies included for this comparison collected data about clinical outcomes.No evidence was found from RCTs making this comparison in males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "Immunogenicity results comparing two doses with three doses of HPV vaccine are reported in Appendix 5. Briefly, two doses were non-inferior to or had higher GMTs than three doses for all nine HPV genotypes measured except HPV 45 (where non-inferiority was inconclusive) one month a er the last dose (moderate-to highcertainty evidence).For seroconversion one month a er the last dose, there was evidence of little to no di erence between groups for all nine HPV genotypes measured (high-certainty evidence).At 60-month follow-up a er the first dose, non-inferiority of two doses of bivalent vaccine was inconclusive for GMTs of HPV 16 and HPV 18 (low-certainty evidence).Two doses of quadrivalent vaccine resulted in non-inferior GMTs for HPV 6, HPV 11 and HPV 16, while results were inconclusive for HPV 18 (low-certainty evidence).At 36-month follow-up a er the first dose, two doses of nonavalent vaccine resulted in non-inferior GMTs for all HPV genotypes measured except HPV 45 and HPV 52 where noninferiority was inconclusive (high-certainty evidence).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "Two studies found that two doses of HPV vaccine resulted in little to no di erence in pain at the injection site compared with three doses of HPV vaccine (RR 0.96, 95% CI 0.91 to 1.03; 2 studies; 1189 participants; Analysis 1.1), but reduced swelling (RR 0.76, 95% CI 0.65 to 0.89; 2 studies; 1189 participants; Analysis 1.2) and redness (RR 0.85, 95% CI 0.75 to 0.96; 2 studies; 1189 participants; Analysis 1.3) at the injection site at up to seven days followup.The comparative evidence about serious adverse events was considered to be of very low-certainty (risk with two doses 36/1158, risk with three doses 35/1159; 4 studies; 2317 participants; Analysis 1.4).We downgraded certainty for imprecision and indirectness of the composite measure of all serious adverse events, which may or may not be clinically relevant, may or may not be related to the vaccine, and may occur outside a biologically plausible time frame relative to vaccine exposure.Two of the studies reported on withdrawals from the study and reported that no participants had withdrawn because of adverse events.One death was reported in the three-dose group (1/898) and no deaths (0/899) in the two-dose group (OR 0.33, 95% CI 0.01 to 8.19; 3 studies; 1797 participants; low-certainty evidence; Analysis 1.5).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "The results for this comparison are presented in Summary of findings 2 and Appendix 6.We included three studies in females that compared two doses with a longer interval between the first and second doses (months 0 and 6 or 12) with a shorter interval between the first and second doses (months 0 and 2 or 6) for immunogenicity outcomes at seven months for all vaccine types and adverse event outcomes throughout the study period (one to five years) (Iversen 2016; Puthanakit 2016; Romanowski 2011) .One of these studies compared a longer interval (months 0 and 12) with a shorter interval (months 0 and 6) in males (Iversen 2016) .No studies included for this comparison collected data about clinical outcomes.As each study compared di erent intervals, we did not pool the results in the meta-analysis.",
                "cite_spans": [
                    {
                        "start": 450,
                        "end": 464,
                        "text": "(Iversen 2016;",
                        "ref_id": null
                    },
                    {
                        "start": 465,
                        "end": 481,
                        "text": "Puthanakit 2016;",
                        "ref_id": null
                    },
                    {
                        "start": 482,
                        "end": 498,
                        "text": "Romanowski 2011)",
                        "ref_id": null
                    },
                    {
                        "start": 616,
                        "end": 630,
                        "text": "(Iversen 2016)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9-to 14year-old females or males",
                "sec_num": "2."
            },
            {
                "text": "Immunogenicity results are reported in Appendix 6.At one month a er the final dose, there was evidence of higher (and non-inferior) GMTs for HPV 16 and HPV 18 with the longer interval schedules compared with the shorter intervals in 9-to 14-year-old females who received bivalent HPV vaccine (moderate-to high-certainty evidence).There was also evidence of higher GMTs for HPV 16 and HPV 18 at 36 months with the longer interval schedules compared with the shorter intervals in 9-to 14-year-old females who received bivalent HPV vaccine (high-certainty evidence).For seroconversion to HPV 16 and HPV 18, there was evidence of no di erence between groups one month a er the final dose (high-certainty evidence).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9-to 14year-old females or males",
                "sec_num": "2."
            },
            {
                "text": "For the nonavalent vaccine in girls and boys, there was evidence that a longer interval produced higher and non-inferior GMTs than a shorter interval for all HPV genotypes (high-certainty evidence).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9-to 14year-old females or males",
                "sec_num": "2."
            },
            {
                "text": "In The Iversen 2016 study reported on serious adverse events in males and females, but disaggregated data were not available by sex (Table 1 ).One of the reported serious adverse events (one case of systemic lupus erythematosus) in the 12-month interval group (Puthanakit 2016), was considered by the study investigators to be related to the vaccine and was the only withdrawal from the studies because of adverse events.No deaths were reported in any of the included trials (Analysis 2.5).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 139,
                        "end": 140,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9-to 14year-old females or males",
                "sec_num": "2."
            },
            {
                "text": "The results for this comparison are presented in Appendix 7. We included one study that compared three doses of quadrivalent HPV vaccine with a longer interval between the second and third doses (doses administered at months 0, 2, and 12) against a shorter interval between the second and third doses (doses administered at months 0, 2, and 6) (Lin 2014).For the immunogenicity outcomes (Appendix 8), there was evidence of higher GMTs for HPV 11 with the longer interval schedule compared with the shorter schedule at one month (2 to 6 weeks test window allowed) a er the last dose.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Longer interval versus shorter interval between second and third doses of quadrivalent HPV vaccine in 18-to 25-year-old males",
                "sec_num": "3."
            },
            {
                "text": "For GMTs for HPV 6, 16, and 18, there was evidence of little to no di erence between groups.The study did not collect data about clinical outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Longer interval versus shorter interval between second and third doses of quadrivalent HPV vaccine in 18-to 25-year-old males",
                "sec_num": "3."
            },
            {
                "text": "This study reported local, general, and serious adverse events.No usable data were available for analysis of local and general adverse events so we summarised the results in Analysis 3.1.Briefly, among all study participants 172 local and general reactions were reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Longer interval versus shorter interval between second and third doses of quadrivalent HPV vaccine in 18-to 25-year-old males",
                "sec_num": "3."
            },
            {
                "text": "The authors reported no significant di erence between groups (P = 0.26).No serious adverse events were reported (120 participants; Analysis 3.2).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Longer interval versus shorter interval between second and third doses of quadrivalent HPV vaccine in 18-to 25-year-old males",
                "sec_num": "3."
            },
            {
                "text": "The results for this comparison are presented in Summary of findings 3. Cochrane Database of Systematic Reviews Analysis 4.6), with confidence intervals that included the possibility of both fewer and more events with the quadrivalent vaccine (lowcertainty evidence for all outcomes).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HPV vaccines versus control in 10-to 26-year-old males",
                "sec_num": "4."
            },
            {
                "text": "In the quadrivalent vaccine group, there were more overall local/ injection site adverse events than with the control (RR 1.12, 95% CI 1.06 to 1.18; 1 study; 3895 participants; high-certainty evidence; Analysis 4.7); the events included pain at injection site (RR 1. 4.12) .None of the reported serious adverse events was considered by the study investigators to be vaccine-related.Two participants from the quadrivalent group and seven participants from the control group discontinued participation in the studies because of adverse events.There were fewer deaths in the group that received quadrivalent vaccine (3 deaths in quadrivalent group; 11 deaths in control group), but confidence intervals for the di erence were compatible with no e ect (OR 0.30, 95% CI 0.09 to 1.01; 2 studies; 5173 participants; low-certainty evidence; Analysis 4.13) at up to three years of follow-up (Giuliano 2011).Lehtinen 2018 reported on serious adverse events for a selected subset of males (data not shown).Fi y-eight of the 2436 subset participants (2.4%) who received the HPV vaccine and 25/1267 subset participants (2.0%) who received the control HBV vaccine experienced serious adverse events (very low-certainty evidence).The investigators reported that four serious adverse events among the males who received the HPV vaccine (abdominal pain, ulcerative colitis, type 1 diabetes mellitus, juvenile idiopathic arthritis) could possibly be vaccinerelated and one event among the males who received the control (type 1 diabetes mellitus) could possibly be vaccine-related.In the study on bivalent vaccine (Petaja 2009), three serious adverse events were reported in the bivalent vaccine group (3/181) and one in the control group (1/89) (Analysis 4.12; very low-certainty evidence).The study investigators did not consider these to be related to the vaccine, and no deaths were reported in either group.",
                "cite_spans": [
                    {
                        "start": 267,
                        "end": 272,
                        "text": "4.12)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HPV vaccines versus control in 10-to 26-year-old males",
                "sec_num": "4."
            },
            {
                "text": "For the secondary outcome of persistent HPV infection, there was evidence that quadrivalent HPV vaccine reduced persistent infection caused by HPV 6, 11, 16 or 18 combined, or by each HPV genotype individually, in 16-to 26-year-old males compared with control (Appendix 9).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HPV vaccines versus control in 10-to 26-year-old males",
                "sec_num": "4."
            },
            {
                "text": "The Giuliano 2011 study also reported immunogenicity outcomes (data not shown).Briefly, there was evidence that quadrivalent vaccine increased GMTs for HPV 6, 11, 16 and 18 when compared with control at 7, 24 and 36 months.There was a trend towards GMTs levelling o a er reaching a peak at month seven.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HPV vaccines versus control in 10-to 26-year-old males",
                "sec_num": "4."
            },
            {
                "text": "Comparative data between quadrivalent vaccine and control were not available for the seropositivity outcomes (control group data not reported), but seropositivity for HPV 6, 11, 16 and 18 at seven months was above 97%.Petaja 2009 also reported immunogenicity outcomes seven months a er the first dose of bivalent vaccine were higher than the HBV vaccine (Appendix 10).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "HPV vaccines versus control in 10-to 26-year-old males",
                "sec_num": "4."
            },
            {
                "text": "The results of this comparison are presented in Summary of findings 4. We included three RCTs that compared nonavalent with quadrivalent HPV vaccine (three doses administered at months 0, 2, and 6): two in females (Joura 2015; Vesikari 2015), and one in males (van Damme 2016).The Joura 2015 study collected data on clinical outcomes in females at up to 4.5 years follow-up.All three trials reported adverse event outcomes throughout the study period and immunogenicity outcomes at seven months for all vaccine types.We did not identify any studies that collected data about clinical outcomes in males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-to 26-year-old females and males",
                "sec_num": "5."
            },
            {
                "text": "In Levin 2010 included 7-to 12-year-old girls and boys with HIV.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-to 26-year-old females and males",
                "sec_num": "5."
            },
            {
                "text": "The study reported immunogenicity outcomes at seven months (Appendix 13).GMTs for HPV 6, 11, 16 and 18 were 123.8 to 935.8-fold higher at seven months, and 29.6 to 189.4-fold higher at 24 months, than in the control group (described as 'identical placebo', the study did not specify the contents of the placebo) (lowcertainty evidence).Seroconversion for the four HPV genotypes was over 97% at seven months (low-certainty evidence).Injection site adverse events were more common with quadrivalent vaccine (21/96) than control (3/30) (1 study; 126 participants; very lowcertainty evidence; Analysis 6.4).Three systemic adverse events were reported, two in the quadrivalent group (2/96) and one in the control group (1/30) (1 study; 126 participants; very lowcertainty evidence; Analysis 6.5) at 14-day follow-up (three doses administered at months 0, 2, and 6).The study did not report on serious adverse events, but reported that 5/96 (5.2%) children in the quadrivalent vaccine group and 2/30 (6.7%) children in the control group experienced adverse events of grade 3 or 4 severity (OR 0.77, 95% CI 0.14 to 4.18, analysis not shown).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-to 26-year-old females and males",
                "sec_num": "5."
            },
            {
                "text": "Hidalgo-Tenorio 2017 included HIV-positive MSM of 18 years of age and above, and compared quadrivalent HPV vaccine with control (saline placebo) (three doses administered at months 0, 2, and 6).This trial reported that 76% of the HPV vaccinated participants were seropositive for at least one of HPV 6, 11, 16, or 18 genotype at seven months compared with 30.2% in the control group (moderatecertainty evidence; Appendix 13).No serious adverse events (1 study; 129 participants; Analysis 6.6) or deaths (1 study; 129 participants; Analysis 6.7) were reported in either group at sevenmonth follow-up (Table 3 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 606,
                        "end": 607,
                        "text": "3",
                        "ref_id": "TABREF114"
                    }
                ],
                "eq_spans": [],
                "section": "Quadrivalent HPV vaccine compared with control in MSM living with HIV",
                "sec_num": "6.1.2"
            },
            {
                "text": "Two studies included HIV-positive males and females of 18 years of age and above and compared quadrivalent HPV vaccine with control (saline placebo in NCT00941889 2016 and 'placebo vaccine' in Wilkin 2018 -the contents of the placebo were not specified).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quadrivalent HPV vaccine compared with control in adults living with HIV",
                "sec_num": "6.1.3"
            },
            {
                "text": "There was only very low-certainty evidence on high-grade anal intraepithelial neoplasia (46/288 in the quadrivalent group, 45/286 in the control group; 1 study; Analysis 6.1), recurrence of anogenital warts in participants treated for anogenital warts (1/7 in the quadrivalent group, 1/5 in the control group; 1 study; Analysis 6.2), or abnormal anal cytology (58/130 in the quadrivalent group, 72/132 in the control group; 1 study; Analysis 6.3).There was limited evidence for serious adverse events (quadrivalent 33/288 events; control 46/287 events; Analysis 6.6) or deaths (quadrivalent 3/288 deaths; control 6/287 deaths; Analysis 6.7) between the groups.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quadrivalent HPV vaccine compared with control in adults living with HIV",
                "sec_num": "6.1.3"
            },
            {
                "text": "The study investigators considered no serious adverse events to be related to vaccination, and no withdrawals from the studies due to adverse events were reported (Table 3 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 170,
                        "end": 171,
                        "text": "3",
                        "ref_id": "TABREF114"
                    }
                ],
                "eq_spans": [],
                "section": "Quadrivalent HPV vaccine compared with control in adults living with HIV",
                "sec_num": "6.1.3"
            },
            {
                "text": "Denny 2013 included HIV-positive 18-to 25-year-old females and reported that, irrespective of baseline HPV serostatus, all participants who received the bivalent HPV vaccine were seropositive for both HPV 16 and HPV 18 a er the second vaccine dose (month two), and remained seropositive at month 12 (moderate-certainty evidence).Pain at injection site (RR 1.86, 95% CI 1.38 to 2.51; 1 study; 120 participants; Analysis 7.1) and swelling at injection site (RR 9.19, 95% CI 2.24 to 37.73; 1 study; 120 participants; Analysis 7.2) were more common in the bivalent group than in the control group (vaccine adjuvant only) at sevenday follow-up.The study reported 3/61 serious adverse events in the bivalent vaccine group and 2/59 events in the control group (OR 1.47, 95% CI 0.24 to 9.15; 1 study; 120 participants; low-certainty evidence; Analysis 7.3).No deaths were reported (Analysis 7.4).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bivalent HPV vaccine compared with control in females living with HIV",
                "sec_num": "6.2"
            },
            {
                "text": "The study investigators considered no serious adverse events to be related to vaccination, and no withdrawals from the study due to adverse events were reported (Table 4 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 168,
                        "end": 169,
                        "text": "4",
                        "ref_id": "TABREF117"
                    }
                ],
                "eq_spans": [],
                "section": "Bivalent HPV vaccine compared with control in females living with HIV",
                "sec_num": "6.2"
            },
            {
                "text": "To 2014 included 92 HIV-positive females and males of 18 years of age and above, and compared bivalent with quadrivalent HPV vaccine (3 doses administered at months 0, 1.5, and 6).There was",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bivalent HPV vaccine compared with quadrivalent HPV vaccine in adults living with HIV",
                "sec_num": "6.3.1"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews evidence of no di erence, and inconclusive non-inferiority, in GMTs for HPV 16 between the bivalent and quadrivalent HPV vaccines at seven-and 12-month follow-up (moderate-to low-certainty evidence; Appendix 13).There was evidence that the quadrivalent vaccine was inferior to bivalent vaccine for GMTs for HPV 18 at seven months (ratio of GMTs 0.13, 95% CI 0.04 to 0.41; moderatecertainty evidence).Injection site reactions were more common in the bivalent group than in the quadrivalent group (RR 1.31, 95% CI 1.06 to 1.62; 1 study; 92 participants; low-certainty evidence; Analysis 8.1) at four-day follow-up.No serious adverse events at sixmonth follow-up were reported (Analysis 8.2; Table 5 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 735,
                        "end": 736,
                        "text": "5",
                        "ref_id": "TABREF13"
                    }
                ],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "One study reported on serious adverse events in 15-to 25-yearold females with HIV who were randomised to receive bivalent or quadrivalent HPV vaccine (NCT01031069 2017).Data for this study were only available through the clinical trials registry, so full details on the methods and other outcome measures were not available.There were nine serious adverse events in 167 female participants with HIV in the bivalent vaccine group and nine in 165 participants in the quadrivalent group (1 study; 332 participants; very low-certainty evidence; Analysis 8.2; Table 5 ).One participant in the quadrivalent group withdrew due to an adverse event.One serious adverse event (immune thrombocytopenic purpura) was considered by study investigators to be related to the bivalent HPV vaccine.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 561,
                        "end": 562,
                        "text": "5",
                        "ref_id": "TABREF13"
                    }
                ],
                "eq_spans": [],
                "section": "Bivalent HPV vaccine compared with quadrivalent HPV vaccine in 15-to 25-year-old females living with HIV",
                "sec_num": "6.3.2"
            },
            {
                "text": "We compared the results from the primary analysis with a sensitivity analysis using Peto odds ratios for outcomes with very low event rates (< 1%; Bradburn 2007).This did not change the size of e ect for most of the analyses, with the exception of some clinical outcomes in the comparison of nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-to 26-year-old females (Appendix 14).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "Changes were seen in the e ect sizes and 95% CIs for the following outcomes:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "\u2022 high-grade cervical disease related to HPV 31, 33, 45, 52, or 58 (Analysis 5.5) ",
                "cite_spans": [
                    {
                        "start": 41,
                        "end": 48,
                        "text": "HPV 31,",
                        "ref_id": null
                    },
                    {
                        "start": 49,
                        "end": 52,
                        "text": "33,",
                        "ref_id": null
                    },
                    {
                        "start": 53,
                        "end": 56,
                        "text": "45,",
                        "ref_id": null
                    },
                    {
                        "start": 57,
                        "end": 60,
                        "text": "52,",
                        "ref_id": null
                    },
                    {
                        "start": 61,
                        "end": 81,
                        "text": "or 58 (Analysis 5.5)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "This review reports on evidence about the e icacy, immunogenicity, and adverse events following reduced dose or alternative vaccine schedules in females and males, HPV vaccination compared to control for males, and e ects of HPV vaccines in people with HIV infection.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I S C U S S I O N",
                "sec_num": null
            },
            {
                "text": "Immunogenicity, e icacy and adverse events with fewer than three doses of HPV vaccine in females",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "In adolescent girls (9 to 15 years) a two-dose schedule was noninferior to a three-dose schedule of any HPV vaccine.There was some evidence that GMTs decrease over time following both twodose and three-dose schedules, and that a two-dose schedule is non-inferior to a three-dose schedule a er five years.There was no di erence in seroconversion between two-dose and threedose schedules at all time points reported; almost all participants seroconverted in both intervention groups.We identified no studies that collected data about e icacy against clinical outcomes.There was very low-certainty evidence of little to no di erence in serious adverse events or deaths between dose schedules.No RCTs that evaluated the e icacy or harms of one dose of HPV vaccine were identified.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "In both females and males, for all HPV vaccines evaluated, a schedule with a longer interval between doses resulted in higher GMTs than a shorter interval.There was very low certainty evidence on the comparative risk of serious adverse events with di erent intervals between two-doses of HPV vaccine, owing to the very low number of events and indirectness.Results from single studies were consistent with lower or higher rates of serious adverse events with the di erent intervals tested in the studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Immunogenicity, e icacy and adverse events with di erent intervals between doses of HPV vaccine in females and males",
                "sec_num": null
            },
            {
                "text": "Three doses of quadrivalent HPV vaccine reduced the incidence of external genital lesions, anogenital warts, and persistent infection by HPV 6, 11, 16 or 18 compared with control among 16-to 26year-old males over a median follow-up of 2.9 years (moderatecertainty evidence).The quadrivalent vaccine resulted in more injection-site adverse events, such as pain or redness, than control (high-certainty evidence).There was very low certainty evidence on the comparative risk of serious adverse events and low certainty evidence on the comparative risk of deaths between quadrivalent vaccine and control among 10-to 26-year old males.Limited data were available regarding the e icacy and adverse events with bivalent HPV vaccine in males.We identified no RCTs that evaluated the e icacy of nonavalent vaccine compared with control in males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E icacy, immunogenicity and adverse events with HPV vaccines in males",
                "sec_num": null
            },
            {
                "text": "Among 16-to 26-year-old women, three doses of nonavalent vaccine or of quadrivalent vaccine resulted in a similar incidence of clinical outcomes regardless of HPV genotype at up to 4.5year follow-up (one RCT, high certainty evidence).The nonavalent vaccine resulted in reduced incidence of persistent HPV infections, CIN1, CIN 2/3, vulval or vaginal intraepithelial neoplasia (grade 1) related to the HPV genotypes unique to the nonavalent vaccine (HPV 31, 33, 45, 52 , and 58) compared with the quadrivalent vaccine.Immunogenicity outcomes for nonavalent and quadrivalent HPV vaccines were similar for males and females.There was high-",
                "cite_spans": [
                    {
                        "start": 448,
                        "end": 456,
                        "text": "(HPV 31,",
                        "ref_id": null
                    },
                    {
                        "start": 457,
                        "end": 460,
                        "text": "33,",
                        "ref_id": null
                    },
                    {
                        "start": 461,
                        "end": 464,
                        "text": "45,",
                        "ref_id": null
                    },
                    {
                        "start": 465,
                        "end": 467,
                        "text": "52",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E icacy, immunogenicity and adverse events with the nonavalent HPV vaccine compared with other HPV vaccines in females and males",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews certainty evidence that the nonavalent vaccine resulted in slightly more local or injection site events but little to no di erence in overall systemic events.The evidence comparing serious adverse events was of low-certainty.There was low-certainty evidence of no di erence in mortality between these vaccines.There were few vaccine-related serious adverse events reported (seven participants in total) in the included studies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In children living with HIV, the quadrivalent HPV vaccine results in higher GMTs than control at seven months, but there was only very low-certainty evidence about local or systemic adverse events.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E icacy, immunogenicity and adverse events with HPV vaccines in people living with HIV",
                "sec_num": null
            },
            {
                "text": "In adults living with HIV, the evidence about clinical outcomes and harms of quadrivalent HPV vaccine compared with control or other HPV vaccines, was of very low-certainty.One RCT in adults living with HIV reported that the bivalent vaccine had similar immunogenicity outcomes for HPV 16 to the quadrivalent vaccine, but resulted in higher GMTs and greater rate of seroconversion to HPV 18.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E icacy, immunogenicity and adverse events with HPV vaccines in people living with HIV",
                "sec_num": null
            },
            {
                "text": "This review collated evidence about the e icacy -in terms of clinical and immunological endpoints -and harms of di erent HPV vaccines and di erent dose schedules in females and males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The information sources searched include electronic databases, websites of the vaccine manufacturers, and a published index of HPV studies (J\u00f8rgensen 2018a), so the level of completeness is high.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The applicability of the evidence to determine clinical e icacy and harms is, however, limited by the nature of HPV-related disease, as well as the design and outcomes of the studies.The evidence from RCTs about e icacy against severe HPV-related disease, including cancer, is limited for three main reasons.First, it is unethical to collect specimens from the cervix of girls who have not had sexual intercourse.Second, few severe clinical outcome events related to HPV infection occur during the study follow-up periods because they take a number of years to develop following HPV infection.Third, trial participants are o ered treatment when HPV-related precancer is found, so progression to cervical cancer would be expected to be very low, even without vaccination.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The focus of this review was on clinical outcomes and harms.Immunogenicity is the primary outcome for many trials of alternative HPV vaccine schedules, however, as noted in the Background, randomised e icacy trials of HPV vaccines were first conducted in women aged 15 to 25 or 26 years (Arbyn 2018 2014) .Bridging studies have also demonstrated non-inferiority of immunogenicity outcomes of a two-dose schedule in boys aged 9-to 14-years compared to three doses in young women aged 15 to 26 years (Iversen 2016).Use of immunogenicity outcomes has limitations because the immunological correlate of protection and the duration of protection remain unknown (Donken 2015).These studies provide lower certainty of evidence, because estimates of clinical outcomes are imprecise and indirect.",
                "cite_spans": [
                    {
                        "start": 299,
                        "end": 304,
                        "text": "2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The nonavalent HPV vaccine was introduced more recently than the bivalent and quadrivalent HPV vaccines.This review included all studies that compared the nonavalent HPV vaccine with other HPV vaccines; two RCTs were identified in females (Joura 2015; Vesikari 2015), and one in males (van Damme 2016).A separate Cochrane Review of completed RCTs of three-dose schedules with bivalent and quadrivalent HPV vaccines in women aged 16 to 26 years shows protection against lesions of grade CIN3, but not invasive cervical cancer (Arbyn 2018).Further comparisons between the di erent HPV vaccines in women will be included in an update of the Arbyn 2018 review.Observational studies in countries that have licensed more than one HPV vaccine will also provide important information on the comparative e icacy and harms of the di erent HPV vaccines.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "With regard to serious adverse events, there is a large degree of uncertainty in the evidence comparing di erent HPV vaccines and di erent dose schedules.The 'Summary of findings' tables show low numbers of serious adverse events and deaths in most included studies.Even when the total number of events is high (e.g.Joura 2015), specific events of clinical relevance are still too rare for meaningful comparative analyses.In this review, we used a composite outcome, that is, the overall frequency of serious adverse events, for each comparison, however, analyses based on a composite outcome can produce results that are di icult to interpret for several reasons.This outcome can include events that are not clinically relevant or are not biologically related to the vaccine (Lineberry 2016), occur outside a plausible time frame relative to vaccine exposure (Huang 2011) , or are not based on standardised definitions (Bonhoe er 2002).In addition, trials measure serious adverse events at di erent time points and there is a large variation in duration of follow-up, which could produce misleading summary estimates (Huang 2011) .Finally, there is heterogeneity among trials with regard to the age and gender of participants and clinical measurements of serious adverse events (Appendix 4).Meta-analyses of serious adverse events, such as those presented in this review, should be considered exploratory rather than confirmatory as the analyses are not planned in advance (i.e. when the included studies were designed) (Huang 2011) .Despite the uncertainty in the evidence about harms when comparing di erent HPV vaccines and dose schedules, a previous systematic review reported similar rates of serious adverse events when HPV vaccines were compared to control (Arbyn 2018).",
                "cite_spans": [
                    {
                        "start": 860,
                        "end": 872,
                        "text": "(Huang 2011)",
                        "ref_id": null
                    },
                    {
                        "start": 1118,
                        "end": 1130,
                        "text": "(Huang 2011)",
                        "ref_id": null
                    },
                    {
                        "start": 1521,
                        "end": 1533,
                        "text": "(Huang 2011)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The risk of bias of the included studies in this review is generally low.We rated studies that received funding from the vaccine manufacturer as 'unclear' for the 'other risk of bias' domain.This judgement was based on the results of a systematic review which showed more favourable e icacy results and conclusions in studies sponsored by manufacturing companies (Lundh 2017) .It has been suggested that industry sponsorship of studies results in overly positive results through a variety of choices in the design and conduct of the trials that leads to bias.Based on the low risk of bias in other methodological domains and adequate reporting in the trials, we did not downgrade the certainty of the evidence using GRADE for this factor.In accordance with Higgins 2017, information on industry sponsorship and other funding sources is captured in the Characteristics of included studies tables.",
                "cite_spans": [
                    {
                        "start": 363,
                        "end": 375,
                        "text": "(Lundh 2017)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "In studies where participants received a control injectionspecifically for the comparisons of HPV vaccines with control in Cochrane Database of Systematic Reviews males and people living with HIV, and di erent interval schedules -many of the included studies used an adjuvant (either aluminium hydroxide or another aluminium compound) as the control rather than a 'true' placebo (NCT00941889 2016 used a saline placebo; Levin 2010 and Wilkin 2018 did not specify the type of placebo).Aluminium adjuvants have been used in vaccines for many years as they are thought to enhance the immune response (HogenEsch 2018), but their suitability as control vaccines in RCTs has been questioned (J\u00f8rgensen 2018b).A previous systematic review found no evidence that aluminium adjuvants in diptheria, tetanus, and pertussis vaccines cause any serious or long-lasting adverse events (Je erson 2004).The rate of serious adverse events was low for both vaccine and control groups in the studies included in the current review.However, the benefits and harms of aluminiumcontaining adjuvants are being further assessed in a Cochrane Review (Djurisic 2017), and research is underway to determine how suitable they are as control vaccines for RCTs.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "For a number of outcomes presented in the 'Summary of findings' tables, especially serious adverse events and deaths, we downgraded the certainty of the evidence for imprecision.In most cases the sample size of the included RCTs was too small to be able to detect an e ect between groups for these outcomes -especially for rare outcomes such as death.This is another limitation of RCTs in determining the harms associated with HPV vaccines, and lends further weight to the future use of large observational studies.We also downgraded the evidence on serious adverse events for indirectness because of the limitations to the use of a composite outcome measure of events, as described in the section on applicability.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "We made great e orts to identify relevant published and unpublished data, through a sensitive electronic database search and screening of vaccine manufacturer websites.By linking clinical trial registry entries with published database searches, and by cross-checking the studies included and excluded from our review against a published index of HPV studies (J\u00f8rgensen 2018a), we attempted to minimise the risk of missed studies, though relevant data may remain unregistered or unpublished (J\u00f8rgensen 2018a).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Potential biases in the review process",
                "sec_num": null
            },
            {
                "text": "We used a priori categories of common adverse events -such as pain or swelling at the injection site -or important outcomes such as serious adverse events and deaths when extracting data from included studies.This method of data extraction could have been limited by the reporting in the included studies, as composite outcomes, such as 'overall injection site/local adverse events', could not be calculated by reports of all events within the study populations.The range of di erent adverse events reported in the included studies, as well as the range of methods used to assess these in the studies, makes it unfeasible to extract all adverse events for the purpose of meta-analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Potential biases in the review process",
                "sec_num": null
            },
            {
                "text": "We analysed and reported on all serious adverse events in the included studies.Serious adverse events are any events that result in hospitalisation and life-threatening illness.This means that any serious injury or illness is included, even if it is unlikely to be related to the vaccine.We also reported on results and attribution methods used to determine whether serious adverse events were related to the vaccine.We did not analyse these results or report them in the 'Summary of findings' tables because attribution methods were either not transparent, or not independent of the study investigators (Appendix 4).These results are reported narratively in the E ects of interventions section.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Potential biases in the review process",
                "sec_num": null
            },
            {
                "text": "We restricted the sensitivity analysis of very rare events to alternative statistical methods available in Review Manager 5 so ware.We applied a sensitivity analysis to a number of outcomes where there were studies with zero events in both arms, but they did not contribute information when either method was used.It is possible that other methods could yield di erent results where there are zero events in both trial arms (Sharma 2017) .",
                "cite_spans": [
                    {
                        "start": 424,
                        "end": 437,
                        "text": "(Sharma 2017)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Potential biases in the review process",
                "sec_num": null
            },
            {
                "text": "The results of this systematic review are in agreement with other published reviews on the e icacy of fewer than three doses of HPV vaccine (D'Addario 2017; Markowitz 2018).The current review aimed to provide further information on clinical outcomes and adverse events.This review provides evidence about other comparisons, such as vaccination of boys and comparisons across types of HPV vaccine, which have not previously been assessed.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Agreements and disagreements with other studies or reviews",
                "sec_num": null
            },
            {
                "text": "In general, the bivalent, quadrivalent and nonavalent human papillomavirus (HPV) vaccines appear to be e icacious in eliciting immunogenic responses in both males and females for the targeted HPV genotypes and, typically, conversion to seropositivity is almost 100% amongst recipients.A two-dose HPV vaccination schedule is simpler to administer than a three-dose schedule.Immunogenicity data show non-inferior results for a two-dose when compared with a three-dose schedule of bivalent, quadrivalent and nonavalent HPV vaccine.The World Health Organization (WHO) strategic advisory group of experts on vaccination recommends a twodose schedule with at least six months between the first and second dose, irrespective of sex, if the first dose is given before 15 years of age (WHO 2017).In practice, 65 countries worldwide have adopted two-dose HPV vaccination schedules for girls, as of 31 December 2017.Amongst high-income countries that recommend HPV vaccination for boys, Australia, Switzerland and the USA recommend a two-dose schedule.Given the decision of the International Agency for Research on Cancer that immunogenicity is a surrogate endpoint for individuals under 16 years of age, randomised controlled trials (RCTs) with clinical endpoints in this age group are unlikely.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for practice",
                "sec_num": null
            },
            {
                "text": "For males, including men who have sex with men (MSM), the quadrivalent HPV vaccine probably reduces the incidence of external genital lesions and anogenital warts (condylomata acuminata) compared with control.There were slightly more injection-site adverse events with the quadrivalent vaccine compared to control, but insu icient evidence to determine the e ects of HPV vaccine on serious adverse events or deaths when compared with control.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for practice",
                "sec_num": null
            },
            {
                "text": "The nonavalent vaccine and quadrivalent vaccines o er similar protection levels against cervical, vaginal, and vulval precancer lesions and cancer in young women and similar levels of immunogenicity for the four HPV genotypes included in both vaccines in females and males.For high-grade disease related to HPV 31, 33, 45, 52, or 58 (i.e.those genotypes covered by",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for practice",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews the nonavalent vaccine and not the quadrivalent vaccine) in women, the e ect favours the nonavalent vaccine.No studies that compared nonavalent and quadrivalent HPV vaccines reported on clinical outcomes in males.The nonavalent vaccine was associated with an increase in local adverse events compared to the quadrivalent vaccine.Comparative evidence about serious adverse events was limited by imprecision and indirectness.Most of the evidence for this comparison comes from the 16 to 26 year-old age group in females, and there are far fewer data for younger females and males.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Evidence about the e icacy and harms of HPV vaccines in people living with HIV is limited because very few trials measured clinical outcomes.In children living with HIV, quadrivalent HPV vaccine probably results in higher GMTs than control at seven months.In adults living with HIV the evidence about clinical outcomes and harms of quadrivalent HPV vaccine, compared with control or other HPV vaccines, was of very low-certainty.The duration of protection of HPV vaccines in people with HIV infection and the e ect of declining immunity on protection are unknown.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We identified no studies for any new HPV vaccines in phase 2 or 3 development that plan to report on the comparisons of interest in this review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Further long-term post-licensure studies are needed to determine the duration of protection of one-dose and two-dose schedules, as well as the e icacy against HPV-related cancer endpoints in women, men, MSM, and people with HIV infection.RCTs of the e ects of virus-like particle HPV vaccines on cervical and anal cancer are likely to study surrogate endpoints such as immunogenicity and persistent HPV infection.For vulval and vaginal cancer, clinical disease is still recommended as an endpoint because of insu icient knowledge about persistent infection (IARC 2014) .The natural history of HPV-associated oropharyngeal cancer is even less well understood.RCTs of the e ects of HPV vaccines will be needed, but might rely on persistent HPV infection as an outcome.The elucidation of the immune correlate of protection for HPV vaccines would be extremely valuable.",
                "cite_spans": [
                    {
                        "start": 557,
                        "end": 568,
                        "text": "(IARC 2014)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "Further RCTs to compare di erent vaccine schedules are needed to determine the most cost-e ective strategy to reduce the incidence of persistent HPV infection and related cancers.Evidence about the e ectiveness of a two-dose HPV vaccine schedule on clinical HPV-related disease still relies on non-randomised comparisons of RCTs (Kreimer 2015; Sankaranarayanan 2016) , and on data from national immunisation programmes (Markowitz 2018) .These studies provide essential ongoing data, but cannot fully overcome confounding e ects of di erences between groups that receive a certain number of doses.In immunisation programme data in particular, those receiving two doses as part of a three-dose schedule might only have received the first two doses with a one or two month gap and might be beyond the recommended age for vaccination.In this situation, these studies might actually underestimate the e ectiveness of a recommended two-dose schedule with at least six months between doses (Markowitz 2018 ).",
                "cite_spans": [
                    {
                        "start": 329,
                        "end": 343,
                        "text": "(Kreimer 2015;",
                        "ref_id": null
                    },
                    {
                        "start": 344,
                        "end": 366,
                        "text": "Sankaranarayanan 2016)",
                        "ref_id": null
                    },
                    {
                        "start": 419,
                        "end": 435,
                        "text": "(Markowitz 2018)",
                        "ref_id": null
                    },
                    {
                        "start": 983,
                        "end": 998,
                        "text": "(Markowitz 2018",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "An RCT that commenced in August 2018 will provide information about the non-inferiority of one and two doses of bivalent and nonavalent HPV vaccines against incident HPV genotype 16/18 infections that persist for six months or more in young women (NCT03180034).In addition, long-term surveillance and registrybased studies, such as linking vaccination databases with diseaseand population-based registries, are needed to establish vaccine e ectiveness and harms over time.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "This review included a wide range of comparisons of alternative HPV vaccine schedules.In future, studies of the e icacy of di erent types of HPV vaccine, studies of alternative dose schedules, and studies of the e ectiveness of HPV vaccines in people living with HIV infection could be examined in separate systematic reviews.This review has highlighted the limitations of data about harms collected in RCTs, especially imprecision, owing to the low frequency of serious adverse events.Longer-term follow-up is needed to investigate links with specific adverse events, such as new chronic diseases or adverse pregnancy outcomes.Postmarketing surveillance allows continued monitoring and reports events following HPV vaccination in the population beyond the duration of follow-up in RCTs.Surveillance studies of large registrybased data from real-world vaccination programmes can also provide more precise estimates of the incidence of specific adverse events and investigate prespecified hypotheses.In these studies, attribution of whether serious adverse events and deaths are related to the vaccine can be performed independently of study investigators and potential conflicts of interest.Future updates of this review will include observational long-term post-licensure studies to allow more detailed investigation of specific harms associated with HPV vaccines, long-term data on the e ectiveness of HPV vaccines, and the value of di erent dose schedules in increasing vaccine coverage.Future reviews should also consider the synthesis of evidence from vaccination programmes in the context of gender-neutral HPV vaccination, where consideration of indirect e ects of HPV vaccination is needed to provide more relevant estimates of vaccine e ectiveness for public health stakeholders.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "The authors would like to acknowledge the contribution of systematic reviewers from Cochrane Response for their assistance in screening abstracts and full-texts for this review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "A C K N O W L E D G E M E N T S",
                "sec_num": null
            },
            {
                "text": "We would also like to thank Sarah Hodgkinson and Helen Wakeford for their editorial comments and support, Elizabeth Royle for copy-editing, and all those providing referee comments, including:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "A C K N O W L E D G E M E N T S",
                "sec_num": null
            },
            {
                "text": "Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso Merck had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Guyatt 2011a",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT00501137",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Guyatt 2011a",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Girls were randomised (1:1) in balanced, stratified blocks of 6 to receive either 2 doses (at 0 and 6 months) or 3 doses (at 0, 2, and 6 months).The co-ordinating centre used SAS, version 9.2 (SAS Institute Inc) to generate randomisation lists for each site.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Co-ordinating centre generated randomisation sequence and allocated girls.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Impossible to blind girls as to whether they were randomised to 2 or 3 doses; the young women were not randomised, all receiving 3 doses.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Low risk Laboratory sta , blinded to group assignment, conducted the HPV antibody assays.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of outcome assessment (detection bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Low risk Data were reported for both ITT and per protocol populations, with full information on exclusions and withdrawals.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "The primary interest was in the per-protocol population; however, the results presented were the ITT population because these results could be generalised more readily.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "No other bias apparent \u2022 boys aged 9-14 years receiving 2 doses nonavalent HPV vaccine;",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Low risk",
                "sec_num": null
            },
            {
                "text": "\u2022 adolescent girls and young women 16-26 years receiving 3 doses of nonavalent HPV vaccine Last report average follow-up time: 13 months (1 month after the last dose)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Low risk",
                "sec_num": null
            },
            {
                "text": "Funding: Merck & Co, manufacturer of the quadrivalent and nonavalent HPV vaccines.Merck, as the study sponsor, was directly involved in the design and conduct of the study in conjunction with external investigators; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript.The presentation also underwent formal review by Merck.However, Merck could not prevent submission of the manuscript.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Low risk",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT01984697",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Low risk",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Randomisation occurred centrally using interactive voice response system/integrated web response system (IVRS/IWRS).Subjects were assigned randomly Cochrane Database of Systematic Reviews to 1 of the 3 vaccination arms based on their age stratum according to a computer-generated allocation schedule.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Randomisation occurred centrally using interactive voice response system/integrated web response system (IVRS/IWRS).Subjects were assigned randomly to 1 of the 3 vaccination arms based on their age stratum according to a computer-generated allocation schedule.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "This was an open-label trial; therefore, the sponsor, investigator and subject knew the treatment administered.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "This was an open-label trial; therefore, the sponsor, investigator and subject knew the treatment administered.Low risk Quote: \"The subjects, investigators (and his/her sta ), laboratory sta , members of the Scientific Advisory Committee, and HPV Vaccine Program Pathology Panel will remain blinded to subject vaccination group allocations for the duration of the study.The SPONSOR will remain blinded to subject vaccination allocations until the required number of cases of the primary efficacy endpoint have been observed and the database is unblinded for the primary efficacy analysis, with the exception of unblinded personnel who will provide data summaries for dose selection and DSMB meetings, and those who will determine when the required number of cases of the primary efficacy endpoint have been observed.These unblinded personnel will not be associated with the conduct of the study or the design of any of the statistical analyses for the study (other than those requested by the DSMB).\"(From protocol, supplementary material online)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Inclusion criteria: born 1992-1995; parental consent; healthy, as established by medical history.If female, not pregnant and not of child-bearing potential or using adequate contraception for 30 days prior to vaccination and to continue for 2 months after completion of the vaccination series",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Vaccine 1: 90% of the girls and boys assigned to receive bivalent HPV vaccine (Cervarix) and 10% assigned to receive hepatitis B vaccine (HBV; Engerix) at 0,1 and 6 months (11 clusters)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Vaccine 2: 90% of the girls assigned to receive bivalent HPV vaccine, 10% of girls assigned to receive HBV vaccine and all boys received HBV-vaccine (11 clusters) Control: all participants assigned to receive active control HBV vaccine (11 clusters) Outcomes Harms: adverse events (active surveillance subgroup 12-month follow-up)",
                "cite_spans": [
                    {
                        "start": 149,
                        "end": 162,
                        "text": "(11 clusters)",
                        "ref_id": null
                    },
                    {
                        "start": 236,
                        "end": 249,
                        "text": "(11 clusters)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Other groups: the data provided on harms in the male participants was based on the 2436 in group 1 who received bivalent vaccine and a sub-set of 1267 of those who received HBV vaccine in group 2.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Last report average follow-up time: 4 years Funding: GlaxoSmithKline",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT00534638",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Cluster-randomised: \"communities were randomly assigned in equal numbers (1:1:1) to the three intervention arms using a random number generator\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Allocation concealment (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Although the trial used central randomisation: \"study participants were to be administered the vaccine dose according to a central randomisation system on Internet\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "High risk Although the study was blinded for participants in the first arm (HPV or HBV vaccine), the participants in the third arm were aware of their allocation (all received HBV vaccine).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "High risk Quote: \"For investigators, the study was open\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of outcome assessment (detection bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "High risk For active adverse event surveillance, data were collected only for a subset of male participants and it was unclear how these participants were selected.Passive adverse event surveillance was conducted for all participants, but not reported for males separately.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No outcomes were reported completely separately for boys and girls.Adverse events were reported in boys separately, but in a selected subset.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Trial funded by vaccine manufacturer.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Unclear risk",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Participants Participants:1075 girls (359 to 2 doses of bivalent HPV; 358 to 2 doses of quadrivalent HPV; 358 to 3 doses of quadrivalent HPV; recruited at 21 sites in France, Hong Kong, Singapore and Sweden Age range: 9-14 years Inclusion criteria: healthy girls aged 9-14 years; girls of childbearing potential could be enrolled if they were abstinent or practised adequate contraception for 30 days prior to vaccination, had a negative pregnancy test on the day of each vaccination, and agreed to continue contraception for up to 2 months after completion of the vaccination series.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Vaccine 1: quadrivalent HPV vaccine; 2 doses: day 1, month 6",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Girls in the 2-dose group received aluminium adjuvant placebo (Al(OH) 3 ) at month 2 to maintain the observer blinding.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Harms: adverse events, deaths Immunogenicity: GMT, seroconversion",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Other groups: 358 girls aged 9-14 years who received 2 doses of bivalent HPV vaccine.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Last report average follow-up time: 36 months Funding: GlaxoSmithKline Biologicals SA funded this study and was involved in all stages of study conduct, including analysis of the data and the development and publication of the manuscript.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT01462357",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The randomisation code was generated using MATEX, a program developed for use in SAS (Cary, NC, USA), by GSK Vaccines, Belgium.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Quote: \"Treatment allocation at the investigator site was performed using a centralized internet-based randomisation system\" Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "The study was conducted in an observer-blind manner (i.e.vaccines were prepared and administered by qualified medical personnel not otherwise involved in the conduct of this study).Personnel involved in subject evaluation and subjects themselves were blinded to group assignments.Girls in the 2dose groups received control Al(OH) 3 at month 2 to maintain observer blinding.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Personnel involved in subject evaluation, and subjects themselves, were blinded to group assignments.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Data appeared to be reported adequately, including reasons for withdrawals.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No reason to suspect that reporting was selective.Clinical trial registry checked.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record states \"Randomized\", but details about how randomisation was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Unclear risk Details of allocation concealment were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record states \"Masking: Double (Participant, Investigator)\", but details about how blinding was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record states \"Masking: Double (Participant, Investigator)\", but details about how blinding was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "High risk Data for 62.5% (20/32) of the participants enrolled were missing due to withdrawal from the study, the online trial record states \"No outcomes data were collected or analysed due to lack of participant follow-up\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "The study did not report on adverse events and the online trial record states \"No outcomes data were collected or analysed due to lack of participant follow-up\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Other bias Unclear risk No published report was identified for this study, data were extracted from the clinical trials record which had insufficient information to establish whether there was a risk of other bias.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High risk",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record and clinical trial result summary state \"Randomized\", but details about how randomisation was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Unclear risk Details of allocation concealment were not reported Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record states \"Triple (Participant, Investigator, Outcomes Assessor)\", but details about how blinding was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record states \"Triple (Participant, Investigator, Outcomes Assessor)\", but details about how blinding was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Low risk Data were provided for the total vaccinated cohort (100% of enrolled participants), together with full information about reasons for exclusions and withdrawals from follow-up.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "High risk Not all outcomes listed in the online trial registration were reported in the trial result summary report.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No published report was identified for this study; data were extracted from the clinical trials results summary on the manufacturer's web site (https:// www.gsk-clinicalstudyregister.com/) which had insufficient information to establish whether there was a risk of other bias.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Unclear risk",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The online clinical trials record and clinical trial result summary state \"Randomized\", details about how randomisation was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Unclear risk Details of allocation concealment were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "The clinical trial record states \"masking: triple (participant, investigator, outcomes assessor\" but no other details were provided.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "The clinical trial record states \"masking: triple (participant, investigator, outcomes assessor\" but no other details were provided.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Low risk Reasons for withdrawals were reported and balanced between groups.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "High risk HPV disease (HPV Type 6, 11, 16, or 18-related condyloma acuminate, penile, perianal, or perineal intraepithelial neoplasia or cancer) was not reported separately; persistent HPV infection and HPV disease were reported as a combined outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No published report was identified for this trial.Trial funded by vaccine manufacturer.Funding: GlaxoSmithKline Biologicals SA.GlaxoSmithKline Biologicals designed the study in collaboration with investigators and co-ordinated gathering, analysis, and interpretation of data and writing of the report.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Unclear risk",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT01381575",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The randomisation list was generated by GSK Vaccines using a standard SAS program.A randomisation blocking scheme (1:1 ratio) ensured that balance between the two 2-dose schedules was maintained.Treatment allocation at each site used a central randomisation system on the Internet.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Treatment allocation at each site used a central randomisation system on the Internet.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "High risk Investigators and participants were not blinded to group assignment.Girls aged 9-14 years were randomised (1:1) to receive 2-dose schedule (months 0, and 6 or months 0, and 12) and women aged 15-25 years were allocated to receive 3-dose schedule (months 0, 1, and 6).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Blinding",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "The randomisation list was computer-generated at GlaxoSmithKline Biologicals.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Treatment allocation at the investigator site was performed using a central randomisation call-in system on the Internet; the randomisation algorithm used a minimisation procedure accounting for centre and age (9-14, 15-19 and 20-25 years).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "The trial was partially blinded within the 2-dose schedule groups (observers were blinded to group assignment) and open in the 3-dose schedule group.In the 2-dose schedule groups, a placebo was administered at month 2 (Groups 20 \u03bcg dose (months 0 and 6) and 40 \u03bcg dose (months 0 and 6)) or at month 6 (Group 40 \u03bcg dose (months 0 and 2) to maintain blinding.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "The trial was partially blinded within the 2-dose schedule groups (observers were blinded to group assignment).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Copyright",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Comparison of di erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review)",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Random allocation sequences were computer generated by the hospital pharmacy.Participants were assigned their study identification number according to the chronological order in which they were enrolled.Participants and investigators were masked to the assigned vaccine throughout the study.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk Random allocation sequences were computer generated by the hospital pharmacy.Participants were assigned their study identification number according to the chronological order in which they were enrolled.Participants and investigators were masked to the assigned vaccine throughout the study.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Low risk Participants and investigators were masked to the assigned vaccine throughout the study.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "To 2014 *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; MSM: men who have sex with men; OR: odds ratio; RR: risk ratio GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect.Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Downgraded one level for risk of bias: details about how randomisation sequence was generated or how blinding was achieved were not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "2 Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potentially beneficial e ect and a potentially harmful e ect.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "3 Downgraded two levels for serious risk of bias: data for 62.5% (20/32) of the participants enrolled were missing due to lack of follow-up.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "In addition, details about how randomisation, allocation concealment, and blinding were achieved were not reported. 4Downgraded two levels for imprecision: few events and wide 95% confidence interval that incorporated a potential beneficial e ect and no e ect. 5 Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a di erence in serious adverse events or mortality.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "6 Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure.This outcome is considered to provide indirect evidence about vaccine safety. 7See Table 1 for details of each serious event.High-grade cervical epithelial neoplasia, adenocarcinoma in situ, and cervical cancer",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 349,
                        "end": 350,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "Blinding of participants and personnel (performance bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bivalent",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "High-grade cervical, vulval, and vaginal disease",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.Data for specific local adverse events (pain and swelling at injection site) are presented in the Data and analyses and Effects of interventions sections.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall local/injection site adverse events",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Serious Cochrane Database of Systematic Reviews *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; OR: odds ratio GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect.Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.Very low quality: We are very uncertain about the estimate. 1Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potentially large beneficial e ect and a potentially large harmful e ect.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "2 Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a di erence in mortality.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "3 Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure.This outcome is considered to provide indirect evidence about vaccine safety. 4See Table 1 for details of each serious event.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 349,
                        "end": 350,
                        "text": "1",
                        "ref_id": "TABREF110"
                    }
                ],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Bivalent HPV vaccine compared with quadrivalent HPV vaccine in adults with HIV Patient or population: adults and adolescents (combined male and female) with HIV, \u2265 15 years old Settings: Brazil, Denmark, Estonia, India, and Thailand",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Intervention: bivalent HPV vaccine (3 doses at 0, 1.5, and 6 months)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Comparison: quadrivalent HPV vaccine (3 doses at 0, 1.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Cochrane Library Trusted evidence. Informed decisions. Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews observed for 30 mins after each injection for any immediate reaction\".",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Non-serious injection site and systemic events \"were not actively solicited\".respective of causality from day 1 (month 0) through 6 months after the last vaccination\").",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "cause, and consistency with the vaccine's known safety profile\").",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Blinding was not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "No definition given for non-serious AEs.SAEs were predefined (\"those events that resulted in death, were deemed life-threatening, led to a persistent or significant disability, required hospitalization, or were associated with a congenital anomaly, cancer, or other important medical event\").",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "after each dose administration.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Attribution was not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "No information on how withdrawals were handled in the analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Joura 2015 Mode of data collection was not reported.Attribution was made by the study co-ordinator.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Blinding not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "The severity of AEs was done using the \"Division of AIDS Attribution method not explicitly described in methods section.However, it seems it was done by the investigator \"Neither of the SAEs were fatal, and both events were considered by the investigator to be unrelated to study vaccination\"; \"the determination of whether a chronic disease is considered to be of new onset will be based on review of the subject's pre-vaccination medical history\".",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Blinding was not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Outcome definition:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "\u2022 \"Solicited local AEs included pain, redness, and swelling at the injection site\"; Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "\u2022 \"Grade 3 solicited AEs were defined as pain that prevented normal activity, redness or swelling larger than 50 mm, fever higher than 39.0 \u00b0C (axillary temperature), urticaria distributed on at least four body areas, or events that prevented normal, everyday activities.Urticaria or rash that appeared within 30 minutes of each vaccine dose was also documented by the investigator\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall systemic events and general symptoms",
                "sec_num": null
            },
            {
                "text": "Comparison of di erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review) Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "Downgraded two levels for serious imprecision: few events reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a di erence in serious adverse events or mortality.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "Downgraded one level for risk of bias: details on how randomisation, allocation concealment, and blinding was achieved was not reported.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporate a potentially large beneficial e ect and a potentially large harmful e ect.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure.This outcome is considered to provide indirect evidence about vaccine safety.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            },
            {
                "text": "See Table1for details of each serious event.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            }
        ],
        "back_matter": [
            {
                "text": "We thank Jo Morrison for her clinical and editorial advice, Jo Platt for assistance with the searches and and Gail Quinn, Clare Jess for their contribution to the editorial process.The World Health Organization retains copyright and all other rights in the manuscript of this review as submitted for publication, including any revisions or updates to the manuscript which WHO may make from time to time.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "acknowledgement",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.Cochrane Database of Systematic Reviews mous cells of undetermined significance at the screening visit.All women had to be willing to undergo HIV counselling and testing and to be informed of their HIV status.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Vaccine: bivalent HPV vaccine; 3 doses: day 0, month 1, month 6Control: aluminium adjuvant placebo (aluminium hydroxide (Al(OH) 3 )); 3 doses: day 0, month 1, month 6Outcomes Harms: adverse events Immunogenicity: GMT, seroconversion",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Other groups: 30 HIV-negative women were enrolled as a control group and received bivalent HPV vaccineLast report average follow-up time: 12 months Funding: GlaxoSmithKline Biologicals SA.The study sponsor designed the study in collaboration with the investigators, and co-ordinated collection, analysis, and interpretation of data.Trial ID: NCT00586339.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Low risk Most analysis per protocol, but baseline data on full cohort provided, data on withdrawals and reasons for withdrawing also provided.Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No reasons to suspect that reporting was selective.Clinical trial record checked.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Trial funded by vaccine manufacturer.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Unclear risk",
                "sec_num": null
            },
            {
                "text": "Phase III, open-label, non-inferiority, controlled, randomised, multi-centre trial Participants Participants: 520 women and young girls (259 to 2-dose quadrivalent HPV vaccine and 261 to 3-dose quadrivalent HPV vaccine) recruited from 3 Canadian provincial centres Age range: girls aged 9-13 years, young women aged 16-26 years",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Methods",
                "sec_num": null
            },
            {
                "text": "No statement provided about allocation concealment.Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "No detailed statement provided about how blinding was maintained or who was blinded.Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "No detailed statement provided about how blinding was maintained or who was blinded.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Low risk Data were provided for the total vaccinated cohort (100% of enrolled participants), together with full information about reasons for exclusions and withdrawals from follow-up.Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No reason to suspect that reporting was selective.Clinical trial record checked.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Randomisation list generated at GlaxoSmithKline Biologicals (Rixensart, Belgium) using a standard SAS program (SAS Institute, Cary, NC).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Participants were assigned a vaccine treatment number; blinding was maintained to the individual treatment allocated.Blinding of participants and personnel (performance bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Participants were assigned a vaccine treatment number; blinding was maintained to the individual treatment allocated.All study personnel were blinded to the vaccines used, except the study nurse administrating the vaccines.Blinding of outcome assessment (detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Participants were assigned a vaccine treatment number; blinding was maintained to the individual treatment allocated.All study personnel were blinded to the vaccines used, except the study nurse administrating the vaccines.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Low risk",
                "sec_num": null
            },
            {
                "text": "Low risk Data for all participants enrolled were reported for adverse events.Reasons for exclusion from immunogenicity analysis was provided.Selective reporting (reporting bias)Low risk All relevant outcomes were reported in clinical trials record and clinical study report.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "No report of industry funding in publication, though the study report is available on GSK web site.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other bias Unclear risk",
                "sec_num": null
            },
            {
                "text": "Trial ID: NCT00092547 Cochrane Database of Systematic Reviews VERY LOW 3,4,5,6 Mortality No studies were identified that reported on this outcome.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; OR: odds ratio; RR: risk ratio GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect.Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "A D D I T I O N A L T A B L E S",
                "sec_num": null
            },
            {
                "text": "We are very uncertain about the estimate.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Very low quality:",
                "sec_num": null
            },
            {
                "text": "No studies were identified that reported on this outcome *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Mortality",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.Cochrane Database of Systematic Reviews CI: confidence interval; HPV: human papillomavirus GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effectFootnotes 1 Downgraded one level for risk of bias: allocation concealment was not reported and the trial was open label.2 Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a di erence in serious adverse events.3 Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure.This outcome is considered to provide indirect evidence about vaccine safety.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Library Trusted evidence. Informed decisions. Better health.Cochrane Database of Systematic Reviews 2 Downgraded one level for risk of bias: details about how randomisation sequence was generated or how blinding was achieved were not reported.3 Downgraded two levels for imprecision: small sample size and very wide 95% confidence interval that incorporates a potential large beneficial e ect and a potential large harmful e ect.4 Downgraded one level for imprecision: wide 95% confidence interval that incorporates a potential beneficial e ect and a potential harmful e ect.Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Appendix 8. Three doses of HPV vaccine with shorter interval versus three doses of HPV vaccine with longer interval in 18-to 25-year-old males -immunogenicity outcomes",
                "sec_num": null
            },
            {
                "text": "The original protocol of this review was developed to match the needs of the WHO Initiative for Vaccine Research, and a number of comparisons investigated were not included in the current review.The protocol did not include adverse events as outcomes, these were extracted and included in this version of the review.In addition, for this version of the review, immunogenicity outcomes were considered as secondary outcomes and included only as Appendices.The outcome of histologically confirmed high-grade disease was amended for males, to include all clinical outcomes.We did not plan to assess the impact of statistical method to calculate odds ratios for very rare events in the protocol.We decided to assess the robustness of our analyses for very rare events (rates less than 1%) in view of the alternative statistical methods that can be used in this scenario (Bradburn 2007).The following comparisons, for non-randomised immuno-bridging studies were included in the original protocol, but were not reported in the current review:\u2022 fewer than three doses in adolescent girls (9 to 14 years) versus three doses in young women (15 to 26 years), using the same vaccine and the same dosage (three-dose arm using the WHO recommended schedule); \u2022 one dose in adolescent girls (9 to 14 years) versus two doses in young women (15 to 26 years), using the same vaccine and the same dosage; \u2022 males versus the same HPV vaccine type in females;\u2022 any HPV vaccine type in men who have sex with men (MSM) versus the same vaccine type in females or heterosexual males;\u2022 any HPV vaccine type in people with HIV infection compared with people without HIV infection.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W",
                "sec_num": null
            }
        ],
        "bib_entries": {
            "BIBREF0": {
                "ref_id": "b0",
                "title": "Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up",
                "authors": [
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Huang",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Liu",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Li",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Liao",
                        "suffix": ""
                    },
                    {
                        "first": "Q",
                        "middle": [],
                        "last": "Shou",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Zheng",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "Vaccine",
                "volume": "36",
                "issue": "11",
                "pages": "1368--1374",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF1": {
                "ref_id": "b1",
                "title": "Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebocontrolled trial in Chinese males and females",
                "authors": [
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Li",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Li",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Radley",
                        "suffix": ""
                    },
                    {
                        "first": "Y",
                        "middle": [],
                        "last": "Liu",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Huang",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [
                            "L"
                        ],
                        "last": "Sings",
                        "suffix": ""
                    }
                ],
                "year": 2012,
                "venue": "Vaccine",
                "volume": "30",
                "issue": "28",
                "pages": "4284--4291",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF3": {
                "ref_id": "b3",
                "title": "Long-term study of a quadrivalent human papillomavirus vaccine",
                "authors": [
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Ferris",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Samakoses",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "L"
                        ],
                        "last": "Block",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Lazcano-Ponce",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "A"
                        ],
                        "last": "Restrepo",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "S"
                        ],
                        "last": "Reisinger",
                        "suffix": ""
                    }
                ],
                "year": 2014,
                "venue": "Pediatrics",
                "volume": "134",
                "issue": "3",
                "pages": "657--665",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF4": {
                "ref_id": "b4",
                "title": "4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents A er 10 Years",
                "authors": [
                    {
                        "first": "D",
                        "middle": [
                            "G"
                        ],
                        "last": "Ferris",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Samakoses",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "L"
                        ],
                        "last": "Block",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Lazcano-Ponce",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "A"
                        ],
                        "last": "Restrepo",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Mehlsen",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "Pediatrics",
                "volume": "140",
                "issue": "6",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF6": {
                "ref_id": "b6",
                "title": "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials",
                "authors": [
                    {
                        "first": "J",
                        "middle": [
                            "P"
                        ],
                        "last": "Higgins",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [
                            "G"
                        ],
                        "last": "Altman",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "C"
                        ],
                        "last": "G\u00f8tzsche",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "J\u00fcni",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Moher",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "D"
                        ],
                        "last": "Oxman",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "BMJ",
                "volume": "343",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF8": {
                "ref_id": "b8",
                "title": "Chapter 8: Assessing risk of bias in included studies",
                "authors": [],
                "year": 2017,
                "venue": "Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF9": {
                "ref_id": "b9",
                "title": "Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want",
                "authors": [
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Hogenesch",
                        "suffix": ""
                    },
                    {
                        "first": "O'",
                        "middle": [],
                        "last": "Hagan",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [
                            "T"
                        ],
                        "last": "Fox",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "B"
                        ],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "npj Vaccines",
                "volume": "3",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF11": {
                "ref_id": "b11",
                "title": "Pitfalls in meta-analyses on adverse events reported from clinical trials",
                "authors": [
                    {
                        "first": "H",
                        "middle": [
                            "Y"
                        ],
                        "last": "Huang",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Andrews",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Jones",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "L"
                        ],
                        "last": "Skovron",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Tilson",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "Pharmacoepidemiology and drug safety",
                "volume": "20",
                "issue": "",
                "pages": "1014--1020",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF12": {
                "ref_id": "b12",
                "title": "Primary Endpoints for Prophylactic HPV Vaccine Trials",
                "authors": [],
                "year": 2014,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF14": {
                "ref_id": "b14",
                "title": "Better reporting of harms in randomized trials: an extension of the CONSORT statement",
                "authors": [
                    {
                        "first": "J",
                        "middle": [
                            "P"
                        ],
                        "last": "Ioannidis",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "J"
                        ],
                        "last": "Evans",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "C"
                        ],
                        "last": "G\u00f8tzsche",
                        "suffix": ""
                    },
                    {
                        "first": "O'",
                        "middle": [],
                        "last": "Neill",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "T"
                        ],
                        "last": "Altman",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [
                            "G"
                        ],
                        "last": "Schulz",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2004,
                "venue": "Annals of Internal Medicine",
                "volume": "141",
                "issue": "10",
                "pages": "781--788",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF16": {
                "ref_id": "b16",
                "title": "Adverse events a er immunisation with aluminium-containing DTP vaccines: systematic review of the evidence",
                "authors": [
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Je Erson",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Rudin",
                        "suffix": ""
                    },
                    {
                        "first": "Di",
                        "middle": [],
                        "last": "Pietrantonj",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2004,
                "venue": "Lancet Infectious Diseases",
                "volume": "4",
                "issue": "2",
                "pages": "84--90",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF17": {
                "ref_id": "b17",
                "title": "Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review",
                "authors": [
                    {
                        "first": "L",
                        "middle": [],
                        "last": "J\u00f8rgensen 2018a J\u00f8rgensen",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "C"
                        ],
                        "last": "G\u00f8tzsche",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Je Erson T ; L",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "C"
                        ],
                        "last": "G\u00f8tzsche",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Je Erson T",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "BMJ Evidence-Based Medicine",
                "volume": "7",
                "issue": "1",
                "pages": "165--168",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF19": {
                "ref_id": "b19",
                "title": "Proof-of-principle evaluation of the e icacy of fewer than three doses of a bivalent HPV16/18 vaccine",
                "authors": [
                    {
                        "first": "A",
                        "middle": [
                            "R"
                        ],
                        "last": "Kreimer",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "C"
                        ],
                        "last": "Rodriguez",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Hildesheim",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Herrero",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Porras",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Schi Man",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "Journal of the National Cancer Institute",
                "volume": "103",
                "issue": "19",
                "pages": "1444--1451",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF21": {
                "ref_id": "b21",
                "title": "E icacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials",
                "authors": [
                    {
                        "first": "A",
                        "middle": [
                            "R"
                        ],
                        "last": "Kreimer",
                        "suffix": ""
                    },
                    {
                        "first": "F",
                        "middle": [],
                        "last": "Struyf",
                        "suffix": ""
                    },
                    {
                        "first": "Del",
                        "middle": [],
                        "last": "Rosario-Raymundo",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "R"
                        ],
                        "last": "Hildesheim",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Skinner",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "R"
                        ],
                        "last": "Wacholder",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "",
                        "suffix": ""
                    }
                ],
                "year": 2015,
                "venue": "Lancet Oncology",
                "volume": "16",
                "issue": "7",
                "pages": "775--786",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF23": {
                "ref_id": "b23",
                "title": "Histological characteristics of human papilloma-virus-positive and-negative invasive and in situ squamous cell tumours of the penis",
                "authors": [
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Krustrup",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [
                            "L"
                        ],
                        "last": "Jensen",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "J"
                        ],
                        "last": "Van Den Brule",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Frisch",
                        "suffix": ""
                    }
                ],
                "year": 2009,
                "venue": "International Journal of Experimental Pathology",
                "volume": "90",
                "issue": "",
                "pages": "182--189",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF25": {
                "ref_id": "b25",
                "title": "Progress in HPV vaccination in lowand lower-middle-income countries",
                "authors": [
                    {
                        "first": "D",
                        "middle": [
                            "S"
                        ],
                        "last": "Lamontagne",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "J"
                        ],
                        "last": "Bloem",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "M"
                        ],
                        "last": "Brotherton",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "E"
                        ],
                        "last": "Gallagher",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [],
                        "last": "Badiane",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Ndiaye",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "International Journal of Gynecology & Obstetrics",
                "volume": "138",
                "issue": "",
                "pages": "7--14",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF27": {
                "ref_id": "b27",
                "title": "Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/ journal editor perspective",
                "authors": [
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Lineberry",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "A"
                        ],
                        "last": "Berlin",
                        "suffix": ""
                    },
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Mansi",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Glasser",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Berkwits",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Klem",
                        "suffix": ""
                    }
                ],
                "year": 2016,
                "venue": "BMJ",
                "volume": "355",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF29": {
                "ref_id": "b29",
                "title": "Industry sponsorship and research outcome",
                "authors": [
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Lundh",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Lexchin",
                        "suffix": ""
                    },
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Mintzes",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "B"
                        ],
                        "last": "Schroll",
                        "suffix": ""
                    },
                    {
                        "first": "L",
                        "middle": [],
                        "last": "Bero",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "",
                "issue": "2",
                "pages": "",
                "other_ids": {
                    "DOI": [
                        "10.1002/14651858.MR000033.pub3"
                    ]
                },
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF31": {
                "ref_id": "b31",
                "title": "Human papillomavirus vaccine e ectiveness by number of doses: systematic review of data from national immunization programs",
                "authors": [
                    {
                        "first": "L",
                        "middle": [
                            "E"
                        ],
                        "last": "Markowitz",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Drolet",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Perez",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Jit",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Brisson",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "Vaccine",
                "volume": "36",
                "issue": "32",
                "pages": "4806--4815",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF33": {
                "ref_id": "b33",
                "title": "Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study",
                "authors": [
                    {
                        "first": "M",
                        "middle": [
                            "R"
                        ],
                        "last": "Mccredie",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [
                            "J"
                        ],
                        "last": "Sharples",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Paul",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Baranyai",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Medley",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "W"
                        ],
                        "last": "Jones",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [
                            "C"
                        ],
                        "last": "Skegg",
                        "suffix": ""
                    }
                ],
                "year": 2008,
                "venue": "Lancet Oncology",
                "volume": "9",
                "issue": "5",
                "pages": "425--434",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF35": {
                "ref_id": "b35",
                "title": "E icacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Paavonen",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Jenkins",
                        "suffix": ""
                    },
                    {
                        "first": "F",
                        "middle": [
                            "X"
                        ],
                        "last": "Bosch",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Naud",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Salmer\u00f3n",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [
                            "M"
                        ],
                        "last": "Wheeler",
                        "suffix": ""
                    }
                ],
                "year": 2007,
                "venue": "Lancet",
                "volume": "369",
                "issue": "",
                "pages": "2161--2170",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF36": {
                "ref_id": "b36",
                "title": "Informed decisions. Better health. Cochrane Database of Systematic Reviews trials: extension of the CONSORT 2010 statement",
                "authors": [
                    {
                        "first": "Cochrane",
                        "middle": [],
                        "last": "Library",
                        "suffix": ""
                    },
                    {
                        "first": "Trusted",
                        "middle": [],
                        "last": "Evidence",
                        "suffix": ""
                    }
                ],
                "year": 2012,
                "venue": "JAMA",
                "volume": "308",
                "issue": "",
                "pages": "2594--2604",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF38": {
                "ref_id": "b38",
                "title": "Immunogenicity and HPV infection a er one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study",
                "authors": [
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Sankaranarayanan",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [
                            "R"
                        ],
                        "last": "Prabhu",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [],
                        "last": "Pawlita",
                        "suffix": ""
                    },
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Gheit",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Bhatla",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Muwonge",
                        "suffix": ""
                    }
                ],
                "year": 2016,
                "venue": "Lancet Oncology",
                "volume": "17",
                "issue": "1",
                "pages": "67--77",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF40": {
                "ref_id": "b40",
                "title": "Explanations for the high potency of HPV prophylactic vaccines",
                "authors": [
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Schiller",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Lowy",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "Vaccine",
                "volume": "36",
                "issue": "32",
                "pages": "4768--4773",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF42": {
                "ref_id": "b42",
                "title": "HPV and anal cancer in HIV-infected individuals: a review",
                "authors": [
                    {
                        "first": "M",
                        "middle": [
                            "F"
                        ],
                        "last": "Schim Van Der Loe",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "H"
                        ],
                        "last": "Mooij",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [],
                        "last": "Richel",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [
                            "J"
                        ],
                        "last": "De Vries",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "M"
                        ],
                        "last": "Prins",
                        "suffix": ""
                    }
                ],
                "year": 2014,
                "venue": "Current HIV/AIDS Reports",
                "volume": "11",
                "issue": "3",
                "pages": "250--262",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF44": {
                "ref_id": "b44",
                "title": "The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials",
                "authors": [
                    {
                        "first": "T",
                        "middle": [],
                        "last": "Sharma",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "G\u00f8tzsche",
                        "suffix": ""
                    },
                    {
                        "first": "O",
                        "middle": [],
                        "last": "Kuss",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "Journal of Clinical Epidemiology",
                "volume": "91",
                "issue": "",
                "pages": "129--136",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF46": {
                "ref_id": "b46",
                "title": "The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia",
                "authors": [
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Smith",
                        "suffix": ""
                    },
                    {
                        "first": "J-B",
                        "middle": [],
                        "last": "Lew",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [
                            "J"
                        ],
                        "last": "Walker",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "M"
                        ],
                        "last": "Brotherton",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Nickson",
                        "suffix": ""
                    },
                    {
                        "first": "K",
                        "middle": [],
                        "last": "Canfell",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "Vaccine",
                "volume": "29",
                "issue": "",
                "pages": "9112--9122",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF47": {
                "ref_id": "b47",
                "title": "Human papillomavirus vaccines",
                "authors": [
                    {
                        "first": ";",
                        "middle": [],
                        "last": "Stanley",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Stanley",
                        "suffix": ""
                    }
                ],
                "year": 2006,
                "venue": "Reviews in Medical Virology",
                "volume": "16",
                "issue": "",
                "pages": "139--149",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF49": {
                "ref_id": "b49",
                "title": "Alternative dosage schedules with HPV virus-like particle vaccines",
                "authors": [
                    {
                        "first": "M",
                        "middle": [
                            "A"
                        ],
                        "last": "Stanley",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [
                            "L"
                        ],
                        "last": "Sudenga",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "R"
                        ],
                        "last": "Giuliano",
                        "suffix": ""
                    }
                ],
                "year": 2013,
                "venue": "Expert Review of Vaccines",
                "volume": "13",
                "issue": "",
                "pages": "1027--1038",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF50": {
                "ref_id": "b50",
                "title": "Human papillomavirus typing in reporting of Condyloma",
                "authors": [
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Sturegard",
                        "suffix": ""
                    },
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Johansson",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Ekstr\u00f6m",
                        "suffix": ""
                    },
                    {
                        "first": "B-G",
                        "middle": [],
                        "last": "Hansson",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [],
                        "last": "Johnsson",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Gustafsson",
                        "suffix": ""
                    }
                ],
                "year": 2013,
                "venue": "Sexually Transmitted Diseases",
                "volume": "40",
                "issue": "",
                "pages": "123--129",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF52": {
                "ref_id": "b52",
                "title": "The role of human papillomavirus infection in head and neck cancers",
                "authors": [
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Syrj\u00e4nen",
                        "suffix": ""
                    }
                ],
                "year": 2010,
                "venue": "Annals of Oncology",
                "volume": "21",
                "issue": "",
                "pages": "243--245",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF54": {
                "ref_id": "b54",
                "title": "External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents",
                "authors": [
                    {
                        "first": "E",
                        "middle": [],
                        "last": "Vardas",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "R"
                        ],
                        "last": "Giuliano",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Goldstone",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [
                            "M"
                        ],
                        "last": "Palefsky",
                        "suffix": ""
                    },
                    {
                        "first": "E",
                        "middle": [
                            "D"
                        ],
                        "last": "Moreira",
                        "suffix": ""
                    },
                    {
                        "first": "",
                        "middle": [],
                        "last": "Jr",
                        "suffix": ""
                    },
                    {
                        "first": "M",
                        "middle": [
                            "E"
                        ],
                        "last": "Penny",
                        "suffix": ""
                    }
                ],
                "year": 2011,
                "venue": "Journal of Infectious Diseases",
                "volume": "203",
                "issue": "1",
                "pages": "58--65",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF56": {
                "ref_id": "b56",
                "title": "Interventions to improve HPV vaccine uptake: a systematic review",
                "authors": [
                    {
                        "first": "E",
                        "middle": [
                            "B"
                        ],
                        "last": "Walling",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Benzoni",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Dornfeld",
                        "suffix": ""
                    },
                    {
                        "first": "R",
                        "middle": [],
                        "last": "Bhandari",
                        "suffix": ""
                    },
                    {
                        "first": "B",
                        "middle": [
                            "A"
                        ],
                        "last": "Sisk",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Garbutt",
                        "suffix": ""
                    }
                ],
                "year": 2016,
                "venue": "Pediatrics",
                "volume": "138",
                "issue": "1",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF57": {
                "ref_id": "b57",
                "title": "WHO 2017 World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017",
                "authors": [],
                "year": 2017,
                "venue": "Weekly Epidemiological Record",
                "volume": "92",
                "issue": "",
                "pages": "241--268",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF58": {
                "ref_id": "b58",
                "title": "Protocol for an update of a systematic review and meta-analysis of the immunogenicity and e icacy of HPV vaccines in females and males aged 9-26 years. osf.io/qchzb",
                "authors": [
                    {
                        "first": "H",
                        "middle": [],
                        "last": "Bergman",
                        "suffix": ""
                    },
                    {
                        "first": "N",
                        "middle": [],
                        "last": "Henschke",
                        "suffix": ""
                    },
                    {
                        "first": "B",
                        "middle": [],
                        "last": "Buckley",
                        "suffix": ""
                    },
                    {
                        "first": "G",
                        "middle": [],
                        "last": "Villanueva",
                        "suffix": ""
                    },
                    {
                        "first": "J",
                        "middle": [],
                        "last": "Petkovic",
                        "suffix": ""
                    },
                    {
                        "first": "C",
                        "middle": [],
                        "last": "Garritty",
                        "suffix": ""
                    }
                ],
                "year": 2018,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF59": {
                "ref_id": "b59",
                "title": "Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis",
                "authors": [
                    {
                        "first": "M",
                        "middle": [],
                        "last": "D'addario ; D'addario",
                        "suffix": ""
                    },
                    {
                        "first": "S",
                        "middle": [],
                        "last": "Redmond",
                        "suffix": ""
                    },
                    {
                        "first": "P",
                        "middle": [],
                        "last": "Scott",
                        "suffix": ""
                    },
                    {
                        "first": "D",
                        "middle": [],
                        "last": "Egli-Gany",
                        "suffix": ""
                    },
                    {
                        "first": "Riveros-Balta",
                        "middle": [],
                        "last": "Ax",
                        "suffix": ""
                    },
                    {
                        "first": "A",
                        "middle": [
                            "M"
                        ],
                        "last": "Restrepo",
                        "suffix": ""
                    }
                ],
                "year": 2017,
                "venue": "Vaccine",
                "volume": "35",
                "issue": "",
                "pages": "2892--2901",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF60": {
                "ref_id": "b60",
                "title": "Ovid MEDLINE search strategy 1. exp Papillomavirus Infections/ 2. exp PAPILLOMAVIRIDAE/ 3. (human papilloma virus or human papillomavirus).tw. 4. 1 or 2 or 3",
                "authors": [
                    {
                        "first": "A",
                        "middle": [],
                        "last": "P P E N D I C E S Appendix 1",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF61": {
                "ref_id": "b61",
                "title": "exp Immunization/ 6. (vaccin* or immuni*).tw. . 5 or 6 8",
                "authors": [],
                "year": null,
                "venue": "Papillomavirus Vaccines/ 10. (human papilloma virus adj (vaccin* or immuni*))",
                "volume": "",
                "issue": "",
                "pages": "4--7",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF62": {
                "ref_id": "b62",
                "title": "human papillomavirus adj (vaccin* or immuni*))",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF63": {
                "ref_id": "b63",
                "title": "HPV vaccin",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF64": {
                "ref_id": "b64",
                "title": "cervarix or gardasil)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "14",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF65": {
                "ref_id": "b65",
                "title": "Comparison of di erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review) Copyright \u00a9 2019 The Authors",
                "authors": [],
                "year": null,
                "venue": "Cochrane Database of Systematic Reviews",
                "volume": "15",
                "issue": "8 or 14 16",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF66": {
                "ref_id": "b66",
                "title": "randomised controlled trial.pt. 17. controlled clinical trial.pt. 18. randomized.ab. 19. placebo.ab. 20. clinical trials as topic.sh. 21. randomly.ab. 22. trial",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "23",
                "issue": "",
                "pages": "22--24",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF67": {
                "ref_id": "b67",
                "title": "Ovid Embase search strategy 1. exp papillomavirus infection/ 2. exp Papillomaviridae/ 3. (human papilloma virus or human papillomavirus).tw. 4. 1 or 2 or 3",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "23--24",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF68": {
                "ref_id": "b68",
                "title": "exp immunization/ 6. (vaccin* or immuni*).tw",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "5",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF69": {
                "ref_id": "b69",
                "title": "Wart virus vaccine/ 10. (human papilloma virus adj (vaccin* or immuni*))",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF70": {
                "ref_id": "b70",
                "title": "human papillomavirus adj (vaccin* or immuni*))",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF71": {
                "ref_id": "b71",
                "title": "HPV vaccin*.tw. 13. (cervarix or gardasil)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "14",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF72": {
                "ref_id": "b72",
                "title": "crossover* or cross over* or cross-over*)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            }
        },
        "ref_entries": {
            "FIGREF1": {
                "text": "Figure 1.Study flow diagram.",
                "fig_num": "12",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF2": {
                "text": "identified seven RCTs that examined HPV vaccines in 1723 people living with HIV (Denny 2013; Hidalgo-Tenorio 2017; Levin 2010; NCT00941889 2016; NCT01031069 2017; To 2014; Wilkin 2018): \u2022 To 2014 compared bivalent with quadrivalent vaccine in females and males \u2265 18-years old; \u2022 NCT01031069 2017 compared bivalent with quadrivalent vaccine in 15-to 25-year-old females; \u2022 Denny 2013 compared bivalent vaccine with control in women aged 18 to 25 years; \u2022 Hidalgo-Tenorio 2017 compared quadrivalent vaccine with control in MSM \u2265 18-years old; \u2022 Wilkin 2018 compared quadrivalent vaccine with control in females and males \u2265 27-years old; \u2022 NCT00941889 2016 compared quadrivalent vaccine with control in females and males \u2265 18-years old that had been treated for anogenital warts; \u2022 Levin 2010 compared three doses of quadrivalent vaccine with control in 126 children aged 7 to 12 years, and four versus three doses of quadrivalent vaccine in the same participants.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF3": {
                "text": "erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review) Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF4": {
                "text": "males (111 to the alternate schedule and 109 to the standard schedule) recruited from the USA Age range: 18-25 years old Inclusion criteria: males 18-25 years with 4 or fewer lifetime sexual partners Interventions Vaccine 1: standard schedule quadrivalent HPV vaccine; 3 doses at 0, 2, and 6 months Vaccine 2: alternate schedule quadrivalent HPV vaccine; 3 doses at 0, 2 and 12 months Outcomes Harms: compliance with third dose, adverse events Immunogenicity: GMT Notes Other groups: N/A Last report average follow-up time: month 7 or 13 (depending on group) Funding: the authors and this work were supported in part by a research grant from the Investigator-Initiated Studies Program of Merck & Co, Inc, manufacturer of Gardasil\u00ae quadrivalent human papilwere randomised as they were scheduled for the initial visit using a simple random number sequence to determine the order of assignment into the Standard schedule or the Alternate schedule\" of 220 participants enrolled, 204 completed the study\" Reasons for withdrawal and protocol violation fully reported.Results for both ITT and per protocol populations reported.HIV-positive males and females with anal warts (15 to the vaccine group and 17 to the control group) recruited from the USA Age range: 18 to 65 years old Inclusion criteria: HIV positive, \u2265 18 years of age, CD4 > 200 and viral RNA < 400 on HAART or CD4 > 350 if not on HARRT, presence of anal warts that required surgical excision or ablation Interventions Vaccine: quadrivalent HPV vaccine; 3 doses at 0, 2, and 6 months Control: saline placebo; 3 doses at 0, 2 and 6 months Outcomes Clinical: persistence and recurrence of anal warts Notes Other groups: N/A Last report average follow-up time: month 18 Funding: Washington University School of Medicine Trial ID: NCT00941889",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF5": {
                "text": "erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review) Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.observer-blind, randomised, controlled, multi-centric study Participants Participants: 649 HIV seropositive and seronegative females aged 15-25 years (331 to the bivalent vaccine group and 330 to the quadrivalent vaccine group) recruited from Brazil, Estonia, India, and Thailand Age range: 15-25 years Inclusion criteria: female 15-25 years old, HIV voluntary counselling and testing Interventions Vaccine 1: bivalent HPV vaccine; 3 doses at day 0, week 6, and month 6Vaccine 2: quadrivalent HPV vaccine; 3 doses at day 0, week 6",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF6": {
                "text": "HPV vaccine compared with control in 18-to 25-year-old females with HIV Patient or population: 18-to 25-year-old females with HIV Settings: South Africa Intervention: bivalent HPV vaccine (3 doses at 0, 1, and 6 months) Comparison: control (vaccine adjuvant-containing placebo) (3 doses at 0, 1 and 6 months)",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF7": {
                "text": "infected males and females Ratio of GMTs (IV, random-effects, 95% CI) Ratio of GMTs 0.79 (0.25 to 2.52) \u2295\u2295\u229d\u229d LOW 3 (Continued) Comparison of di erent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males (Review) Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "TABREF1": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td/><td/><td/><td>site) are presented in the analysis</td></tr><tr><td/><td/><td/><td/><td/><td/><td>section.</td></tr><tr><td>Overall systemic events and</td><td>248 per 1000</td><td>245 per 1000</td><td>RR 0.99</td><td>5008</td><td>\u2295\u2295\u2295\u229d</td><td/></tr><tr><td>general symptoms</td><td/><td>(223 to 268)</td><td>(0.90 to 1.08)</td><td>(2 RCTs)</td><td>MODERATE 4</td><td/></tr><tr><td>at 15-day follow-up</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>Control:</td><td>Bivalent vaccine: 17</td><td>OR 1.48 (0.15 to</td><td>270</td><td>\u2295\u229d\u229d\u229d</td><td/></tr><tr><td/><td>11 per 1000</td><td>per 1000 (2 to 141)</td><td>14.46)</td><td>(1 RCT)</td><td>VERY LOW 2,4</td><td/></tr><tr><td/><td/><td/><td>Relative effect</td><td>\u2116 of partici-</td><td>Certainty of</td><td>Comments</td></tr><tr><td/><td/><td/><td>(95% CI)</td><td>pants</td><td>the evidence</td><td/></tr><tr><td/><td/><td/><td/><td>(studies)</td><td>(GRADE)</td><td/></tr><tr><td>Invasive anal or penile can-</td><td colspan=\"3\">No studies were identified that reported on this outcome</td><td/><td/><td/></tr><tr><td>cer</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Penile or anal intraepithelial</td><td>3/2824 per-</td><td>0/2833 person-years</td><td>Rate ratio 0.17</td><td>2805 partic-</td><td>\u2295\u2295\u229d\u229d</td><td/></tr><tr><td>neoplasia</td><td>son-years</td><td/><td>(0.01 to 3.27)</td><td>ipants (5657</td><td>LOW 2</td><td/></tr><tr><td>at up to 3-year follow-up</td><td/><td/><td/><td>person-years)</td><td/><td/></tr><tr><td/><td/><td/><td/><td>(1 RCT)</td><td/><td/></tr><tr><td>External genital lesions (any</td><td>36/3081 per-</td><td>6/3173 person-years</td><td>Rate ratio 0.16</td><td>2545 partic-</td><td>\u2295\u2295\u2295\u229d</td><td/></tr><tr><td>genotype)</td><td>son-years</td><td/><td>(0.07 to 0.38)</td><td>ipants (6254</td><td>MODERATE 1</td><td/></tr><tr><td>at up to 3-year follow-up</td><td/><td/><td/><td>person-years)</td><td/><td/></tr><tr><td/><td/><td/><td/><td>(1 RCT)</td><td/><td/></tr><tr><td>Anogenital warts</td><td>28/2814 per-</td><td>3/2831 person-years</td><td>Rate ratio 0.11</td><td>2805 partic-</td><td>\u2295\u2295\u2295\u229d</td><td/></tr><tr><td>at up to 3-year follow-up</td><td>son-years</td><td/><td>(0.03 to 0.38)</td><td>person-years) ipants (5645</td><td>MODERATE 1</td><td/></tr><tr><td/><td/><td/><td/><td>(1 RCT)</td><td/><td/></tr><tr><td>Overall local/injection site</td><td>537 per 1000</td><td>601 per 1000</td><td>RR 1.12</td><td>3895</td><td>\u2295\u2295\u2295\u2295</td><td>Data for specific local adverse events</td></tr><tr><td>adverse events</td><td/><td>(569 to 634)</td><td>(1.06 to 1.18)</td><td>(1 RCT)</td><td>HIGH 3</td><td>(pain, swelling, redness at injection</td></tr><tr><td>at 15-day follow-up</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF2": {
                "text": "Please see Table1for list of events in each RCT.",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">at 15-day follow-up Trusted evidence. Cochrane Informed decisions. Library Better health.</td><td/><td/><td/><td/><td/></tr><tr><td>Serious adverse events</td><td>25 per 1000</td><td>15 per 1000</td><td>OR 0.60</td><td>15,863</td><td>\u2295\u2295\u229d\u229d</td><td/></tr><tr><td>at up to 4.5-year fol-low-up</td><td/><td>(4 to 63)</td><td>(0.14 to 2.61)</td><td>(3 RCTs)</td><td>LOW 2,3</td><td>Numbers of events/number of participants (%) were: in 16-to 26-year-old females receiving nonavalent vaccine, 242/7686 (3.1%) vs quadri-</td></tr><tr><td/><td/><td/><td/><td/><td/><td>valent vaccine, 184/7078 (2.6%) over a peri-</td></tr><tr><td/><td/><td/><td/><td/><td/><td>od of 4.5 years follow-up; in 16-to 26-year-old</td></tr><tr><td/><td/><td/><td/><td/><td/><td>males receiving nonavalent vaccine, 0/249 (0%)</td></tr><tr><td/><td/><td/><td/><td/><td/><td>vs quadrivalent vaccine, 6/251 (2.4%) over 7</td></tr><tr><td/><td/><td/><td/><td/><td/><td>months follow-up; in 9-to 15-year-old females</td></tr><tr><td/><td/><td/><td/><td/><td/><td>receiving nonavalent vaccine, 1/299 (0.3%)</td></tr><tr><td/><td/><td/><td/><td/><td/><td>vs quadrivalent vaccine, 2/300 (0.7%) over 7</td></tr><tr><td/><td/><td/><td/><td/><td/><td>months follow-up.</td></tr><tr><td>Mortality</td><td>1 per 1000</td><td>1 per 1000</td><td>OR 1.20</td><td>15,248</td><td/><td/></tr><tr><td>low-up at up to 4.5-year fol-</td><td/><td>(0 to 3)</td><td>Relative effect (95% CI) (0.37 to 3.94)</td><td>\u2116 of partici-pants (3 RCTs)</td><td>Certainty of the evidence</td><td>Comments</td></tr><tr><td/><td/><td/><td/><td>(studies)</td><td>(GRADE)</td><td/></tr><tr><td>High-grade cervical in-</td><td>47 per 1000</td><td>47 per 1000</td><td>OR 1.00</td><td>13,753</td><td>\u2295\u2295\u2295\u2295</td><td>No studies were identified which reported on</td></tr><tr><td>traepithelial neoplasia,</td><td/><td>(41 to 55)</td><td>(0.85 to 1.16)</td><td>(1 RCT)</td><td>HIGH 1</td><td>invasive anal or penile cancer in males</td></tr><tr><td>adenocarcinoma in situ,</td><td/><td/><td/><td/><td/><td/></tr><tr><td>and cervical cancer</td><td/><td/><td/><td/><td/><td/></tr><tr><td>at up to 4.5-year fol-</td><td/><td/><td/><td/><td/><td/></tr><tr><td>low-up</td><td/><td/><td/><td/><td/><td/></tr><tr><td>High-grade cervical, vul-</td><td>49 per 1000</td><td>48 per 1000</td><td>OR 0.99</td><td>14,054</td><td>\u2295\u2295\u2295\u2295</td><td>No studies were identified which reported on</td></tr><tr><td>val, and vaginal disease</td><td/><td>(42 to 56)</td><td>(0.85 to 1.15)</td><td>(1 RCT)</td><td>HIGH 1</td><td>penile or anal intraepithelial neoplasia in males</td></tr><tr><td>at up to 4.5-year fol-</td><td/><td/><td/><td/><td/><td/></tr><tr><td>low-up</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Overall local/injection</td><td>846 per 1000</td><td>905 per 1000</td><td>RR 1.07</td><td>15,863</td><td>\u2295\u2295\u2295\u2295</td><td>Data for specific local adverse events (pain,</td></tr><tr><td>site adverse events</td><td/><td>(888 to 914)</td><td>(1.05 to 1.08)</td><td>(3 RCTs)</td><td>HIGH</td><td>swelling, redness at injection site) are present-</td></tr><tr><td>at 15-day follow-up</td><td/><td/><td/><td/><td/><td>ed in the analysis section.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF3": {
                "text": "This review was initially commissioned in 2016 by the WHO Initiative for Vaccine Research to update the evidence for the twodose recommendation and is an update of D'Addario 2017.We produced a revised protocol for this update(Bergman 2017).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">2017; WHO 2017). As of 30 December 2017, 80 countries had</td><td/></tr><tr><td colspan=\"2\">fully introduced HPV vaccination and four countries had partially</td><td/></tr><tr><td colspan=\"2\">introduced HPV vaccination into their national immunisation</td><td/></tr><tr><td colspan=\"2\">programmes, with 65 countries having implemented a two-dose</td><td/></tr><tr><td colspan=\"2\">schedule in girls 9 to 14 years old (www.who.int/immunization/</td><td/></tr><tr><td colspan=\"2\">monitoring_surveillance/data/en).</td><td/></tr><tr><td colspan=\"2\">In 2018, a Cochrane Review concluded that the licensed three-dose</td><td/></tr><tr><td colspan=\"2\">schedules of the bivalent and quadrivalent HPV vaccines result</td><td/></tr><tr><td colspan=\"2\">in limited adverse events and are e ective against precancerous</td><td/></tr><tr><td colspan=\"2\">cervical lesions in females (Arbyn 2018). Since the 2014 WHO</td><td/></tr><tr><td colspan=\"2\">recommendation and original systematic review of two-dose HPV</td><td/></tr><tr><td colspan=\"2\">vaccination schedules (D'Addario 2017; WHO 2017), the evidence</td><td/></tr><tr><td colspan=\"2\">base from RCTs about alternative vaccination schedules has</td><td/></tr><tr><td colspan=\"2\">expanded to include more data about the nonavalent HPV vaccine</td><td/></tr><tr><td colspan=\"2\">(Iversen 2016), about HPV vaccination in males, including MSM</td><td/></tr><tr><td colspan=\"2\">(Giuliano 2011), and amongst people living with HIV infection (To</td><td/></tr><tr><td>2014).</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF4": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>\u2022 In females, histologically-confirmed high-grade cervical (CIN2,</td></tr><tr><td>CIN3, and adenocarcinoma in situ), vaginal, vulval, or anal</td></tr><tr><td>intraepithelial neoplasia, irrespective of HPV genotype, or any</td></tr><tr><td>lesions associated with the HPV genotypes included in the</td></tr><tr><td>vaccine</td></tr><tr><td>\u2022 In males, histologically-confirmed anal, or penile, perianal or</td></tr><tr><td>perineal intraepithelial neoplasia of any grade, irrespective of</td></tr><tr><td>HPV genotype, or any lesions associated with the HPV genotypes</td></tr><tr><td>included in the vaccine</td></tr><tr><td>\u2022 Anogenital warts</td></tr></table>",
                "type_str": "table"
            },
            "TABREF7": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>high risk of performance bias due to no, or partial blinding, of</td></tr><tr><td>participants, personnel, or both (Dobson 2013; Lehtinen 2018;</td></tr><tr><td>Puthanakit 2016; Iversen 2016; Lin 2014).</td></tr><tr><td>Less than half of the studies reported adequate blinding of outcome</td></tr><tr><td>assessors (9/20 = 45%); we considered those that did to be at</td></tr><tr><td>low risk of detection bias. Eight studies did not report details</td></tr><tr><td>regarding blinding of outcome assessment and we assessed them</td></tr><tr><td>as being at unclear risk of bias (Denny 2013; Hidalgo-Tenorio</td></tr><tr><td>2017; Levin 2010; Lin 2014; NCT01031069 2017; NCT00941889 2016;</td></tr><tr><td>NCT01862874 2018; Wilkin 2018), and three studies did not blind</td></tr><tr><td>outcome assessment and were assessed as being at high risk of</td></tr><tr><td>detection bias (Iversen 2016; Lehtinen 2018; Puthanakit 2016).</td></tr><tr><td>Five studies did not report their methods to conceal</td></tr><tr><td>allocation adequately (Levin 2010; Lin 2014; NCT01031069 2017;</td></tr><tr><td>NCT00941889 2016; NCT01862874 2018), and five did not report</td></tr><tr><td>the method of sequence generation adequately (Levin 2010;</td></tr><tr><td>NCT01031069 2017; NCT00941889 2016; NCT01862874 2018; Wilkin</td></tr><tr><td>2018); we assessed them as being at unclear risk of bias.</td></tr><tr><td>Blinding</td></tr><tr><td>Blinding of participants and providers was explicitly reported by</td></tr><tr><td>less than half of the included studies (7/20 = 35%), we assessed</td></tr><tr><td>those studies that did as being at low risk of performance bias.</td></tr><tr><td>We assessed eight studies as being at unclear risk of performance</td></tr><tr><td>bias as they did not report blinding status of participants</td></tr><tr><td>and personnel clearly (Denny 2013; Hidalgo-Tenorio 2017; Levin</td></tr><tr><td>2010; NCT00941889 2016; NCT01031069 2017; NCT01862874 2018;</td></tr><tr><td>Romanowski 2011; Wilkin 2018), and five studies as being at</td></tr></table>",
                "type_str": "table"
            },
            "TABREF9": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Two studies compared quadrivalent HPV vaccine</td></tr><tr><td>with control (vaccine adjuvant only) (three doses administered</td></tr><tr><td>at months 0, 2, and 6) in males (Giuliano 2011, NCT01862874</td></tr><tr><td>2018), and two studies compared bivalent vaccine with HBV</td></tr><tr><td>vaccine (Lehtinen 2018; Petaja 2009). Lehtinen 2018, a cluster-</td></tr><tr><td>randomised trial, was designed to investigate direct and indirect</td></tr><tr><td>e ects of vaccinating boys and girls (gender-neutral) compared</td></tr><tr><td>with girls-only HPV vaccination. They reported that gender-neutral</td></tr><tr><td>vaccination was associated with herd e ects and cross-protection</td></tr><tr><td>against a number of non-vaccine HPV types. Clinical outcomes in</td></tr><tr><td>girls are presented in another Cochrane Review (Arbyn 2018), which</td></tr><tr><td>covers comparison of bivalent and quadrivalent HPV vaccine with a</td></tr><tr><td>control HBV vaccine in females; no clinical outcomes in boys were</td></tr><tr><td>reported.</td></tr><tr><td>One study reported clinical outcomes at a median of 2.9 years</td></tr><tr><td>(Giuliano 2011). There were fewer outcomes of external genital</td></tr><tr><td>lesions (any genotype) (rate ratio 0.16, 95% CI 0.07 to 0.38; 1</td></tr><tr><td>study; 2545 participants; 6254 person-years; moderate-certainty</td></tr><tr><td>evidence; Analysis 4.1), external genital lesions (HPV 6, 11, 16, 18)</td></tr><tr><td>(rate ratio 0.10, 95% CI 0.03 to 0.31; 1 study; 2805 participants; 5643</td></tr><tr><td>person-years; Analysis 4.2), and anogenital warts (rate ratio 0.11,</td></tr><tr><td>95% CI 0.03 to 0.38; 1 study; 2805 participants; 5645 person-years;</td></tr><tr><td>moderate-certainty evidence; Analysis 4.3) with the quadrivalent</td></tr><tr><td>HPV vaccine than the control, in both intention-to-treat and per-</td></tr><tr><td>protocol analyses (per-protocol analyses not shown). There was</td></tr><tr><td>evidence in favour of quadrivalent HPV vaccine for the outcomes</td></tr><tr><td>of all penile, perianal, or perineal intraepithelial neoplasia (PIN)</td></tr><tr><td>lesions (rate ratio 0.17, 95% CI 0.01 to 3.27; 1 study; 2805</td></tr><tr><td>participants; 5657 person-years; Analysis 4.4), PIN grade 1 (rate</td></tr><tr><td>ratio 0.25, 95% CI 0.01 to 6.22; 1 study; 2805 participants; 5659</td></tr><tr><td>person-years; Analysis 4.5), or PIN grade 2 or 3 (rate ratio 0.50,</td></tr><tr><td>95% CI 0.02 to 14.80; 1 study; 2805 participants; 5658 person-years;</td></tr></table>",
                "type_str": "table"
            },
            "TABREF11": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>four in the nonavalent group (allergic reaction; fever, body pain,</td><td/></tr><tr><td>and headache; hypersomnia; postural orthostatic tachycardia</td><td/></tr><tr><td>syndrome) and three in the quadrivalent group (headache;</td><td/></tr><tr><td>paraesthesia and burning sensation; orthostatic intolerance).</td><td/></tr><tr><td>Thirteen participants who received nonavalent vaccine and six who</td><td/></tr><tr><td>received quadrivalent vaccine discontinued participation because</td><td/></tr><tr><td>of adverse events. There was little to no di erence in the number</td><td/></tr><tr><td>of deaths between nonavalent (6/7370) and quadrivalent (5/7378)</td><td/></tr><tr><td>HPV vaccine groups (OR 1.20, 95% CI 0.37 to 3.94; 2 studies; 15,248</td><td/></tr><tr><td>participants; low-certainty evidence; Analysis 5.17) at up to 4.5</td><td/></tr><tr><td>years follow-up. The study investigators considered none of the</td><td/></tr><tr><td>deaths reported to be related to the vaccine.</td><td/></tr><tr><td>Secondary outcomes (persistent infection and immunogenicity)</td><td/></tr><tr><td>are presented in Appendix 11 and Appendix 12. Briefly, there was</td><td/></tr><tr><td>evidence of decreased rates of persistent infection with HPV 31,</td><td/></tr><tr><td>33, 45, 52, and 58 at six and 12 months with nonavalent vaccine</td><td/></tr><tr><td>compared with quadrivalent vaccine (Joura 2015). There was little</td><td/></tr><tr><td>to no di erence in immunogenicity between the nonavalent and</td><td/></tr><tr><td>quadrivalent HPV vaccines and GMTs were non-inferior for HPV 6,</td><td/></tr><tr><td>11, 16, and 18 at up to 42 months. The nonavalent HPV vaccine resulted in substantially higher GMTs for HPV 31, 33, 45, 52, and 58 than the quadrivalent HPV vaccine. For seroconversion to HPV 6, 11, 16, and 18 up to 24 months follow-up, 100% of participants seroconverted in both the nonavalent and quadrivalent HPV vaccine groups. The data for GMTs and seroconversion to HPV 31, 33, 45, 52, and 58 were not reported in full (Joura 2015; Vesikari 2015).</td><td>females there was little to no di erence between nonavalent and quadrivalent HPV vaccines in the incidence of the combined outcome of high-grade cervical epithelial neoplasia, adenocarcinoma in situ, or cervical cancer (OR 1.00, 95% CI 0.85 to 1.16; 1 study; 13,753 participants; high-certainty evidence; Analysis 5.1), or high-grade cervical, vulval, or vaginal disease (OR 0.99, 95% CI 0.85 to 1.15; 1 study; 14,054 participants; high-certainty evidence; Analysis 5.2) at up to 4.5 years follow-up. For high grade cervical</td></tr><tr><td>6.</td><td>disease related to HPV 31, 33, 45, 52, or 58 (i.e. genotypes covered by the nonavalent vaccine but not the quadrivalent vaccine), the</td></tr><tr><td/><td>e ect was in favour of the nonavalent vaccine (OR 0.03, 95% CI 0.00</td></tr><tr><td/><td>to 0.21; 1 study; 11,892 participants; Analysis 5.5), but few cases</td></tr><tr><td/><td>were reported (1/5949 women in the nonavalent vaccine group and</td></tr><tr><td/><td>35/5943 women in the quadrivalent vaccine group).</td></tr><tr><td/><td>Nonavalent HPV vaccine resulted in slightly more local/injection</td></tr><tr><td/><td>site adverse events than the quadrivalent vaccine (RR 1.07, 95%</td></tr><tr><td/><td>CI 1.05 to 1.08; 3 studies; 15,863 participants; high-certainty</td></tr><tr><td/><td>evidence; Analysis 5.11). There was little to no di erence between</td></tr><tr><td/><td>the vaccines for overall systemic events and general symptoms</td></tr><tr><td/><td>at 15-day follow-up (RR 1.01, 95% CI 0.98 to 1.04; 3 studies;</td></tr><tr><td/><td>15,863 participants; moderate-certainty evidence, Analysis 5.15).</td></tr><tr><td/><td>For serious adverse events overall, the evidence was considered</td></tr><tr><td/><td>to be of low-certainty due to imprecision and indirectness (OR</td></tr><tr><td/><td>0.60, 95% CI 0.14 to 2.61; 3 studies; 15,863 participants; I 2 =</td></tr><tr><td/><td>51%; Analysis 5.16). One study reported similar numbers of events</td></tr><tr><td/><td>(1/299 with the nonavalent vaccine, 2/300 with the quadrivalent</td></tr><tr><td/><td>vaccine) in females aged 9 to 15 years over a period of 7 months</td></tr><tr><td/><td>follow-up (Vesikari 2015). In males, there were no events in 249</td></tr><tr><td/><td>participants receiving the nonavalent vaccine and 6/251 with the</td></tr><tr><td/><td>quadrivalent vaccine over a period of 7 months follow-up (van</td></tr><tr><td/><td>Damme 2016). In the largest study, in 16-to 26-year-old females,</td></tr><tr><td/><td>3.1% (242/7686) of those who received the nonavalent vaccine</td></tr><tr><td/><td>and 2.6% (184/7078) of those who received the quadrivalent</td></tr><tr><td/><td>vaccine experienced any serious adverse event a er up to 4.5</td></tr><tr><td/><td>years of follow-up (Joura 2015). No serious adverse events,</td></tr><tr><td/><td>when analysed by system organ class, were more common</td></tr><tr><td/><td>with the nonavalent than with the quadrivalent vaccine. The</td></tr><tr><td/><td>study authors examined 2269 pregnancy-related events in 2321</td></tr><tr><td/><td>women and found no di erences between the nonavalent and</td></tr><tr><td/><td>quadrivalent vaccine arms. The study investigators considered</td></tr><tr><td/><td>seven serious adverse events to be related to the vaccines,</td></tr></table>",
                "type_str": "table"
            },
            "TABREF12": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Seven RCTs reported on the e ects of bivalent and quadrivalent</td></tr><tr><td>HPV vaccines in females, males, or children living with HIV</td></tr><tr><td>(Denny 2013; Hidalgo-Tenorio 2017; Levin 2010; NCT00941889 2016;</td></tr><tr><td>NCT01031069 2017; To 2014; Wilkin 2018). Two of the studies</td></tr><tr><td>collected data about clinical outcomes such as anal intraepithelial</td></tr><tr><td>neoplasia, anogenital warts or persistent infection (NCT00941889</td></tr><tr><td>2016; Wilkin 2018). These results are summarised in Table 3; Table</td></tr><tr><td>4; and</td></tr></table>",
                "type_str": "table"
            },
            "TABREF13": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF17": {
                "text": "Simon Beddows, Jesse Berlin, Maggie Cruickshank, Nicole Fusco, Henry Kitchener, Yoon Loke and Mary Lunnen.Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE.Inconclusive evidence for non-inferior immunogenicity of two-compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis.Journal of Infection 2015;71:61-73.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">REFERENCES 9-valent HPV L1 virus-like particle vaccine in 16-26 year old only vaccination against human papillomavirus -results of a papillomavirus vaccination among college age males. Vaccine 9-14 year old females. clinicaltrials.gov/ct2/show/results/ adjuvanted vaccination prevents recurrent high grade cervical Neuzil 2011 {published data only} References to ongoing studies (TheraVACCS). clinicaltrials.gov/ct2/show/NCT02750202 Bonhoe er 2002 Donken 2015</td></tr><tr><td colspan=\"2\">References to studies included in this review Denny 2013 {published and unpublished data} * Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo controlled study. Vaccine 2013;31(48):5745-53. GSK 107863 (HPV-020 PRI). Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects. www.gsk-clinicalstudyregister.com/files2/gsk-107863-clinical-study-report2-redact.pdf (accessed 16 August 2018). GlaxoSmithKline. Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects. clinicaltrials.gov/ct2/show/results/ NCT00586339 (accessed 16 August 2018). Dobson 2013 {published data only (unpublished sought but not used)} women. Journal of Lower Genital Tract Disease 2015;19(3 Suppl 1):S10. Joura E, Giuliano A, Iversen OE, Bautista O, Chen J, Moeller E, et al. End of study e icacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women. EUROGIN 2015 Abstracts: HPV Infection and Related Cancers 2015;OC6:174. Joura E, Vuocolo S. E icacy of a novel 9-valent HPV vaccine against high-grade lesions and cancer in 16-to 26-year-old women. International Journal of Gynecological Cancer 2014;24(9):S4:32. Joura EA. Clinical e icacy and immunogenicity of the nonavalent HPV vaccine. Acta Cytologica 2016;60:35-6. * Joura EA, Giuliano AR, Iverson OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 2015;372:711-23. Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemporary Clinical Trials 2015;42:18-25. 2014;32:693-9. Merck Sharp, Dohme. Randomized trial of alternative HPV vaccination schedules in males in a university setting. clinicaltrials.gov/ct2/show/results/NCT01184079 (accessed 16 August 2018). Wu RF, Zimmerman RK, Lin CJ. The e ect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males. Human Vaccines &amp; Immunotherapeutics 2017;13:676-9. NCT00941889 2016 {unpublished data only} NCT00941889. The e ect of HPV vaccination on recurrence rates in HIV patients with condylomata. clinicaltrials.gov/ct2/show/ results/NCT00941889?view=results (accessed 27 August 2018). NCT01031069 2017 {unpublished data only} * GlaxoSmithKline. Safety and immunogenicity of Cervarix\u2122 in human immunodeficiency virus infected females. www.gsk-clinicalstudyregister.com/files2/109823-clinical-study-result-summary.pdf (accessed 27 August 2018). NCT01031069. Evaluation of safety and immunogenicity of a human papillomavirus (HPV) vaccine in human 27 August 2018). August 2018). vaccine. clinicaltrials.gov/ct2/show/NCT02405520 (accessed on clinicaltrials.gov/ct2/show/NCT01031069 (accessed on 27 recombinant human papillomavirus virus type 6/11 bivalent immunodeficiency virus (HIV) infected females. intraepithelial neoplasia a er definitive surgical therapy: post-hoc analysis from a randomized controlled trial. International Journal of Cancer 2016;139(12):2812-26. Gilca 2015 {published data only} Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Bonhoe er J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, NCT01735006 {published data only} NCT01735006. E icacy and immunogenicity study of recombinant human papillomavirus bivalent (type 16/18) vaccine. clinicaltrials.gov/ct2/show/NCT01735006 (accessed 27 August 2018). et al: The Brighton Colloaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002;21:298-302. Ouakki M, et al. The e ect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Human Vaccines &amp; Immunotherapeutics 2015;11(3):732-8. Hamsikova 2017 {published data only} Hamsikova E, Smahelova J, Ludvikova V, Salakova M, Rychla J, Skrenkova J, et al. The prevalence of HPV infections in HPV-vaccinated women from the general population. Apmis 2017;125(6):585-95. Harari 2016 {published data only} Harari A, Chen Z, Rodr\u00edguez A, Hildesheim A, Porras C, Herrero R, et al. Crossprotection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections. Journal of Infectious Diseases 2016;213(6):939-47. Bosch 2002 NCT01824537 {published data only} NCT01824537. Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study (TRAP-HPV). clinicaltrials.gov/ct2/ show/NCT01824537 (accessed 27 August 2018). NCT02009800 {published data only} Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002;55:244-65. Bouvard 2009 Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, NCT02009800. ICI-VPH: impact of HPV immunisation schedules against HPV (ICI-VPH). clinicaltrials.gov/ct2/show/NCT02009800 (accessed 27 August 2018). NCT02087384 {published data only} NCT02087384. HPV (human papilloma virus) vaccination a er treatment of anal intraepithelial neoplasia (AIN) (VACCAIN-P). clinicaltrials.gov/ct2/show/NCT02087384 (accessed 27 August 2018). NCT02405520 {published data only} NCT02405520. Safety and immunogenicity study of the et al: WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncology 2009;10(4):321-2. Bradburn 2007 Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77.</td><td>Moreira ED Jr, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Human Vaccines 2011;7(7):768-75. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine 2011;365:1576-85. Hidalgo-Tenorio 2017 {published data only (unpublished sought but not used)} Hidalgo-Tenorio C, Ramirez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, et al. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Research and Therapy 2017;14:34. Iversen 2016 {published and unpublished data} community-randomized clinical trial (I). International Journal of Cancer 2018;142(5):949-58. NCT00534638. E ectiveness, safety and immunogenicity of GSK Biologicals' HPV vaccine GSK580299 (Cervarix TM) administered in healthy adolescents. clinicaltrials.gov/ct2/show/results/ NCT00534638 (accessed 25 August 2018). Leung 2015 {published and unpublished data} GSK 115411 (HPV-071 PRI). Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine and Merck's Gardasil\u00ae vaccine when administered according to alternative 2-dose schedules in 9-14 year old females. www.gsk-clinicalstudyregister.com/files2/gsk-115411-clinical-study-report-redact.pdf (accessed 16 August 2018). GlaxoSmithKline. Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine and Merck's Gardasil\u00ae vaccine when administered according to alternative 2-dose schedules in 9-14 year old females. clinicaltrials.gov/ct2/show/results/NCT01462357 (accessed 16 August 2018). NCT01381575 (accessed 16 August 2018). Huang LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, et al. Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: a randomized trial. Journal of Infectious Neuzil KM, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011;305(14):1424-31. Wheeler 2016 {published data only} (accessed on 27 August 2018). NCT02834637 {published data only} NCT02834637. A dose reduction immunobridging and safety study of two HPV vaccines in Tanzanian girls (DoRIS). clinicaltrials.gov/ct2/show/NCT02834637 (accessed 27 August Diseases 2017;215:1711-9. * Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. Journal of Infectious Diseases 2016;214:525-36. Romanowski 2011 {published and unpublished data} GSK 110659 (HPV-048 PRI). Evaluation of the safety and immunogenicity of GSK Biologicals' HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing. www.gsk-clinicalstudyregister.com/files2/gsk-110659-clinical-study-report-redact.pdf (accessed 16 August 2018). Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. E icacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infectious Diseases 2016;16(10):1154-68. Zhu 2017 {published data only} Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, et al. E icacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Medicine 2017;6(1):12-25. 2018). Drolet 2019 Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M, on behalf of the NCT02888418 {published data only} HPV Vaccination Impact Study Group. Population-level NCT02888418. Safety and immunogenicity study of human impact and herd e ects following the introduction of papilloma virus vaccine in women aged 9 to 30 and men aged 9 to 17. clinicaltrials.gov/ct2/show/NCT02888418 (accessed 27 human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;pii: August 2018). S0140-6736(19):30298-3. NCT03180034 {published data only} Gallagher 2018 * NCT03180034. Scientific evaluation of one or two doses of Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV the bivalent or nonavalent prophylactic HPV vaccines. https:// clinicaltrials.gov/ct2/show/NCT03180034 (accessed on 27 vaccine introduction and barriers to country uptake. Vaccine 2018;36(32 Pt A):4761-7. August 2018) 2017. Gillison 2015 Sampson JN, Hildesheim A, Herrero R, Gonzalez P, Kreimer AR, Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Gail MH. Design and statistical considerations for studies Epidemiology of human papillomavirus-positive head and evaluating the e icacy of a single dose of the human neck squamous cell carcinoma. Journal of Clinical Oncology papillomavirus (HPV) vaccine. Contemporary Clinical Trials 2018;68:35-44. 2015;33(29):3235-42.</td></tr><tr><td colspan=\"2\">Ogilvie G, Sauvageau C, Dionne M, McNeil S, Krajden M, Money D, et al. Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years a er 60 months. JAMA 2017;317:1687-8. Giuliano 2011 {published and unpublished data} * Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. E icacy of quadrivalent HPV vaccine against HPV Infection and disease in males. New England Journal of Medicine 2011;364:401-11. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clinical and Vaccine Immunology 2012;19:261-7. Merck Sharp, Dohme. A randomized, international, double-blinded (with in-house blinding), controlled with gardasil, dose-ranging, tolerability, immunogenicity, and e icacy study of a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to 16-to 26-year-old women. clinicaltrials.gov/ct2/show/results/NCT00543543 (accessed 16 August 2018). Lehtinen 2018 {published and unpublished data} GSK 106636 (HPV-040 PRI). Evaluation of the e ectiveness of two vaccination strategies using GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered in healthy adolescents. www.gsk-clinicalstudyregister.com/study/106636? search=study&amp;search_ terms=106636#csr (accessed 25 August 2018). Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination e ectiveness trial. Vaccine 2015;33(10):1284-90. Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, et al. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: interim analysis of a large community-randomized controlled trial. Human Vaccines &amp; Immunotherapeutics 2016;12(12):3177-85. NCT01862874 2018 {published data only} NCT02562508 {published data only} Bruni 2010 NCT01862874. E icacy and tolerability study of V501 in Japanese males (V501-122). clinicaltrials.gov/ct2/show/ NCT01862874 (accessed 27 August 2018). Petaja 2009 {published and unpublished data} GSK 580299/011 (HPV-011). A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years. www.gsk-clinicalstudyregister.com/files2/gsk-580299-011-* Pet\u00e4j\u00e4 T, Ker\u00e4nen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. Journal of Adolescent Health 2009;44(1):33-40. Puthanakit 2016 {published and unpublished data} GSK 114700 (HPV-070 PRI). Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9-14 year old females. www.gsk-clinicalstudyregister.com/ files2/gsk-114700-clinical-study-report-redact.pdf (accessed 16 August 2018). GlaxoSmithKline. Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in Luxembourg A, Kjaer SK, Nygard M, Ellison MC, Group T, Marshall JB, et al. Design of a long-term follow-up e ectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Contemporary Clinical Money 2016 {published data only} Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human NCT02750202. E ectiveness study of human papilloma Issue 9. [DOI: 10.1002/14651858.CD012805] NCT02750202 {published data only} intervention. Cochrane Database of Systematic Reviews 2017, papillomavirus vaccine. Vaccine 2016;34(40):4799-806. of human papillomavirus (HPV)-16/18 in adolescent females. Aluminium adjuvants used in vaccines versus placebo or no 2018). Djurisic S, Jakobsen JC, Petersen SB, Kenfelt M, Gluud C. clinicaltrials.gov/ct2/show/NCT02740777 (accessed 27 August Djurisic 2017 NCT02740777. Evaluating the 2-dose immunization schedule Controlled Clinical Trials 1986;7(3):177-88. NCT02740777 {published data only} DerSimonian R, Laird N. Meta-analysis in clinical trials. Trials 2017;52:54-61. NCT02733068. A phase III study of human papillomavirus (accessed 27 August 2018). DerSimonian 1986 (HPV)-16/18 vaccine. clinicaltrials.gov/ct2/show/NCT02733068 study. Lancet Oncology 2010;11:1048-56. cervical cancer: a retrospective cross-sectional worldwide NCT02733068 {published data only} Group. Human papillomavirus genotype attribution in invasive Luxembourg 2017 {published data only} NCT02710851. Immunogenicity study of the recombinant Retrospective International Survey and HPV Time Trends Study August 2018). Klaustermeier JE, Lloveras B, et al on behalf of the clinicaltrials.gov/ct2/show/NCT02710851 (accessed on 27 de Sanjose S, Quint WG, Alemany L, Geraets DT, human papillomavirus virus type 6/11 bivalent vaccine. de Sanjose 2010 clinical-study-report-redact.pdf (accessed 16 August 2018). NCT02710851 {published data only} NCT02562508. A bridging study of a recombinant human Bruni L, Diaz M, Castellsagu\u00e9 X, Ferrer E, Bosch FX, papillomavirus 16/18 bivalent vaccine in preadolescent girls. de Sanjos\u00e9 S. Cervical human papillomavirus prevalence clinicaltrials.gov/ct2/show/NCT02562508 (accessed 27 August 2018). in 5 continents: meta-analysis of 1 million women with normal cytological findings. The Journal of Infectious Diseases 2010;202(12):1789-99. NCT02567955 {published data only} 27 August 2018). Cervarix. clinicaltrials.gov/ct2/show/NCT02567955 (accessed on NCT02567955. Immunogenicity and safety of Gardasil-9 and</td><td>Merck Sharp, Dohme. Phase III study of a 2-dose regimen of a multivalent human papillomavirus (HPV) vaccine (V503), administered to 9 to 14 year-olds and compared to young women, 16 to 26 years old (V503-010). clinicaltrials.gov/ct2/ show/results/NCT01984697 (accessed 16 August 2018). Joura 2015 {published and unpublished data} Bouchard C, Vuocolo S, Merck. E ect of the 9vHPV vaccine on abnormal cytology and genital procedures related to HPV31/33/45/52/58. Journal of Lower Genital Tract Disease 2014;18(5 Suppl 1):S9. Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clinical Trials Journal 2015;12(1):84-90. Guevara A, Cabello R, Woelber L, Moreira ED Jr, Joura E, Reich O, et al. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine 2017;35:5050-7. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final e icacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017;390:2143-59. Levin MJ, Moscicki AB, Song L-Y, Fenton T, Meyer WA, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. Journal of Acquired Immune Deficiency Syndromes 2010;55(2):197. Weinberg A, Song L-Y, Saah A, Brown M, Moscicki AB, Meyer WA, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes a er administration of quadrivalent human papillomavirus vaccine to HIV-infected children. Journal of Infectious Diseases 2012;206(8):1309-18. randomized study. Human Vaccines &amp; Immunotherapeutics 2014;10:1155-65. * Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Human Vaccines 2011;7:1374-86. To 2014 {published data only (unpublished sought but not used)} Faust H, To L, Sehr P, M\u00fcller M, Bonde J, Forslund O, et al. Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects a er vaccination with quadrivalent and bivalent HPV vaccines. Vaccine 2016;34(13):1559-65. 2006;118(5):2135-45. female adolescents and young adult women. Pediatrics 6, 11, 16, and 18) L1 virus-like particle vaccine in male and of a prophylactic quadrivalent human papillomavirus (types et al. Comparison of the immunogenicity and reactogenicity Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Block 2006 Reviews 2018, Issue 5. [DOI: 10.1002/14651858.CD009069.pub3] cancer and its precursors. Cochrane Database of Systematic vaccination against human papillomaviruses to prevent cervical Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic Arbyn 2018 Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 dose schedule up to 4 years a er vaccination: results from a Cancer 2014;50:2846-54. AS04-adjuvanted vaccine administered as a 2-dose or 3-Greer 1995 Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (HPV) type distribution Additional references and serological response to HPV type 6 virus-like particles in Alemany 2014 patients with genital warts. Journal of Clinical Microbiology lesions: a worldwide study in 597 samples. European Journal of contribution of human papillomavirus in vaginal neoplastic Alejo M, et al on behalf of the HPV VVAP study group. Large Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, 1995;33:2058-63.</td></tr><tr><td colspan=\"2\">virus (HPV) vaccines to prevent recurrence of genital warts</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF18": {
                "text": "Ministries of Health in the provinces of British Columbia, Nova Scotia, and Quebec.Merck Laboratories Inc conducted the antibody assays at no cost to the study.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"2\">Inclusion criteria: healthy participants 9-13 years of age (girls) or 16-26 years of age (young women),</td></tr><tr><td/><td>with 4 or fewer lifetime sexual partners</td><td/></tr><tr><td>Interventions</td><td>Vaccine 1: quadrivalent HPV vaccine; 2 doses: day 1, month 6</td><td/></tr><tr><td/><td colspan=\"2\">Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6</td></tr><tr><td>Outcomes</td><td>Harms: adverse events</td><td/></tr><tr><td/><td>Immunogenicity: GMT, seroconversion</td><td/></tr><tr><td>Notes</td><td colspan=\"2\">Other groups: in our analyses we did not include the cohort of 16-26-year-old women that were not ran-</td></tr><tr><td/><td>domised within the trial</td><td/></tr><tr><td/><td>Last report average follow-up time: 36 months</td><td/></tr><tr><td/><td>Funding:</td><td/></tr><tr><td/><td>Guyatt 2011b</td><td/></tr><tr><td/><td colspan=\"2\">Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J,</td></tr><tr><td/><td colspan=\"2\">Helfland M, et al. GRADE guidelines: 7. Rating the quality of</td></tr><tr><td/><td colspan=\"2\">evidence-inconsistency. Journal of Clinical Epidemiology</td></tr><tr><td/><td>2011;64(12):1294-302.</td><td/></tr><tr><td/><td>Guyatt 2011c</td><td/></tr><tr><td/><td colspan=\"2\">Guyatt GH, Oxman AD, Montori M, Vist G, Kunz R, Brozek J,</td></tr><tr><td/><td colspan=\"2\">et al. GRADE guidelines: 5. Rating the quality of evidence</td></tr><tr><td/><td colspan=\"2\">-publication bias. Journal of Clinical Epidemiology</td></tr><tr><td/><td>2011;64(12):1277-82.</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF19": {
                "text": "Cochrane Database of Systematic ReviewsMethodsPhase III, double-blind, parallel, placebo-controlled, randomised and multi-site trial Participants Participants: 4065 boys and men (2032 to the vaccine group and 2033 to the control group) recruited from 18 countries in five regions (Africa, Asia-Pacific, Europe, Latin America, North America) Merck, in collaboration with external investigators and an external data and safety monitoring board.The sponsor co-designed the trial, collated the data, monitored the conduct of the trial, performed statistical analyses, and co-ordinated the writing of the manuscript with all the authors.Canada, Chile, Colombia, Czech Republic, Denmark, Israel, Malaysia, Norway, South Korea, South Africa, Spain, Taiwan, Thailand, Turkey, and the USA)Age range: girls and boys aged 9-14 years and girls and young women aged 16-26 years Inclusion criteria: girls and boys 9-14 years had to be generally healthy and not sexually active prior to enrolment.Girls and young women 16-26 years had to be generally healthy with 4 or fewer lifetime sexual partners, without a history of abnormal Papanicolaou test results or other cervical abnormalities, and to agree to use effective contraception through to study month 7.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">Dobson 2013 (Continued) Hidalgo-Tenorio 2017 (Continued)</td></tr><tr><td>Incomplete outcome data</td><td/><td>Low risk</td><td>129 of 162 screened subjects were included. Reasons for ineligibility, with-</td></tr><tr><td>(attrition bias)</td><td/><td/><td>drawal, and protocol violation fully reported.</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-</td><td/><td>Low risk</td><td>No reason to suspect that reporting was selective. Trial registered retrospec-</td></tr><tr><td>porting bias)</td><td/><td>Age range: 16-26 years</td><td>tively.</td></tr><tr><td>Other bias</td><td/><td colspan=\"2\">Inclusion criteria: heterosexual males 16-23 years old with between 1-5 lifetime female sexual partners, plus males who have sex with male partners 16-26 years old with 1-5 lifetime male or female partners Low risk No other bias apparent.</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">Vaccine: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6</td></tr><tr><td/><td/><td colspan=\"2\">Control: aluminium adjuvant placebo (amorphous aluminium hydroxy-phosphate sulphate (AAHS)); 3</td></tr><tr><td/><td/><td colspan=\"2\">doses: day 1, month 2, month 6</td></tr><tr><td>Methods</td><td/><td colspan=\"2\">Phasae III, open-label, controlled, randomised and multi-centre trial</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Clinical: external genital lesions; penile, perianal, or perineal intraepithelial neoplasia; or penile, peri-</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">anal, or perineal cancer Participants: 1518 girls, boys, and young women (301 girls aged 9-14 years and 301 boys aged 9-14</td></tr><tr><td/><td/><td colspan=\"2\">years received 2 doses 6 months apart; 301 girls and boys aged 9-14 years received 2 doses 12 months Harms: adverse events, deaths apart; 301 girls aged 9-14 years and 314 young women aged 16-26 years received 3 doses at 0, 2, 6</td></tr><tr><td colspan=\"4\">Immunogenicity: GMT, seroconversion Other groups: N/A Last report average follow-up time: 36 months Funding: Trial ID: NCT00090285 months) recruited from 15 countries (Interventions Notes Vaccine 1: nonavalent HPV vaccine; 2 doses: day 1, month 6</td></tr><tr><td>Risk of bias</td><td/><td colspan=\"2\">Vaccine 2: nonavalent HPV vaccine; 2 doses: day 1, month 12</td></tr><tr><td/><td/><td colspan=\"2\">Vaccine 3: nonavalent HPV vaccine; 3 doses: day 1, month 2, month 6</td></tr><tr><td>Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Harms: adverse events, deaths</td></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias)</td><td colspan=\"2\">Low risk Immunogenicity: GMT, seroconversion A computer-generated allocation schedule was produced by the sponsor. Fol-lowing informed consent and determination that all entry criteria were met,</td></tr><tr><td/><td/><td/><td>eligible subjects were randomised to a vaccination group. (Hillman 2012, com-</td></tr><tr><td>Notes</td><td/><td>Other groups:</td><td>panion paper)</td></tr><tr><td>Allocation concealment</td><td/><td>Low risk</td><td>Following informed consent and determination that all entry criteria were</td></tr><tr><td>(selection bias)</td><td/><td/><td>met, eligible subjects were randomised to a vaccination group. All investi-</td></tr><tr><td/><td/><td/><td>gators and site personnel, subjects, monitors, and laboratory personnel re-</td></tr><tr><td/><td/><td/><td>mained blinded to treatment allocation throughout the study. Sta of the</td></tr><tr><td/><td/><td/><td>sponsor were blinded from the study onset through the database lock for this</td></tr><tr><td/><td/><td/><td>analysis. (Hillman 2012, companion paper)</td></tr><tr><td>Blinding of participants</td><td/><td>Low risk</td><td>Quote: \"visually indistinguishable AAHS-containing placebo\"; All investigators</td></tr><tr><td>and personnel (perfor-</td><td/><td/><td>and site personnel, subjects, monitors, and laboratory personnel remained</td></tr><tr><td>mance bias)</td><td/><td/><td>blinded to treatment allocation throughout the study. Sta of the sponsor</td></tr><tr><td>All outcomes</td><td/><td/><td>were blinded from the study onset through the database lock for this analysis.</td></tr><tr><td/><td/><td/><td>(Hillman 2012)</td></tr><tr><td>Blinding of outcome as-</td><td/><td>Low risk</td><td>All biopsy specimens were processed independently to prevent contamina-</td></tr><tr><td>sessment (detection bias)</td><td/><td/><td>tion of HPV DNA and were assessed in a blinded fashion, first for the purpose of</td></tr><tr><td>All outcomes</td><td/><td/><td>clinical management by pathologists at the central laboratory (Diagnostic Cy-</td></tr><tr><td/><td/><td/><td>tology Laboratories) and then for end-point adjudication by a 4-member panel</td></tr><tr><td/><td/><td/><td>of pathologists.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF20": {
                "text": "An Interactive Voice Response System (IVRS) was used to allocate study subjects and balance randomisation between sites.Subjects were assigned an allocation number from an allocation schedule via the IVRS.Study personnel utilized IVRS at each vaccination visit for assignment of the clinical material from the appropriate vaccination group to be administered to the subject.\"(From protocol, supplementary material online) The subjects, investigators (and his/her sta ), laboratory sta , members of the Scientific Advisory Committee, and HPV Vaccine Program Pathology Panel will remain blinded to subject vaccination group allocations for the duration of the study.\"(From protocol, supplementary material online)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Iversen 2016 (Continued)</td><td/><td/></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td>Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Low risk</td><td>Quote: \"An Interactive Voice Response System (IVRS) was used to allocate</td></tr><tr><td>tion (selection bias)</td><td/><td/><td>study subjects and balance randomisation between sites. Subjects were as-</td></tr><tr><td/><td/><td/><td>signed an allocation number from an allocation schedule via the IVRS. Study</td></tr><tr><td/><td/><td/><td>personnel utilized IVRS at each vaccination visit for assignment of the clini-</td></tr><tr><td/><td/><td/><td>cal material from the appropriate vaccination group to be administered to the</td></tr><tr><td/><td/><td/><td>subject.\" (From protocol, supplementary material online)</td></tr><tr><td colspan=\"4\">Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias Allocation concealment (selection bias) Quote: \"Blinding of participants Low risk Acceptable dropout rate and reasons for withdrawal provided. Low risk No reason to suspect that reporting was selective. Trial protocol and clinical trial registry checked. Unclear risk Low risk and personnel (perfor-mance bias) All outcomes Low risk Quote: \"Blinding of outcome as-Trial funded by vaccine manufacturer. sessment (detection bias)</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Joura 2015</td><td/><td/></tr><tr><td>Methods</td><td/><td colspan=\"2\">Phase II/III, double-blind, randomised, multi-centre trial</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">Participants: 14215 women (6792 in the nonavalent HPV vaccine group and 6795 in the quadrivalent</td></tr><tr><td/><td/><td colspan=\"2\">HPV vaccine group) recruited from 18 countries (Austria, Brazil, Canada, Chile, Colombia, Denmark,</td></tr><tr><td/><td/><td colspan=\"2\">Germany, Hong Kong, Japan, Korea, Mexico, New Zealand, Norway, Peru, Sweden, Taiwan, Thailand,</td></tr><tr><td/><td/><td colspan=\"2\">and the USA (including Puerto Rico))</td></tr><tr><td/><td/><td>Age range: 16-26 years</td></tr><tr><td/><td/><td colspan=\"2\">Inclusion criteria: no history of an abnormal result on a Papanicolaou (Pap) test, no more than 4 life-</td></tr><tr><td/><td/><td colspan=\"2\">time sexual partners, and no previous abnormal finding on cervical biopsy</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">Vaccine 1: nonavalent HPV vaccine; 3 doses: day 1, month 2, month 6</td></tr><tr><td/><td/><td colspan=\"2\">Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Clinical: high grade cervical, vulval, and vaginal disease; cervical cancer; persistent HPV infection</td></tr><tr><td/><td/><td colspan=\"2\">Harms: adverse events, deaths</td></tr><tr><td/><td/><td colspan=\"2\">Immunogenicity: GMT, seroconversion</td></tr><tr><td>Notes</td><td/><td>Other groups: N/A</td></tr><tr><td/><td/><td colspan=\"2\">Last report average follow-up time: 54 months</td></tr><tr><td/><td/><td>Funding: Merck</td></tr><tr><td/><td/><td>Trial ID: NCT00543543</td></tr></table>",
                "type_str": "table"
            },
            "TABREF22": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Methods</td><td>Phase 3, parallel, randomised, controlled trial</td><td/></tr><tr><td>Participants</td><td colspan=\"2\">Participants: 1124 boys and men (562 received vaccine, 562 received placebo) recruited from Japan</td></tr><tr><td/><td>Age range:16-26 years</td><td/></tr><tr><td/><td colspan=\"2\">Inclusion criteria: Japanese males with no clinical evidence of sexually transmitted disease and no clin-</td></tr><tr><td/><td>ically present external genital warts</td><td/></tr><tr><td>Interventions</td><td colspan=\"2\">Vaccine: quadrivalent HPV vaccine; 3 doses at day 1, month 2, month 6</td></tr><tr><td/><td colspan=\"2\">Control: aluminium adjuvant placebo (placebo formulated with aluminium hydroxyphosphate sulfate</td></tr><tr><td/><td>adjuvant); 3 doses at day 1, month 2, month 6</td><td/></tr><tr><td>Outcomes</td><td>Incidence of persistent HPV-6/11/16/18 infection or disease</td><td/></tr><tr><td/><td>Adverse events</td><td/></tr><tr><td>Notes</td><td>Other groups: N/A</td><td/></tr><tr><td/><td>Last report average follow-up time: month 36</td><td/></tr><tr><td/><td>Funding: Merck Sharp &amp; Dohme Corp</td><td/></tr><tr><td/><td>Trial ID: NCT01862874</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF26": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"3\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"5\">To 2014 (Continued) Characteristics of studies awaiting assessment [ordered by study ID] NCT02733068 NCT02888418 Outcome or subgroup ti-No. of studies No. of partici-Statistical method Analysis 1.2.</td><td>Effect size</td></tr><tr><td>Blinding of outcome as-sessment (detection bias) Li 2012 NCT02405520 Trial name or title Trial name or title tle</td><td/><td colspan=\"3\">Low risk HPV-16 and 18 related diseases, immunogenicity and safety of HPV-16/18 vaccine in healthy fe-Blinded analysis at the joint Chemical Biology Core Facility of the German Can-cer Research Center and the European Molecular Biology Laboratory, Heidel-nary immunogenicity of tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) A phase III double blinded, randomized controlled study to evaluate efficacy of protection against Random, double blind, placebo controlled phase I clinical trials to estimate the safety and prelimi-pants</td></tr><tr><td>All outcomes Methods (overall) Trial name or title 4 Serious adverse events</td><td/><td>4</td><td colspan=\"2\">berg, Germany Randomised, double-blind, placebo-controlled trial lent vaccine Safety and immunogenicity study of the recombinant human papillomavirus virus type 6/11 biva-males aged 18-30 years (Hansenula polymorpha) in women of 9-30 years old and men of 9-17 years old 2317 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.64, 1.66]</td></tr><tr><td>Incomplete outcome data (attrition bias) All outcomes Participants Methods Methods Participants Participants Methods 4.1 Bivalent vaccine</td><td/><td colspan=\"3\">Low risk RCT RCT Participants: 100 healthy Chinese males and 500 healthy Chinese females (302 received the quadri-Data appeared to be reported adequately, and included reasons for with-drawals. Females aged 18-30 years Males 9-17 years old, females 9-30 years old valent vaccine and 298 received the control vaccine) from Wuzhou, Guangxi, China RCT 1 479 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.64, 2.59]</td></tr><tr><td>Selective reporting (re-Participants 4.2 Quadrivalent vaccine</td><td/><td colspan=\"3\">Low risk Age range: males aged 9-15 years and females aged 9-45 years No reason to suspect that reporting was selective. Clinical trials registry Males and females 18-55 years Country: China Country China 2 1236 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.35, 1.74]</td></tr><tr><td>porting bias) Interventions Interventions 4.3 Nonavalent vaccine</td><td/><td>1</td><td colspan=\"2\">checked. Inclusion criteria: no history of severe allergic reaction or allergic reaction to any vaccine compo-nent and a lifetime number of no more than 4 sex partners. Country: China \u2022 HPV-16/18 vaccine \u2022 Tetravalent recombinant human papillomavirus vaccine (6,11,16,18 type) (Hansenula polymor-602 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.32, 3.14]</td></tr><tr><td>Other bias van Damme 2016 Interventions 5 Deaths Interventions Outcomes Outcomes 5.1 Bivalent vaccine Outcomes Starting date Starting date 5.2 Quadrivalent vaccine</td><td/><td colspan=\"3\">Low risk Exclusion criteria: pregnant post-pubertal females; history of an abnormal Papanicolaou test or No other bias apparent. \u2022 Low dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses \u2022 Medium dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses \u2022 placebo pha) 3 1797 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.19] \u2022 Control vaccine biopsy showing cervical intraepithelial neoplasia (CIN) or worse \u2022 High dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses \u2022 Aluminium adjuvant at 0, 1, 6 month for 3 doses Clinical outcomes, adverse events, immunogenicity 1 479 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0] Adverse events and immunogenicity Vaccine: quadrivalent HPV vaccine (Gardasil/Silgard, Merck, Whitehouse Station, NJ) (3 doses: day 1, month 2, month 6) Adverse events; anti-HPV 6/11 antibody November 2014 October 2016 1 716 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]</td></tr><tr><td>Methods Starting date Contact information Contact information 5.3 Nonavalent vaccine</td><td/><td colspan=\"3\">Phase III, double-blind, controlled, randomised and multicenter trial Control: adjuvant-containing placebo (3 doses: day 1, month 2, month 6) March 2015 Zhaojun Mo, Guangxi Center for Disease Prevention and Control Beijing Chaoyang District Centre for Disease Control and Prevention 1 602 Odds Ratio (M-H, Random, 95% CI)</td><td>0.33 [0.01, 8.19]</td></tr><tr><td>Participants Outcomes Notes Contact information Notes</td><td/><td colspan=\"3\">Participants: 500 males (249 to the nonavalent HPV vaccine arm, 251 to the quadrivalent HPV vaccine arm) recruited from Belgium, Germany, and the Netherlands Sponsors: Shanghai Zerun Biotechnology Co, Ltd; Guangxi Center for Disease Control and Preven-Immunogenicity: GMTs, seroconversion Jun Zhang, Xiamen University; Zhao-Jun Mo, Guangxi Center for Disease Prevention and Control; tion Sponsors: Beijing Chaoyang District Centre for Disease Control and Prevention</td></tr><tr><td colspan=\"5\">Age range: 16-26 years Inclusion criteria: good physical health, no more than 5 lifetime female and no male sexual partners Safety: adverse events, serious adverse events, death Other groups: N/A Ting Wu, Xiamen University Sponsors: Jun Zhang; Xiamen Innovax Biotech Co, Ltd; Beijing Wantai Biological Pharmacy Enter-prise Co, Ltd Trial status in August 2018: active, not recruiting Trial status in August 2018: unknown, in August 2016 it was 'Not yet recruiting' Analysis 1.1. Study or subgroup Interventions Notes Notes 2 doses 3 doses Risk Ratio Weight Risk Ratio Last report average follow-up time: 7 months Vaccine 1: nonavalent HPV vaccine; 3 doses: day 1, month 2, and month 6 Funding: Merck Sharp &amp; Dohme Corp Trial status in August 2018: active, not recruiting NCT02740777 n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI NCT03180034 1.1.1 Bivalent vaccine Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, and month 6 Outcomes Trial name or title Immunogenicity study of a 2-dose immunization schedule of recombinant human papillomavirus Trial name or title A scientific evaluation of one or two doses of vaccine against human papillomavirus: the ESCUDDO Romanowski 2011 222/238 225/238 59.84% 0.99[0.94,1.03] Trial ID: NCT01427777 virus-like particle vaccine (type 16 and 18 l1 proteins, yeast) in adolescent females aged 9 to 14 study Subtotal (95% CI) 238 238 59.84% 0.99[0.94,1.03] Harms: adverse events, deaths years Total events: 222 (2 doses), 225 (3 doses)</td></tr><tr><td>Methods Heterogeneity: Not applicable</td><td/><td colspan=\"3\">Immunogenicity: GMT, seroconversion RCT</td></tr><tr><td colspan=\"2\">Notes Participants Reisinger 2007 Trial name or title Methods Test for overall effect: Z=0.57(P=0.57)</td><td colspan=\"3\">Other groups: N/A vaccine (E.coli) in healthy female subjects aged 9-17 years Females 12-16 years old Immunogenicity and safety study of a bivalent human papillomavirus (type 16, 18) recombinant RCT</td></tr><tr><td>Methods Methods Participants 1.1.2 Quadrivalent vaccine Leung 2015</td><td/><td colspan=\"3\">Last report average follow-up time: 7 months Randomised, double-blind, placebo-controlled, multicenter study RCT Females aged 9-14 years Country: China Country: Costa Rica 276/357 295/356</td><td>40.16%</td><td>0.93[0.87,1]</td></tr><tr><td colspan=\"5\">Funding: Sanofi Pasteur MSD provided financial support for the conduct of the research and prepara-tion of the article and were involved in the study design, in the collection, analysis and interpretation of data and in the writing of the trial report. Trial ID: NCT02114385 Authors' judgement Support for judgement Low risk Quote: \"An interactive Web Response System (IWRS) was used to allocate par-ticipants to 9vHPV or qHPV vaccine in a blinded manner. The system assigned an allocation number from a randomised, age-stratified (16-17 years and 18-26 years) allocation schedule.\" Participants: 1781 boys and girls (1181 received the quadrivalent vaccine and 597 received the non-aluminium placebo) from 47 study sites located in 10 countries in North America, Latin America, Europe and Asia Age: 9-15 years old Inclusion criteria: healthy, sexually naive boys and girls Vaccine: quadrivalent HPV-6/11/16/18 L1 VLP vaccine (GARDASIL/SILGARD, Merck and Co, Inc, 357 356 40.16% 0.93[0.87,1] \u2022 Cervarix, 1 dose Females 9-26 years Country: China HPV-16/18 vaccine (2 doses) HPV-16/18 vaccine (3 doses) Total events: 276 (2 doses), 295 (3 doses) Risk of bias Bias Random sequence genera-tion (selection bias) Participants Interventions Participants Interventions Subtotal (95% CI) Interventions Interventions \u2022 Gardasil 9, 1 dose Heterogeneity: Not applicable \u2022 Cervarix, 2 doses Test for overall effect: Z=1.85(P=0.06) \u2022 Gardasil 9, 2 doses \u2022 3 doses of HPV 16/18 bivalent vaccine \u2022 2 doses of HPV 16/18 bivalent vaccine Outcomes Adverse events and immunogenicity Outcomes Adverse events and immunogenicity Starting date Outcomes Total (95% CI) 595 594 100% 0.96[0.91,1.03] Clinical outcomes, adverse events, immunogenicity Total events: 498 (2 doses), 520 (3 doses) February 2016 Starting date Heterogeneity: Tau =0; Chi =2.24, df=1(P=0.13); I =55.26% 26 June 2018 Whitehouse Station, NJ) Starting date 5 December 2015 Contact information Test for overall effect: Z=1.11(P=0.27) Zhaojun Mo, Guangxi Center for Disease Prevention and Control Contact information Aimee R Kreimer (kreimera@mail.nih.gov), National Cancer Institute Test for subgroup differences: Chi =1.61, df=1 (P=0.2), I =37.77% Control: placebo vaccine (identical components to those in the vaccine, with the exception of HPV L1 VLPs and aluminium adjuvant) Outcomes Trial status in August 2018: recruiting Trial status in August 2018: recruiting Immunogenicity: GMT, seroconversion Contact information Ting Wu, Xiamen University; Yuemei Hu, Jiangsu Provincial Centre for Disease Control and Preven-tion Notes tion Notes Sponsors: National Cancer Institute; Bill and Melinda Gates Foundation Sponsors: Shanghai Zerun Biotechnology Co, Ltd; Guangxi Center for Disease Control and Preven-Favours 2 doses 1 1 1 Favours 3 doses</td></tr><tr><td>Allocation concealment Notes</td><td/><td colspan=\"3\">Low risk Safety: adverse events, serious adverse events, death Quote: \"An interactive Web Response System (IWRS) was used to allocate par-Sponsors: Jun Zhang; Xiamen Innovax Biotech Co, Ltd; Beijing Wantai Biological Pharmacy Enter-</td></tr><tr><td>(selection bias)</td><td/><td/><td>prise Co, Ltd</td><td>ticipants to 9vHPV or qHPV vaccine in a blinded manner. The system assigned</td></tr><tr><td>Notes</td><td/><td/><td>Other groups: N/A</td><td>an allocation number from a randomised, age-stratified (16-17 years and 18-26 years) allocation schedule.\"</td></tr><tr><td/><td/><td/><td colspan=\"2\">Last report average follow-up time: 18 months</td></tr><tr><td/><td/><td/><td colspan=\"2\">Funding: Merck and Co, Inc</td></tr></table>",
                "type_str": "table"
            },
            "TABREF27": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>2 doses</td><td>3 doses</td><td/><td colspan=\"2\">Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td colspan=\"5\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>1.2.1 Bivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>83/238</td><td>118/238</td><td/><td/><td/><td/><td>51.77%</td><td>0.7[0.57,0.87]</td></tr><tr><td>Subtotal (95% CI)</td><td>238</td><td>238</td><td/><td/><td/><td/><td>51.77%</td><td>0.7[0.57,0.87]</td></tr><tr><td>Total events: 83 (2 doses), 118 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.2(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>1.2.2 Quadrivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Leung 2015</td><td>98/357</td><td>118/356</td><td/><td/><td/><td/><td>48.23%</td><td>0.83[0.66,1.04]</td></tr><tr><td>Subtotal (95% CI)</td><td>357</td><td>356</td><td/><td/><td/><td/><td>48.23%</td><td>0.83[0.66,1.04]</td></tr><tr><td>Total events: 98 (2 doses), 118 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.65(P=0.1)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>595</td><td>594</td><td/><td/><td/><td/><td>100%</td><td>0.76[0.65,0.89]</td></tr><tr><td>Total events: 181 (2 doses), 236 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =1.07, df=1(P=0.3); I =6.16%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.34(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =1.06, df=1 (P=0.3), I =5.57%</td><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours 2 doses</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours 3 doses</td></tr><tr><td colspan=\"2\">Analysis 1.3.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF28": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>Analysis 1.4.</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>2 doses</td><td>3 doses</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"2\">M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>1.3.1 Bivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>123/238</td><td>145/238</td><td/><td/><td/><td/><td>55.38%</td><td>0.85[0.72,0.99]</td></tr><tr><td>Subtotal (95% CI)</td><td>238</td><td>238</td><td/><td/><td/><td/><td>55.38%</td><td>0.85[0.72,0.99]</td></tr><tr><td colspan=\"2\">Total events: 123 (2 doses), 145 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=2.02(P=0.04)</td><td/><td/><td/><td/><td/></tr><tr><td>1.3.2 Quadrivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Leung 2015</td><td>134/357</td><td>157/356</td><td/><td/><td/><td/><td>44.62%</td><td>0.85[0.71,1.02]</td></tr><tr><td>Subtotal (95% CI)</td><td>357</td><td>356</td><td/><td/><td/><td/><td>44.62%</td><td>0.85[0.71,1.02]</td></tr><tr><td colspan=\"2\">Total events: 134 (2 doses), 157 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.78(P=0.08)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>595</td><td>594</td><td/><td/><td/><td/><td>100%</td><td>0.85[0.75,0.96]</td></tr><tr><td colspan=\"2\">Total events: 257 (2 doses), 302 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=1(P=0.98); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=2.69(P=0.01)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =0, df=1 (P=0.98), I =0%</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours 2 doses</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours 3 doses</td></tr></table>",
                "type_str": "table"
            },
            "TABREF29": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>2 doses</td><td>3 doses</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>1.4.1 Bivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>19/240</td><td>15/239</td><td/><td/><td/><td/><td>46.72%</td><td>1.28[0.64,2.59]</td></tr><tr><td>Subtotal (95% CI)</td><td>240</td><td>239</td><td/><td/><td/><td/><td>46.72%</td><td>1.28[0.64,2.59]</td></tr><tr><td>Total events: 19 (2 doses), 15 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.7(P=0.49)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>1.4.2 Quadrivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Dobson 2013</td><td>0/259</td><td>0/261</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Leung 2015</td><td>11/358</td><td>14/358</td><td/><td/><td/><td/><td>35.65%</td><td>0.78[0.35,1.74]</td></tr><tr><td>Subtotal (95% CI)</td><td>617</td><td>619</td><td/><td/><td/><td/><td>35.65%</td><td>0.78[0.35,1.74]</td></tr><tr><td>Total events: 11 (2 doses), 14 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.61(P=0.54)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>1.4.3 Nonavalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Iversen 2016</td><td>6/301</td><td>6/301</td><td/><td/><td/><td/><td>17.62%</td><td>1[0.32,3.14]</td></tr><tr><td>Subtotal (95% CI)</td><td>301</td><td>301</td><td/><td/><td/><td/><td>17.62%</td><td>1[0.32,3.14]</td></tr><tr><td>Total events: 6 (2 doses), 6 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>1158</td><td>1159</td><td/><td/><td/><td/><td>100%</td><td>1.03[0.64,1.66]</td></tr><tr><td>Total events: 36 (2 doses), 35 (3 doses)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0.85, df=2(P=0.66); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.11(P=0.91)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =0.85, df=1 (P=0.66), I =0%</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours 2 doses</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours 3 doses</td></tr></table>",
                "type_str": "table"
            },
            "TABREF30": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>2 doses</td><td>3 doses</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>1.5.3 Nonavalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Iversen 2016</td><td>0/301</td><td>1/301</td><td/><td/><td/><td/><td>100%</td><td>0.33[0.01,8.19]</td></tr><tr><td>Subtotal (95% CI)</td><td>301</td><td>301</td><td/><td/><td/><td/><td>100%</td><td>0.33[0.01,8.19]</td></tr><tr><td colspan=\"2\">Total events: 0 (2 doses), 1 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.67(P=0.5)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>899</td><td>898</td><td/><td/><td/><td/><td>100%</td><td>0.33[0.01,8.19]</td></tr><tr><td colspan=\"2\">Total events: 0 (2 doses), 1 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.67(P=0.5)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours 2 doses</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours 3 doses</td></tr><tr><td>Comparison 2.</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>2 doses</td><td>3 doses</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>1.5.1 Bivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>0/240</td><td>0/239</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>240</td><td>239</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (2 doses), 0 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>1.5.2 Quadrivalent vaccine</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Leung 2015</td><td>0/358</td><td>0/358</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>358</td><td>358</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (2 doses), 0 (3 doses)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours 2 doses</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours 3 doses</td></tr></table>",
                "type_str": "table"
            },
            "TABREF31": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">4.1 Bivalent vaccine (0, 2 months vs 0, 6</td><td>1</td><td>481</td><td>Odds Ratio (M-H, Random,</td><td>1.15 [0.55, 2.41]</td></tr><tr><td>months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">4.2 Bivalent vaccine (0 and 6 months vs</td><td>1</td><td>965</td><td>Odds Ratio (M-H, Random,</td><td>1.63 [0.89, 2.99]</td></tr><tr><td>0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">4.3 Nonavalent vaccine (0 and 6 months</td><td>1</td><td>903</td><td>Odds Ratio (M-H, Random,</td><td>0.80 [0.31, 2.07]</td></tr><tr><td colspan=\"2\">vs 0 and 12 months) -females and males</td><td/><td/><td>95% CI)</td></tr><tr><td>5 Deaths</td><td/><td>3</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.1 Bivalent vaccine (0 and 2 months vs</td><td>1</td><td>481</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td>0 and 6 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.2 Bivalent vaccine (0 and 6 months vs</td><td>1</td><td>965</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td>0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.3 Nonavalent vaccine (0 and 6 months</td><td>1</td><td>452</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td>vs 0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td/><td/><td/><td/><td>Statistical method</td><td>Effect size</td></tr><tr><td colspan=\"2\">Analysis 2.1.</td><td/><td/><td/></tr><tr><td>1 Pain at injection site</td><td/><td>2</td><td/><td>Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.1 Bivalent vaccine (0 and 2 months vs</td><td>1</td><td>477</td><td>Risk Ratio (M-H, Random,</td><td>1.01 [0.96, 1.06]</td></tr><tr><td>0 and 6 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">1.2 Bivalent vaccine (0 and 6 months vs</td><td>1</td><td>963</td><td>Risk Ratio (M-H, Random,</td><td>1.02 [0.98, 1.06]</td></tr><tr><td>0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>2 Swelling at injection site</td><td/><td>2</td><td/><td>Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1 Bivalent vaccine (0 and 2 months vs</td><td>1</td><td>477</td><td>Risk Ratio (M-H, Random,</td><td>0.95 [0.76, 1.20]</td></tr><tr><td>0 and 6 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.2 Bivalent vaccine (0 and 6 months vs</td><td>1</td><td>963</td><td>Risk Ratio (M-H, Random,</td><td>1.01 [0.87, 1.18]</td></tr><tr><td>0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td>3 Redness at injection site</td><td/><td>2</td><td/><td>Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">3.1 Bivalent vaccine (0 and 2 months vs</td><td>1</td><td>477</td><td>Risk Ratio (M-H, Random,</td><td>1.02 [0.84, 1.24]</td></tr><tr><td>0 and 6 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">3.2 Bivalent vaccine (0 and 6 months vs</td><td>1</td><td>963</td><td>Risk Ratio (M-H, Random,</td><td>1.06 [0.93, 1.22]</td></tr><tr><td>0 and 12 months)</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">4 Serious adverse events (overall)</td><td>3</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF32": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Longer interval</td><td>Shorter</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td/><td>interval</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">2.1.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)</td><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>225/239</td><td>222/238</td><td/><td>100%</td><td>1.01[0.96,1.06]</td></tr><tr><td>Subtotal (95% CI)</td><td>239</td><td>238</td><td/><td>100%</td><td>1.01[0.96,1.06]</td></tr><tr><td colspan=\"2\">Total events: 225 (Longer interval), 222 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.39(P=0.7)</td><td/><td/><td/><td/><td/></tr><tr><td>2.1</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF33": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Puthanakit 2016</td><td>381/413</td><td>499/550</td><td>100%</td><td>1.02[0.98,1.06]</td></tr><tr><td>Subtotal (95% CI)</td><td>413</td><td>550</td><td>100%</td><td>1.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF34": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 2.2.</td><td/></tr><tr><td colspan=\"2\">Total events: 381 (Longer interval), 499 (Shorter interval)</td><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.84(P=0.4)</td><td/></tr><tr><td/><td>Favours longer interval</td><td>1 1 1</td><td>Favours shorter interval</td></tr></table>",
                "type_str": "table"
            },
            "TABREF35": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Longer interval</td><td>Shorter</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td colspan=\"2\">interval</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td colspan=\"2\">M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">2.2.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)</td><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>88/239</td><td>92/238</td><td/><td>100%</td><td>0.95[0.76,1.2]</td></tr><tr><td>Subtotal (95% CI)</td><td>239</td><td>238</td><td/><td>100%</td><td>0.95[0.76,1.2]</td></tr><tr><td colspan=\"2\">Total events: 88 (Longer interval), 92 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.41(P=0.68)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">2.2.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)</td><td/><td/><td/><td/></tr><tr><td>Puthanakit 2016</td><td>171/413</td><td>225/550</td><td/><td>100%</td><td>1.01[0.87,1.18]</td></tr><tr><td>Subtotal (95% CI)</td><td>413</td><td>550</td><td/><td>100%</td><td>1.01[0.87,1.18]</td></tr><tr><td colspan=\"2\">Total events: 171 (Longer interval), 225 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.15(P=0.88)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =0.19, df=1 (P=0.67), I =0%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours longer interval</td><td>1 1 1</td><td>Favours shorter interval</td><td/></tr><tr><td>Analysis 2.3.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF36": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Longer interval</td><td>Shorter</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td/><td>interval</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">2.3.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)</td><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>112/239</td><td>109/238</td><td/><td>100%</td><td>1.02[0.84,1.24]</td></tr><tr><td>Subtotal (95% CI)</td><td>239</td><td>238</td><td/><td>100%</td><td>1.02[0.84,1.24]</td></tr><tr><td colspan=\"2\">Total events: 112 (Longer interval), 109 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.23(P=0.82)</td><td/><td/><td/><td/><td/></tr><tr><td>2.3</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF37": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Puthanakit 2016</td><td>197/413</td><td>247/550</td><td>100%</td><td>1.06[0.93,1.22]</td></tr><tr><td>Subtotal (95% CI)</td><td>413</td><td>550</td><td>100%</td><td>1.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF38": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 2.4.</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Total events: 197 (Longer interval), 247 (Shorter interval)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.86(P=0.39)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =0.1, df=1 (P=0.76), I =0%</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Favours longer interval</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours shorter interval</td></tr></table>",
                "type_str": "table"
            },
            "TABREF39": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Longer interval</td><td>Shorter</td><td>Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td colspan=\"2\">interval</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">2.4.1 Bivalent vaccine (0, 2 months vs 0, 6 months)</td><td/><td/><td/><td/></tr><tr><td>Romanowski 2011</td><td>16/241</td><td>14/240</td><td/><td>100%</td><td>1.15[0.55,2.41]</td></tr><tr><td>Subtotal (95% CI)</td><td>241</td><td>240</td><td/><td>100%</td><td>1.15[0.55,2.41]</td></tr><tr><td colspan=\"2\">Total events: 16 (Longer interval), 14 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.37(P=0.72)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">2.4.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)</td><td/><td/><td/><td/></tr><tr><td>Puthanakit 2016</td><td>24/415</td><td>20/550</td><td/><td>100%</td><td>1.63[0.89,2.99]</td></tr><tr><td>Subtotal (95% CI)</td><td>415</td><td>550</td><td/><td>100%</td><td>1.63[0.89,2.99]</td></tr><tr><td colspan=\"2\">Total events: 24 (Longer interval), 20 (Shorter interval)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.57(P=0.12)</td><td/><td/><td/><td/><td/></tr><tr><td>2.4.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF40": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Iversen 2016</td><td>6/301</td><td>15/602</td><td/><td/><td/><td/><td>100%</td><td>0.8[0.31,2.07]</td></tr><tr><td>Subtotal (95% CI)</td><td>301</td><td>602</td><td/><td/><td/><td/><td>100%</td><td>0.8[0.31,2.07]</td></tr><tr><td colspan=\"2\">Total events: 6 (Longer interval), 15 (Shorter interval)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.47(P=0.64)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =1.62, df=1 (P=0.44), I =0%</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours longer interval</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours shorter interval</td></tr><tr><td>Analysis 2.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF41": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Romanowski 2011</td><td>0/241</td><td>0/240</td><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>241</td><td>240</td><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Longer interval), 0 (Shorter interval)</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/></tr><tr><td>2.5.</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF42": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Longer interval</td><td>Shorter</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td/><td>interval</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Subtotal (95% CI)</td><td>151</td><td>301</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Longer interval), 0 (Shorter interval)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours longer interval</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours shorter interval</td></tr><tr><td>Comparison 3.</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Puthanakit 2016</td><td>0/415</td><td>0/550</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>415</td><td>550</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Longer interval), 0 (Shorter interval)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">2.5.3 Nonavalent vaccine (0 and 6 months vs 0 and 12 months)</td><td/><td/><td/><td/></tr><tr><td>Iversen 2016</td><td>0/151</td><td>0/301</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td/><td colspan=\"2\">Favours longer interval</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours shorter interval</td></tr></table>",
                "type_str": "table"
            },
            "TABREF43": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td>pants</td><td/><td/></tr><tr><td>1 Adverse events</td><td/><td/><td>Other data</td><td>No numeric data</td></tr><tr><td>2 Serious adverse events (overall)</td><td>1</td><td>220</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td/><td/><td/><td>95% CI)</td><td/></tr><tr><td>Analysis 3.1.</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF44": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>Adverse events</td></tr><tr><td>Study</td><td/></tr><tr><td>Lin 2014</td><td>Adverse events data not reported separately for each arm.</td></tr><tr><td/><td>\"Participants reported side effects following 646 separate vaccinations; 172 local</td></tr><tr><td/><td>and general reactions were reported, with no difference in proportion of side ef-</td></tr><tr><td/><td>fects reported between Standard (24.4%) and Alternate (28.9%) schedule groups (P</td></tr><tr><td/><td>= 0.26). The majority of side effects were pain and redness at the injection site (86%;</td></tr><tr><td/><td>n = 148), with the remainder composed of fever (3.5%; n = 6), and miscellaneous</td></tr><tr><td/><td>symptoms (10.5%; n = 18). There were no reports of any serious side effects.\"</td></tr></table>",
                "type_str": "table"
            },
            "TABREF45": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td colspan=\"2\">No. of studies</td><td colspan=\"2\">No. of partici-</td><td colspan=\"2\">Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td>pants</td><td/><td/></tr><tr><td colspan=\"2\">9.1 Bivalent vaccine (10-to 18-year-</td><td>1</td><td/><td>268</td><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>2.51 [1.17, 5.42]</td></tr><tr><td>olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">9.2 Quadrivalent vaccine (16-to 26-</td><td>2</td><td/><td>5162</td><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>1.29 [1.04, 1.60]</td></tr><tr><td>year olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">10 Redness at injection site</td><td>3</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">10.1 Bivalent vaccine (10-to 18-year-</td><td>1</td><td/><td>268</td><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>1.66 [0.99, 2.79]</td></tr><tr><td>olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">10.2 Quadrivalent vaccine (16-to 26-</td><td>2</td><td/><td>5162</td><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>1.12 [0.99, 1.27]</td></tr><tr><td>year olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">11 Overall systemic events and gener-</td><td>2</td><td/><td/><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td>al symptoms</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">11.1 Quadrivalent vaccine (16-to 26-</td><td>2</td><td/><td>5008</td><td/><td colspan=\"2\">Risk Ratio (M-H, Random,</td><td>0.99 [0.90, 1.08]</td></tr><tr><td>year olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">12 Serious adverse events (overall)</td><td>3</td><td/><td/><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">12.1 Bivalent vaccine (10-to 18-year-</td><td>1</td><td/><td>270</td><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>1.48 [0.15, 14.46]</td></tr><tr><td>olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">12.2 Quadrivalent vaccine (16-to 26-</td><td>2</td><td/><td>5162</td><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>0.69 [0.29, 1.66]</td></tr><tr><td>year olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td>13 Deaths</td><td/><td>3</td><td/><td/><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">13.1 Bivalent vaccine (10-to 18-year-</td><td>1</td><td/><td>270</td><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td>olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td colspan=\"2\">13.2 Quadrivalent vaccine (16-to 26-</td><td>2</td><td/><td>5173</td><td/><td colspan=\"2\">Odds Ratio (M-H, Random,</td><td>0.30 [0.09, 1.01]</td></tr><tr><td>year olds)</td><td/><td/><td/><td/><td/><td colspan=\"2\">95% CI)</td></tr><tr><td>Study or subgroup</td><td colspan=\"2\">Longer interval</td><td>Shorter</td><td/><td colspan=\"2\">Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td/><td/><td>interval</td><td/><td/><td/></tr><tr><td>Analysis 4.1.</td><td>n/N</td><td/><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Lin 2014</td><td colspan=\"2\">0/111</td><td>0/109</td><td/><td/><td/><td>Not estimable</td></tr><tr><td>Total (95% CI)</td><td colspan=\"2\">111</td><td>109</td><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Longer interval), 0 (Shorter interval)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours longer interval</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours shorter interval</td></tr></table>",
                "type_str": "table"
            },
            "TABREF46": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td colspan=\"2\">Analysis 4.2.</td><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.1.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-1.8 (0.441)</td><td/><td/><td/><td>100%</td><td>0.16[0.07,0.38]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.16[0.07,0.38]</td></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=4.13(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF47": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.2.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-2.3 (0.594)</td><td/><td/><td/><td>100%</td><td>0.1[0.03,0.31]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.1[0.03,0.31]</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=3.94(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Analysis 4.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF48": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.3.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-2.2 (0.646)</td><td/><td/><td/><td>100%</td><td>0.11[0.03,0.38]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.11[0.03,0.38]</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.46(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td colspan=\"2\">Analysis 4.4.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF49": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF50": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-1.8 (1.52)</td><td>100%</td><td>0.17[0.01,3.27]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td>100%</td><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF51": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.18(P=0.24)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Favours quadrivalent</td><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td><td>Favours control</td></tr><tr><td>Analysis 4.5</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF52": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.85(P=0.4)</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td><td>Favours control</td></tr><tr><td colspan=\"2\">Analysis 4.6.</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.5.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-1.4 (1.641)</td><td/><td/><td/><td>100%</td><td>0.25[0.01,6.22]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.25[0.01,6.22]</td></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF53": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>log[Rate</td><td/><td/><td>Rate Ratio</td><td>Weight</td><td>Rate Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td>Ratio]</td><td/><td/><td/></tr><tr><td/><td>N</td><td>N</td><td>(SE)</td><td/><td colspan=\"3\">IV, Random, 95% CI</td><td>IV, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.6.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>0</td><td>0</td><td>-0.7 (1.73)</td><td/><td/><td/><td>100%</td><td>0.5[0.02,14.8]</td></tr><tr><td>Subtotal (95% CI)</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.5[0.02,14.8]</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.4(P=0.69)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.001</td><td>0.1</td><td>1</td><td>10</td><td>1000</td><td>Favours control</td></tr><tr><td/><td colspan=\"2\">Analysis 4.7.</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF54": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>4.7.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF55": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Giuliano 2011</td><td>1169/1945</td><td>1047/1950</td><td/><td>100%</td><td>1.12[1.06,1.18]</td></tr><tr><td>Subtotal (95% CI)</td><td>1945</td><td>1950</td><td/><td>100%</td><td>1.12[1.06,1.18]</td></tr><tr><td colspan=\"2\">Total events: 1169 (Quadrivalent vaccine), 1047 (Control)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=4.03(P&lt;0.0001)</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>1 1 1</td><td>Favours control</td></tr><tr><td>Analysis 4.8.</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF56": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td/><td>Risk Ratio</td><td/><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>NCT01862874 2018</td><td>304/554</td><td>271/559</td><td/><td/><td/><td/><td/><td/><td>21.3%</td><td>1.13[1.01,1.27]</td></tr><tr><td>Subtotal (95% CI)</td><td>2574</td><td>2588</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>1.13[1.07,1.19]</td></tr><tr><td colspan=\"2\">Total events: 1420 (HPV vaccine), 1263 (Control)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=1(P=0.98); I =0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=4.56(P&lt;0.0001)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =20.45, df=1 (P&lt;0.0001), I =95.11%</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.1</td><td>0.2</td><td>0.5</td><td>1</td><td>2</td><td>5</td><td>10</td><td>Favours control</td></tr><tr><td>Analysis 4.9.</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td/><td>Risk Ratio</td><td/><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.8.1 Bivalent vaccine (10-to 18-year-olds)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Petaja 2009</td><td>159/180</td><td>39/88</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>1.99[1.57,2.53]</td></tr><tr><td>Subtotal (95% CI)</td><td>180</td><td>88</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>1.99[1.57,2.53]</td></tr><tr><td colspan=\"2\">Total events: 159 (HPV vaccine), 39 (Control)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=5.63(P&lt;0.0001)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.8.2 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>1116/2020</td><td>992/2029</td><td/><td/><td/><td/><td/><td/><td>78.7%</td><td>1.13[1.06,1.2]</td></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.1</td><td>0.2</td><td>0.5</td><td>1</td><td>2</td><td>5</td><td>10</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF57": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.9.1 Bivalent vaccine (10-to 18-year-olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Petaja 2009</td><td>36/180</td><td>7/88</td><td/><td/><td/><td/><td>100%</td><td>2.51[1.17,5.42]</td></tr><tr><td>Subtotal (95% CI)</td><td>180</td><td>88</td><td/><td/><td/><td/><td>100%</td><td>2.51[1.17,5.42]</td></tr><tr><td colspan=\"2\">Total events: 36 (HPV vaccine), 7 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=2.35(P=0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.9.2 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>219/2020</td><td>187/2029</td><td/><td/><td/><td/><td>58.35%</td><td>1.18[0.98,1.42]</td></tr><tr><td>NCT01862874 2018</td><td>118/554</td><td>81/559</td><td/><td/><td/><td/><td>41.65%</td><td>1.47[1.14,1.9]</td></tr><tr><td>Subtotal (95% CI)</td><td>2574</td><td>2588</td><td/><td/><td/><td/><td>100%</td><td>1.29[1.04,1.6]</td></tr><tr><td colspan=\"2\">Total events: 337 (HPV vaccine), 268 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0.01; Chi =1.9, df=1(P=0.17); I =47.38%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=2.32(P=0.02)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =2.68, df=1 (P=0.1), I =62.71%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Analysis 4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF58": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =2.14, df=1 (P=0.14), I =53.35%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td/><td>Analysis 4.</td><td/><td/><td/><td/><td/></tr><tr><td>Petaja 2009</td><td>51/180</td><td>15/88</td><td/><td/><td/><td/><td>100%</td><td>1.66[0.99,2.79]</td></tr><tr><td>Subtotal (95% CI)</td><td>180</td><td>88</td><td/><td/><td/><td/><td>100%</td><td>1.66[0.99,2.79]</td></tr><tr><td colspan=\"2\">Total events: 51 (HPV vaccine), 15 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.93(P=0.05)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.10.2 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>304/2020</td><td>275/2029</td><td/><td/><td/><td/><td>66.94%</td><td>1.11[0.95,1.29]</td></tr><tr><td>NCT01862874 2018</td><td>136/554</td><td>121/559</td><td/><td/><td/><td/><td>33.06%</td><td>1.13[0.91,1.41]</td></tr><tr><td>Subtotal (95% CI)</td><td>2574</td><td>2588</td><td/><td/><td/><td/><td>100%</td><td>1.12[0.99,1.27]</td></tr><tr><td colspan=\"2\">Total events: 440 (HPV vaccine), 396 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0.02, df=1(P=0.87); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.77(P=0.08)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF59": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td colspan=\"4\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">4.11.1 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>616/1945</td><td>622/1950</td><td/><td/><td/><td/><td>90.31%</td><td>0.99[0.91,1.09]</td></tr><tr><td>NCT01862874 2018</td><td>80/554</td><td>86/559</td><td/><td/><td/><td/><td>9.69%</td><td>0.94[0.71,1.24]</td></tr><tr><td>Subtotal (95% CI)</td><td>2499</td><td>2509</td><td/><td/><td/><td/><td>100%</td><td>0.99[0.9,1.08]</td></tr><tr><td colspan=\"2\">Total events: 696 (Quadrivalent vaccine), 708 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0.14, df=1(P=0.71); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.28(P=0.78)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours control</td></tr><tr><td>Analysis 4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF60": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td>Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>4.12.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF61": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Petaja 2009</td><td>3/181</td><td>1/89</td><td>100%</td><td>1.48[0.15,14.46]</td></tr><tr><td>Subtotal (95% CI)</td><td>181</td><td>89</td><td>100%</td><td>1.48[0.15,14.46]</td></tr><tr><td>Total events: 3 (HPV vaccine), 1 (Control)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.34(P=0.73)</td><td/><td/><td/><td/></tr><tr><td>4</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF62": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Giuliano 2011</td><td>8/2020</td><td>11/2029</td><td>92.49%</td><td>0.73[0.29,1.82]</td></tr><tr><td>NCT01862874 2018</td><td>0/554</td><td>1/559</td><td>7.51%</td><td>0.34[0.01,8.26]</td></tr><tr><td>Subtotal (95% CI)</td><td>2574</td><td>2588</td><td>100%</td><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF63": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Total events: 8 (HPV vaccine), 12 (Control)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Tau =0; Chi =0.21, df=1(P=0.65); I =0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.83(P=0.4)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Chi =0.38, df=1 (P=0.54), I =0%</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Analysis 4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF64": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Petaja 2009</td><td>0/181</td><td>0/89</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>181</td><td>89</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (HPV vaccine), 0 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">4.13.2 Quadrivalent vaccine (16-to 26-year olds)</td><td/><td/><td/><td/><td/></tr><tr><td>Giuliano 2011</td><td>3/2020</td><td>10/2029</td><td/><td/><td/><td/><td>86.01%</td><td>0.3[0.08,1.09]</td></tr><tr><td>NCT01862874 2018</td><td>0/562</td><td>1/562</td><td/><td/><td/><td/><td>13.99%</td><td>0.33[0.01,8.19]</td></tr><tr><td>Subtotal (95% CI)</td><td>2582</td><td>2591</td><td/><td/><td/><td/><td>100%</td><td>0.3[0.09,1.01]</td></tr><tr><td colspan=\"2\">Total events: 3 (HPV vaccine), 11 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=1(P=0.95); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.94(P=0.05)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Comparison 5.</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>HPV vaccine</td><td>Control</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td/><td colspan=\"2\">Favours HPV vaccine</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF65": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Outcome or subgroup title</td><td>No. of studies No. of studies</td><td>No. of partici-No. of partici-</td><td>Statistical method Statistical method</td><td>Effect size Effect size</td></tr><tr><td/><td/><td/><td>pants pants</td><td/></tr><tr><td colspan=\"2\">cal cancer related to HPV 31, 33, 45, 52, or 58 15.2 16-to 26-year-old females</td><td>1</td><td>14764</td><td>95% CI) Risk Ratio (M-H, Random,</td><td>1.01 [0.98, 1.04]</td></tr><tr><td colspan=\"2\">11 Overall local/injection site adverse events 15.3 16-to 26-year-old males</td><td>3 1</td><td>15863 500</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>1.07 [1.05, 1.08] 1.02 [0.82, 1.26]</td></tr><tr><td colspan=\"2\">11.1 9-to 15-year-old females 16 Serious adverse events (overall)</td><td>1 3</td><td>599 15863</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.04 [0.98, 1.09] 0.60 [0.14, 2.61]</td></tr><tr><td colspan=\"2\">11.2 16-to 26-year-old females 16.1 9-to 15-year-old females</td><td>1 1</td><td>14764 599</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.07 [1.05, 1.08] 0.5 [0.05, 5.54]</td></tr><tr><td colspan=\"2\">11.3 16-to 26-year-old males 16.2 16-to 26-year-old females</td><td>1 1</td><td>500 14764</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.10 [1.00, 1.22] 1.22 [1.00, 1.48]</td></tr><tr><td colspan=\"2\">12 Pain at injection site 16.3 16-to 26-year-old males</td><td>3 1</td><td>15863 500</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.06 [1.02, 1.11] 0.08 [0.00, 1.35]</td></tr><tr><td colspan=\"2\">12.1 9-to 15-year-old females 17 Deaths</td><td>1 3</td><td>599 15248</td><td>Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.01 [0.96, 1.07] 1.20 [0.37, 3.94]</td></tr><tr><td colspan=\"2\">12.2 16-to 26-year-old females 17.1 9-to 15-year old females</td><td>1 1</td><td>14764 599</td><td>Statistical method Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>Effect size 1.07 [1.06, 1.09] 0.0 [0.0, 0.0]</td></tr><tr><td colspan=\"2\">1 High-grade cervical epithelial neo-plasia, adenocarcinoma in situ, and 12.3 16-to 26-year-old males 17.2 16-to 26-year-old females</td><td>1 1 1</td><td>13753 500 14149</td><td>Odds Ratio (M-H, Random, 95% CI) Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>1.00 [0.85, 1.16] 1.12 [1.01, 1.24] 1.20 [0.37, 3.94]</td></tr><tr><td colspan=\"2\">cervical cancer 2 High-grade cervical, vulval, and 13 Swelling at injection site 17.3 16-to 26-year-old males</td><td>1 3 1</td><td>14054 15863 500</td><td>Odds Ratio (M-H, Random, Risk Ratio (M-H, Random, 95% CI) 95% CI) Odds Ratio (M-H, Random,</td><td>0.99 [0.85, 1.15] 1.37 [1.31, 1.44] 0.0 [0.0, 0.0]</td></tr><tr><td colspan=\"2\">vaginal disease 13.1 9-to 15-year-old females</td><td>1</td><td>599</td><td>95% CI) Risk Ratio (M-H, Random,</td><td>1.33 [1.10, 1.60]</td></tr><tr><td colspan=\"2\">3 High-grade cervical disease related</td><td>1</td><td>11656</td><td>Odds Ratio (M-H, Random, 95% CI)</td><td>1.00 [0.06, 16.01]</td></tr><tr><td colspan=\"2\">to HPV 6, 11, 16, or 18 4 High-grade vulval and vaginal dis-13.2 16-to 26-year-old females Analysis 5.1.</td><td>1 1</td><td>11769 14764</td><td>95% CI) Odds Ratio (M-H, Random, Risk Ratio (M-H, Random, 95% CI)</td><td>0.14 [0.01, 2.77] 1.38 [1.31, 1.44]</td></tr><tr><td colspan=\"2\">ease related to HPV 6, 11, 16, or 18 13.3 16-to 26-year-old males</td><td>1</td><td>500</td><td>95% CI) Risk Ratio (M-H, Random,</td><td>1.58 [0.96, 2.58]</td></tr><tr><td colspan=\"2\">5 High-grade cervical disease related</td><td>1</td><td>11892</td><td>Odds Ratio (M-H, Random, 95% CI)</td><td>0.03 [0.00, 0.21]</td></tr><tr><td colspan=\"2\">to HPV 31, 33, 45, 52, or 58 14 Redness at injection site</td><td>3</td><td>15863</td><td>95% CI) Risk Ratio (M-H, Random,</td><td>1.20 [1.00, 1.44]</td></tr><tr><td colspan=\"2\">6 High-grade vulval and vaginal dis-</td><td>1</td><td>12021</td><td>Odds Ratio (M-H, Random, 95% CI)</td><td>0.14 [0.01, 2.77]</td></tr><tr><td colspan=\"2\">ease related to HPV 31, 33, 45, 52, or 58 14.1 9-to 15-year-old females</td><td>1</td><td>599</td><td>95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>1.16 [0.92, 1.47]</td></tr><tr><td colspan=\"2\">7 Cervical intraepithelial neoplasia 2 related to HPV 6, 11, 16, or 18 14.2 16-to 26-year-old females</td><td>1 1</td><td>11656 14764</td><td>Odds Ratio (M-H, Random, 95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>3.00 [0.12, 73.77] 1.32 [1.26, 1.39]</td></tr><tr><td colspan=\"2\">8 Cervical intraepithelial neoplasia 2 related to HPV 31, 33, 45, 52, or 58 14.3 16-to 26-year-old males</td><td>1 1</td><td>11892 500</td><td>Odds Ratio (M-H, Random, 95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>0.03 [0.00, 0.23] 0.89 [0.60, 1.33]</td></tr><tr><td colspan=\"2\">9 Cervical intraepithelial neoplasia 3, adenocarcinoma in situ, and cervical cancer related to HPV 6, 11, 16, or 18 al symptoms 15 Overall systemic events and gener-</td><td>1 3</td><td>11656 15863</td><td>Odds Ratio (M-H, Random, 95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>0.33 [0.01, 8.19] 1.01 [0.98, 1.04]</td></tr><tr><td colspan=\"2\">10 Cervical intraepithelial neoplasia 3, adenocarcinoma in situ, and cervi-15.1 9-to 15-year-old females</td><td>1 1</td><td>11892 599</td><td>Odds Ratio (M-H, Random, 95% CI) 95% CI) Risk Ratio (M-H, Random,</td><td>0.07 [0.00, 1.16] 0.91 [0.78, 1.07]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF66": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 5.2.</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>325/6882</td><td>326/6871</td><td/><td/><td/><td/><td>100%</td><td>1[0.85,1.16]</td></tr><tr><td>Total (95% CI)</td><td>6882</td><td>6871</td><td/><td/><td/><td/><td>100%</td><td>1[0.85,1.16]</td></tr><tr><td colspan=\"3\">Total events: 325 (Nonavalent vaccine), 326 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.06(P=0.95)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF67": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>340/7027</td><td>344/7027</td><td/><td/><td/><td/><td>100%</td><td>0.99[0.85,1.15]</td></tr><tr><td>Total (95% CI)</td><td>7027</td><td>7027</td><td/><td/><td/><td/><td>100%</td><td>0.99[0.85,1.15]</td></tr><tr><td colspan=\"3\">Total events: 340 (Nonavalent vaccine), 344 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.16(P=0.88)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Analysis 5.3.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF68": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>1/5824</td><td>1/5832</td><td/><td/><td/><td/><td>100%</td><td>1[0.06,16.01]</td></tr><tr><td>Total (95% CI)</td><td>5824</td><td>5832</td><td/><td/><td/><td/><td>100%</td><td>1[0.06,16.01]</td></tr><tr><td colspan=\"3\">Total events: 1 (Nonavalent vaccine), 1 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0(P=1)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Analysis 5.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF69": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Joura 2015</td><td>0/5876</td><td>3/5893</td><td>100%</td><td>0.14[0.01,2.77]</td></tr><tr><td>Total (95% CI)</td><td>5876</td><td>5893</td><td>100%</td><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF70": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 5.5</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Total events: 0 (Nonavalent vaccine), 3 (Quadrivalent vaccine)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.29(P=0.2)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF71": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>1/5949</td><td>35/5943</td><td/><td/><td/><td/><td>100%</td><td>0.03[0,0.21]</td></tr><tr><td>Total (95% CI)</td><td>5949</td><td>5943</td><td/><td/><td/><td/><td>100%</td><td>0.03[0,0.21]</td></tr><tr><td colspan=\"3\">Total events: 1 (Nonavalent vaccine), 35 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.51(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Analysis 5.6.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF72": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>0/6009</td><td>3/6012</td><td/><td/><td/><td/><td>100%</td><td>0.14[0.01,2.77]</td></tr><tr><td>Total (95% CI)</td><td>6009</td><td>6012</td><td/><td/><td/><td/><td>100%</td><td>0.14[0.01,2.77]</td></tr><tr><td colspan=\"3\">Total events: 0 (Nonavalent vaccine), 3 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.29(P=0.2)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Analysis 5.7.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF73": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Joura 2015</td><td>1/5824</td><td>0/5832</td><td>100%</td><td>3[0.12,73.77]</td></tr><tr><td>Total (95% CI)</td><td>5824</td><td>5832</td><td>100%</td><td>3[0</td></tr></table>",
                "type_str": "table"
            },
            "TABREF74": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 5.8.</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Total events: 1 (Nonavalent vaccine), 0 (Quadrivalent vaccine)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.67(P=0.5)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF75": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>1/5949</td><td>32/5943</td><td/><td/><td/><td/><td>100%</td><td>0.03[0,0.23]</td></tr><tr><td>Total (95% CI)</td><td>5949</td><td>5943</td><td/><td/><td/><td/><td>100%</td><td>0.03[0,0.23]</td></tr><tr><td colspan=\"3\">Total events: 1 (Nonavalent vaccine), 32 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.42(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Analysis 5.9.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF76": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Joura 2015</td><td>0/5824</td><td>1/5832</td><td/><td/><td/><td/><td>100%</td><td>0.33[0.01,8.19]</td></tr><tr><td>Total (95% CI)</td><td>5824</td><td>5832</td><td/><td/><td/><td/><td>100%</td><td>0.33[0.01,8.19]</td></tr><tr><td colspan=\"3\">Total events: 0 (Nonavalent vaccine), 1 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.67(P=0.5)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td colspan=\"2\">Analysis 5.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF77": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 5.</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>0/5949</td><td>7/5943</td><td/><td/><td/><td/><td>100%</td><td>0.07[0,1.16]</td></tr><tr><td>Total (95% CI)</td><td>5949</td><td>5943</td><td/><td/><td/><td/><td>100%</td><td>0.07[0,1.16]</td></tr><tr><td colspan=\"2\">Total events: 0 (Nonavalent vaccine), 7 (Quadrivalent vaccine)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.86(P=0.06)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF78": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.11.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>274/299</td><td>265/300</td><td/><td>4.87%</td><td>1.04[0.98,1.09]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>4.87%</td><td>1.04[0.98,1.09]</td></tr><tr><td colspan=\"3\">Total events: 274 (Nonavalent vaccine), 265 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.35(P=0.18)</td><td/><td/><td/><td/><td/></tr><tr><td>5.11.2 16-to 26-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>6961/7686</td><td>6009/7078</td><td/><td>93.78%</td><td>1.07[1.05,1.08]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td>93.78%</td><td>1.07[1.05,1.08]</td></tr><tr><td colspan=\"3\">Total events: 6961 (Nonavalent vaccine), 6009 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=10.4(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td>5.11.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>196/249</td><td>179/251</td><td/><td>1.35%</td><td>1.1[1,1.22]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td>1.35%</td><td>1.1[1,1.22]</td></tr><tr><td colspan=\"3\">Total events: 196 (Nonavalent vaccine), 179 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.9(P=0.06)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td>100%</td><td>1.07[1.05,1.08]</td></tr><tr><td colspan=\"3\">Total events: 7431 (Nonavalent vaccine), 6453 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =1.47, df=2(P=0.48); I =0%</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=10.59(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =1.46, df=1 (P=0.48), I =0%</td><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr><tr><td colspan=\"2\">Analysis</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF79": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">Test for overall effect: Z=11.06(P&lt;0.0001)</td><td/><td/><td/><td/></tr><tr><td>5.12.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>193/249</td><td>174/251</td><td/><td>13.37%</td><td>1.12[1.01,1.24]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td>13.37%</td><td>1.12[1.01,1.24]</td></tr><tr><td colspan=\"3\">Total events: 193 (Nonavalent vaccine), 174 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=2.06(P=0.04)</td><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td>100%</td><td>1.06[1.02,1.11]</td></tr><tr><td colspan=\"3\">Total events: 7362 (Nonavalent vaccine), 6351 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =4.6, df=2(P=0.1); I =56.48%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=2.66(P=0.01)</td><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =4.56, df=1 (P=0.1), I =56.17%</td><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr><tr><td colspan=\"2\">Analysis 5.</td><td/><td/><td/><td/></tr><tr><td/><td/><td/><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.12.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>269/299</td><td>266/300</td><td/><td>30.53%</td><td>1.01[0.96,1.07]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>30.53%</td><td>1.01[0.96,1.07]</td></tr><tr><td colspan=\"3\">Total events: 269 (Nonavalent vaccine), 266 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.51(P=0.61)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">5.12.2 16-to 26-year-old females</td><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>6900/7686</td><td>5911/7078</td><td/><td>56.1%</td><td>1.07[1.06,1.09]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td>56.1%</td><td>1.07[1.06,1.09]</td></tr><tr><td colspan=\"3\">Total events: 6900 (Nonavalent vaccine), 5911 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF80": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.13.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>144/299</td><td>109/300</td><td/><td>5.45%</td><td>1.33[1.1,1.6]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>5.45%</td><td>1.33[1.1,1.6]</td></tr><tr><td colspan=\"3\">Total events: 144 (Nonavalent vaccine), 109 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=2.9(P=0)</td><td/><td/><td/><td/><td/></tr><tr><td>5.13.2 16-to 26-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>3039/7686</td><td>2035/7078</td><td/><td>93.73%</td><td>1.38[1.31,1.44]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td>93.73%</td><td>1.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF81": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Analysis 5.</td><td/><td/><td/></tr><tr><td colspan=\"3\">Total events: 3039 (Nonavalent vaccine), 2035 (Quadrivalent vaccine)</td><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=13.6(P&lt;0.0001)</td><td/><td/><td/></tr><tr><td>5.13.3 16-to 26-year-old males</td><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>36/249</td><td>23/251</td><td/><td>0.81%</td><td>1.58[0.96,2.58]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td>0.81%</td><td>1.58[0.96,2.58]</td></tr><tr><td colspan=\"2\">Total events: 36 (Nonavalent vaccine), 23 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.81(P=0.07)</td><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td>100%</td><td>1.37[1.31,1.44]</td></tr><tr><td colspan=\"3\">Total events: 3219 (Nonavalent vaccine), 2167 (Quadrivalent vaccine)</td><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0.44, df=2(P=0.8); I =0%</td><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=14.01(P&lt;0.0001)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =0.44, df=1 (P=0.8), I =0%</td><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF82": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td colspan=\"2\">lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.14.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>102/299</td><td>88/300</td><td/><td>29.52%</td><td>1.16[0.92,1.47]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>29.52%</td><td>1.16[0.92,1.47]</td></tr><tr><td colspan=\"3\">Total events: 102 (Nonavalent vaccine), 88 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.25(P=0.21)</td><td/><td/><td/><td/><td/></tr><tr><td>5.14.2 16-to 26-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>2602/7686</td><td>1810/7078</td><td/><td>55.01%</td><td>1.32[1.26,1.39]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td>55.01%</td><td>1.32[1.26,1.39]</td></tr><tr><td colspan=\"3\">Total events: 2602 (Nonavalent vaccine), 1810 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=10.88(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td>5.14.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>38/249</td><td>43/251</td><td/><td>15.47%</td><td>0.89[0.6,1.33]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td>15.47%</td><td>0.89[0.6,1.33]</td></tr><tr><td colspan=\"3\">Total events: 38 (Nonavalent vaccine), 43 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.57(P=0.57)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td>100%</td><td>1.2[1,1.44]</td></tr><tr><td colspan=\"3\">Total events: 2742 (Nonavalent vaccine), 1941 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Tau =0.02; Chi =4.72, df=2(P=0.09); I =57.64%</td><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.93(P=0.05)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =4.72, df=1 (P=0.09), I =57.63%</td><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr><tr><td>Analysis</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF83": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"3\">Total events: 4268 (Nonavalent vaccine), 3886 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.77(P=0.44)</td><td/><td/><td/><td/></tr><tr><td>5.15.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>101/249</td><td>100/251</td><td/><td>1.76%</td><td>1.02[0.82,1.26]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td>1.76%</td><td>1.02[0.82,1.26]</td></tr><tr><td colspan=\"3\">Total events: 101 (Nonavalent vaccine), 100 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.16(P=0.87)</td><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td>100%</td><td>1.01[0.98,1.04]</td></tr><tr><td colspan=\"3\">Total events: 4511 (Nonavalent vaccine), 4142 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =1.5, df=2(P=0.47); I =0%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.57(P=0.57)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Chi =1.5, df=1 (P=0.47), I =0%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr><tr><td colspan=\"2\">Analysis 5.</td><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.15.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>142/299</td><td>156/300</td><td/><td>3.09%</td><td>0.91[0.78,1.07]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>3.09%</td><td>0.91[0.78,1.07]</td></tr><tr><td colspan=\"3\">Total events: 142 (Nonavalent vaccine), 156 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0, df=0(P&lt;0.0001); I =100%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.1(P=0.27)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">5.15.2 16-to 26-year-old females</td><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>4268/7686</td><td>3886/7078</td><td/><td>95.15%</td><td>1.01[0.98,1.04]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td>95.15%</td><td>1.01[0.98,1.04]</td></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>1 1 1</td><td>Favours quadrivalent</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF84": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td>Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>5.16.1 9-to 15-year-old females</td><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>1/299</td><td>2/300</td><td/><td>22.92%</td><td>0.5[0.05,5.54]</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td>22.92%</td><td>0.5[0.05,5.54]</td></tr><tr><td colspan=\"3\">Total events: 1 (Nonavalent vaccine), 2 (Quadrivalent vaccine)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.56(P=0.57)</td><td/><td/><td/><td/><td/></tr><tr><td>5</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF85": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =4.06, df=1 (P=0.13), I =50.77%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td/><td>Analysis 5.</td><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>242/7686</td><td>184/7078</td><td/><td/><td/><td/><td>59%</td><td>1.22[1,1.48]</td></tr><tr><td>Subtotal (95% CI)</td><td>7686</td><td>7078</td><td/><td/><td/><td/><td>59%</td><td>1.22[1,1.48]</td></tr><tr><td colspan=\"3\">Total events: 242 (Nonavalent vaccine), 184 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.99(P=0.05)</td><td/><td/><td/><td/><td/></tr><tr><td>5.16.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>0/249</td><td>6/251</td><td/><td/><td/><td/><td>18.08%</td><td>0.08[0,1.35]</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td/><td/><td/><td>18.08%</td><td>0.08[0,1.35]</td></tr><tr><td colspan=\"3\">Total events: 0 (Nonavalent vaccine), 6 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.76(P=0.08)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>8234</td><td>7629</td><td/><td/><td/><td/><td>100%</td><td>0.6[0.14,2.61]</td></tr><tr><td colspan=\"3\">Total events: 243 (Nonavalent vaccine), 192 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0.94; Chi =4.1, df=2(P=0.13); I =51.25%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.68(P=0.5)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr></table>",
                "type_str": "table"
            },
            "TABREF86": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Nonava-</td><td>Quadriva-</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>5.17.1 9-to 15-year old females</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Vesikari 2015</td><td>0/299</td><td>0/300</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>299</td><td>300</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"3\">Total events: 0 (Nonavalent vaccine), 0 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.17.2 16-to 26-year-old females</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Joura 2015</td><td>6/7071</td><td>5/7078</td><td/><td/><td/><td/><td>100%</td><td>1.2[0.37,3.94]</td></tr><tr><td>Subtotal (95% CI)</td><td>7071</td><td>7078</td><td/><td/><td/><td/><td>100%</td><td>1.2[0.37,3.94]</td></tr><tr><td colspan=\"3\">Total events: 6 (Nonavalent vaccine), 5 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.3(P=0.76)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>5.17.3 16-to 26-year-old males</td><td/><td/><td/><td/><td/><td/></tr><tr><td>van Damme 2016</td><td>0/249</td><td>0/251</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>249</td><td>251</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"3\">Total events: 0 (Nonavalent vaccine), 0 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>7619</td><td>7629</td><td/><td/><td/><td/><td>100%</td><td>1.2[0.37,3.94]</td></tr><tr><td colspan=\"3\">Total events: 6 (Nonavalent vaccine), 5 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.3(P=0.76)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours nonavalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Comparison 6.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF87": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">2 Recurrence of anogenital warts</td><td>1</td><td/><td>Risk Ratio (M-H, Random, 95%</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">2.1 18-to 65-year-old females and</td><td>1</td><td>12</td><td>Risk Ratio (M-H, Random, 95%</td><td>0.71 [0.06, 8.90]</td></tr><tr><td colspan=\"2\">males with HIV treated for anogeni-</td><td/><td/><td>CI)</td></tr><tr><td>tal warts</td><td/><td/><td/><td/></tr><tr><td>3 Abnormal anal cytology</td><td/><td>1</td><td/><td>Risk Ratio (M-H, Random, 95%</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">3.1 \u2265 27-year-old females and males</td><td>1</td><td>262</td><td>Risk Ratio (M-H, Random, 95%</td><td>0.82 [0.64, 1.05]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4 Overall local/injection site adverse</td><td>1</td><td/><td>Risk Ratio (M-H, Random, 95%</td><td>Subtotals only</td></tr><tr><td>events</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">4.1 7-to 12-year-old children with</td><td>1</td><td>126</td><td>Risk Ratio (M-H, Random, 95%</td><td>2.19 [0.70, 6.83]</td></tr><tr><td>HIV</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">5 Overall systemic event and gener-</td><td>1</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td>al symptoms</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">5.1 7-to 12-year-old children with</td><td>1</td><td>126</td><td>Odds Ratio (M-H, Random,</td><td>0.62 [0.05, 7.05]</td></tr><tr><td>HIV</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">6 Serious adverse events (overall)</td><td>2</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">6.1 \u2265 27 year old females and males</td><td>1</td><td>575</td><td>Odds Ratio (M-H, Random,</td><td>0.68 [0.42, 1.10]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">6.2 \u2265 18-year-old MSM with HIV</td><td>1</td><td>129</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td>7 Deaths</td><td/><td>2</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">7.1 \u2265 27-year-old females and males</td><td>1</td><td>575</td><td>Odds Ratio (M-H, Random,</td><td>0.49 [0.12, 1.99]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">7.2 \u2265 18-year-old MSM with HIV</td><td>1</td><td>129</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"3\">Outcome or subgroup title Analysis 6.1. No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">1 High-grade anal intraepithelial</td><td>1</td><td/><td>Risk Ratio (M-H, Random, 95%</td><td>Subtotals only</td></tr><tr><td>neoplasia</td><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"2\">1.1 \u2265 27-year-old females and males</td><td>1</td><td>574</td><td>Risk Ratio (M-H, Random, 95%</td><td>1.02 [0.70, 1.48]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>CI)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF88": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Subtotal (95% CI)</td><td>288</td><td>286</td><td/><td/><td/><td/><td>100%</td><td>1.02[0.7,1.48]</td></tr><tr><td colspan=\"2\">Total events: 46 (Quadrivalent vaccine), 45 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.08(P=0.94)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours control</td></tr><tr><td/><td>Analysis 6.2.</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">6.1.1 \u2265 27-year-old females and males with HIV</td><td/><td/><td/><td/><td/></tr><tr><td>Wilkin 2018</td><td>46/288</td><td>45/286</td><td/><td/><td/><td/><td>100%</td><td>1.02[0.7,1.48]</td></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF89": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"3\">6.2.1 18-to 65-year-old females and males with HIV treated for</td><td/><td/><td/><td/></tr><tr><td>anogenital warts</td><td/><td/><td/><td/><td/><td/></tr><tr><td>NCT00941889 2016</td><td>1/7</td><td>1/5</td><td/><td/><td/><td/><td>100%</td><td>0.71[0.06,8.9]</td></tr><tr><td>Subtotal (95% CI)</td><td>7</td><td>5</td><td/><td/><td/><td/><td>100%</td><td>0.71[0.06,8.9]</td></tr><tr><td colspan=\"2\">Total events: 1 (Quadrivalent vaccine), 1 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.26(P=0.79)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td/><td>Analysis 6.3.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF90": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>Risk Ratio</td><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>6.3.1 \u2265</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF91": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Wilkin 2018</td><td>58/130</td><td>72/132</td><td>100%</td><td>0.82[0.64,1.05]</td></tr><tr><td>Subtotal (95% CI)</td><td>130</td><td>132</td><td>100%</td><td>0.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF92": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Total events: 58 (Quadrivalent vaccine), 72 (Control)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.6(P=0.11)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Analysis 6.4.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF93": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.35(P=0.18)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td colspan=\"2\">Analysis 6.5.</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">6.4.1 7-to 12-year-old children with HIV</td><td/><td/><td/><td/><td/></tr><tr><td>Levin 2010</td><td>21/96</td><td>3/30</td><td/><td/><td/><td/><td>100%</td><td>2.19[0.7,6.83]</td></tr><tr><td>Subtotal (95% CI)</td><td>96</td><td>30</td><td/><td/><td/><td/><td>100%</td><td>2.19[0.7,6.83]</td></tr><tr><td colspan=\"2\">Total events: 21 (Quadrivalent vaccine), 3 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF94": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">6.5.1 7-to 12-year-old children with HIV</td><td/><td/><td/><td/><td/></tr><tr><td>Levin 2010</td><td>2/96</td><td>1/30</td><td/><td/><td/><td/><td>100%</td><td>0.62[0.05,7.05]</td></tr><tr><td>Subtotal (95% CI)</td><td>96</td><td>30</td><td/><td/><td/><td/><td>100%</td><td>0.62[0.05,7.05]</td></tr><tr><td colspan=\"2\">Total events: 2 (Quadrivalent vaccine), 1 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.39(P=0.7)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td colspan=\"2\">Analysis 6.6.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF95": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td>Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td>M-H, Random, 95% CI</td><td/><td>M-H, Random, 95% CI</td></tr><tr><td>6.6.1 \u2265</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF96": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Wilkin 2018</td><td>33/288</td><td>46/287</td><td>100%</td><td>0.68[0.42,1.1]</td></tr><tr><td>Subtotal (95% CI)</td><td>288</td><td>287</td><td>100%</td><td>0.68[0.42,1.1]</td></tr><tr><td colspan=\"2\">Total events: 33 (Quadrivalent vaccine), 46 (Control)</td><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=1.58(P=0.11)</td><td/><td/><td/><td/></tr><tr><td>6.6</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF97": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Analysis 6.7.</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Hidalgo-Tenorio 2017</td><td>0/66</td><td>0/63</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>66</td><td>63</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Quadrivalent vaccine), 0 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr></table>",
                "type_str": "table"
            },
            "TABREF98": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Quadriva-</td><td>Control</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>lent vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">6.7.1 \u2265 27-year-old females and males with HIV</td><td/><td/><td/><td/><td/></tr><tr><td>Wilkin 2018</td><td>3/288</td><td>6/287</td><td/><td/><td/><td/><td>100%</td><td>0.49[0.12,1.99]</td></tr><tr><td>Subtotal (95% CI)</td><td>288</td><td>287</td><td/><td/><td/><td/><td>100%</td><td>0.49[0.12,1.99]</td></tr><tr><td colspan=\"2\">Total events: 3 (Quadrivalent vaccine), 6 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.99(P=0.32)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>6.7.2 \u2265 18-year-old MSM with HIV</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Hidalgo-Tenorio 2017</td><td>0/66</td><td>0/63</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>66</td><td>63</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Quadrivalent vaccine), 0 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours quadrivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Comparison 7.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF99": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td>Statistical method</td><td>Effect size</td></tr><tr><td>1 Pain at injection site</td><td>1</td><td>120</td><td>Risk Ratio (M-H, Random, 95% CI)</td><td>1.86 [1.38, 2.51]</td></tr><tr><td>2 Swelling at injection site</td><td>1</td><td>120</td><td>Risk Ratio (M-H, Random, 95% CI)</td><td>9.19 [2.24, 37.73]</td></tr><tr><td>3 Serious adverse events</td><td>1</td><td>120</td><td>Odds Ratio (M-H, Random, 95% CI)</td><td>1.47 [0.24, 9.15]</td></tr><tr><td>(overall)</td><td/><td/><td/><td/></tr><tr><td>4 Deaths</td><td>1</td><td>120</td><td>Odds Ratio (M-H, Random, 95% CI)</td><td>0.0 [0.0, 0.0]</td></tr></table>",
                "type_str": "table"
            },
            "TABREF100": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Bivalent</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Denny 2013</td><td>52/61</td><td>27/59</td><td/><td/><td/><td/><td>100%</td><td>1.86[1.38,2.51]</td></tr><tr><td>Total (95% CI)</td><td>61</td><td>59</td><td/><td/><td/><td/><td>100%</td><td>1.86[1.38,2.51]</td></tr><tr><td colspan=\"2\">Total events: 52 (Bivalent vaccine), 27 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=4.11(P&lt;0.0001)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Comparison</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF101": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>Analysis 7.2.</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF102": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Bivalent</td><td>Control</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Denny 2013</td><td>19/61</td><td>2/59</td><td/><td/><td/><td/><td>100%</td><td>9.19[2.24,37.73]</td></tr><tr><td>Total (95% CI)</td><td>61</td><td>59</td><td/><td/><td/><td/><td>100%</td><td>9.19[2.24,37.73]</td></tr><tr><td colspan=\"2\">Total events: 19 (Bivalent vaccine), 2 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=3.08(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td colspan=\"2\">Analysis 7.3.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF103": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Bivalent</td><td>Control</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>vaccine</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td>Denny 2013</td><td>3/61</td><td>2/59</td><td/><td/><td/><td/><td>100%</td><td>1.47[0.24,9.15]</td></tr><tr><td>Total (95% CI)</td><td>61</td><td>59</td><td/><td/><td/><td/><td>100%</td><td>1.47[0.24,9.15]</td></tr><tr><td colspan=\"2\">Total events: 3 (Bivalent vaccine), 2 (Control)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.42(P=0.68)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td/><td>Analysis 7.4.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF104": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Denny 2013</td><td>0/61</td><td>0/59</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Total (95% CI)</td><td>61</td><td>59</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Total events: 0 (Bivalent vaccine), 0 (Control)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours control</td></tr><tr><td>Comparison 8.</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF105": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td>pants</td><td/><td/></tr><tr><td>1 Overall local/injection site adverse</td><td>1</td><td/><td>Risk Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td>events</td><td/><td/><td>95% CI)</td><td/></tr><tr><td>Comparison</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF106": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title</td><td>No. of studies</td><td>No. of partici-</td><td>Statistical method</td><td>Effect size</td></tr><tr><td/><td/><td/><td>pants</td><td/></tr><tr><td colspan=\"2\">1.1 \u2265 18-year-old females and males</td><td>1</td><td>92</td><td>Risk Ratio (M-H, Random,</td><td>1.31 [1.06, 1.62]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2 Serious adverse events (overall)</td><td>2</td><td/><td>Odds Ratio (M-H, Random,</td><td>Subtotals only</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.1 \u2265 18-year-old females and males</td><td>1</td><td>92</td><td>Odds Ratio (M-H, Random,</td><td>0.0 [0.0, 0.0]</td></tr><tr><td>with HIV</td><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">2.2 15-to 25-year-old females with HIV</td><td>1</td><td>332</td><td>Odds Ratio (M-H, Random,</td><td>0.99 [0.38, 2.55]</td></tr><tr><td/><td/><td/><td/><td>95% CI)</td></tr><tr><td colspan=\"2\">Analysis 8.1.</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF107": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>Bivalent</td><td>Quadriva-</td><td/><td/><td>Risk Ratio</td><td/><td>Weight</td><td>Risk Ratio</td></tr><tr><td/><td>vaccine</td><td>lent vaccine</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"3\">M-H, Random, 95% CI</td><td>M-H, Random, 95% CI</td></tr><tr><td colspan=\"2\">8.1.1 \u2265 18-year-old females and males with HIV</td><td/><td/><td/><td/><td/></tr><tr><td>To 2014</td><td>42/46</td><td>32/46</td><td/><td/><td/><td/><td>100%</td><td>1.31[1.06,1.62]</td></tr><tr><td>Subtotal (95% CI)</td><td>46</td><td>46</td><td/><td/><td/><td/><td>100%</td><td>1.31[1.06,1.62]</td></tr><tr><td colspan=\"3\">Total events: 42 (Bivalent vaccine), 32 (Quadrivalent vaccine)</td><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=2.53(P=0.01)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td colspan=\"2\">Analysis 8.2.</td><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF108": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>To 2014</td><td>0/46</td><td>0/46</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Subtotal (95% CI)</td><td>46</td><td>46</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td colspan=\"2\">Total events: 0 (Bivalent vaccine), 0 (Quadrivalent vaccine)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>8.2.2 15-to 25-year-old females with HIV</td><td/><td/><td/><td/><td/><td/></tr><tr><td>NCT01031069 2017</td><td>9/167</td><td>9/165</td><td/><td/><td/><td/><td>100%</td><td>0.99[0.38,2.55]</td></tr><tr><td>Subtotal (95% CI)</td><td>167</td><td>165</td><td/><td/><td/><td/><td>100%</td><td>0.99[0.38,2.55]</td></tr><tr><td colspan=\"2\">Total events: 9 (Bivalent vaccine), 9 (Quadrivalent vaccine)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.03(P=0.98)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Test for subgroup differences: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours bivalent</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours quadrivalent</td></tr><tr><td>Comparison</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF109": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td/><td>month interval in</td><td/><td>Chikungunya virus infection, bacterial meningitis, pneumonia,</td></tr><tr><td/><td>males)</td><td/><td>concussion, epilepsy</td></tr><tr><td/><td>Vaccine (nonava-</td><td>3(6)/301</td><td>1 female participant with atopic dermatitis</td></tr><tr><td/><td>lent; 2-dose, 12-month interval in males and females)</td><td/><td>2 male participants with appendicitis, forearm fracture At 37 month follow-up there were 3 additional serious adverse events: gastritis, oral herpes, radiculopathy (disaggregated da-</td></tr><tr><td/><td/><td/><td>ta by sex were not available)</td></tr><tr><td/><td>Vaccine (nonava-</td><td>6/301</td><td>6 participants with 8 events: cardiac arrest, appendicitis, subcu-</td></tr><tr><td/><td>lent; 3-dose in fe-</td><td/><td>taneous abscess, papillary thyroid cancer, encephalitis autoim-</td></tr><tr><td/><td>males)</td><td/><td>mune, status epilepticus, depression, ovarian cyst</td></tr><tr><td>Joura 2015</td><td>Vaccine (nonava-</td><td>242/7686</td><td>242 participants with 269 events: Anaemia, aortic valve incom-</td></tr><tr><td/><td>lent)</td><td/><td>petence, postural orthostatic tachycardia syndrome, vertigo</td></tr><tr><td/><td/><td/><td>positional, anal fistula, coeliac disease, Crohn's disease, diar-</td></tr><tr><td/><td/><td/><td>rhoea, gastritis, haemorrhoids, inguinal hernia, irritable bow-</td></tr><tr><td/><td/><td/><td>el syndrome, pyrexia, sudden death, cholangitis, cholecysti-</td></tr><tr><td/><td/><td/><td>tis, cholelithiasis, allergy to vaccine, anaphylactic reaction,</td></tr><tr><td/><td/><td/><td>hypersensitivity, sarcoidosis, jaw abscess, appendicitis (10),</td></tr><tr><td/><td/><td/><td>cholecystitis infective, chronic tonsillitis, dengue fever, infec-</td></tr><tr><td/><td/><td/><td>tious enteritis (2), gastroenteritis, viral gastroenteritis, haem-</td></tr><tr><td/><td/><td/><td>orrhagic fever, infectious mononucleosis, influenza, pharyn-</td></tr><tr><td/><td/><td/><td>gitis, pyelonephritis (2), pyelonephritis acute, septic shock,</td></tr><tr><td/><td/><td/><td>tonsillitis, tonsillitis streptococcal, urinary tract infection (3),</td></tr><tr><td/><td/><td/><td>urosepsis, wound infection, bladder injury, burns second de-</td></tr><tr><td/><td/><td/><td>gree, craniocerebral injury, femur fracture, humerus fracture</td></tr><tr><td/><td/><td/><td>(2), ligament rupture, lower limb fracture, multiple injuries (2),</td></tr><tr><td/><td/><td/><td>pubis fracture, road traffic accident, spinal compression frac-</td></tr><tr><td/><td/><td/><td>ture, hyperglycaemia, myalgia, osteoarthritis, acute lymphocyt-</td></tr><tr><td/><td/><td/><td>ic leukaemia, acute promyelocytic leukaemia, adenocarcino-</td></tr><tr><td/><td/><td/><td>ma of the cervix, brain neoplasm, ependymoma, leukaemic in-</td></tr><tr><td/><td/><td/><td>filtration brain, malignant melanoma (2), malignant melanoma</td></tr><tr><td/><td/><td/><td>in situ, nasal cavity cancer, ovarian neoplasm, diabetic coma,</td></tr><tr><td/><td/><td/><td>epilepsy, hypersomnia, Intracranial venous sinus thrombosis,</td></tr><tr><td/><td/><td/><td>migraine, multiple sclerosis (2), presyncope, sciatica, sensory</td></tr><tr><td/><td/><td/><td>disturbance, syncope (2), tension headache, abortion sponta-</td></tr><tr><td/><td/><td/><td>neous (40), abortion spontaneous incomplete, blighted ovum,</td></tr><tr><td/><td/><td/><td>cephalo-pelvic disproportion (4), cervix dystocia, false labour,</td></tr><tr><td/><td/><td/><td>foetal death (2), foetal distress syndrome (5), labour complica-</td></tr><tr><td/><td/><td/><td>tion, pre-eclampsia (2), premature labour, premature rupture of</td></tr><tr><td/><td/><td/><td>membranes (4), prolonged labour (2), uterine contractions dur-</td></tr><tr><td/><td/><td/><td>ing pregnancy, anorexia and bulimia syndrome, bipolar disor-</td></tr><tr><td/><td/><td/><td>der (3), completed suicide, major depression, calculus ureteric,</td></tr><tr><td/><td/><td/><td>calculus urinary, nephrolithiasis, renal failure (2), bartholinitis,</td></tr><tr><td/><td/><td/><td>cervical dysplasia (5), cervix haemorrhage uterine, endometrio-</td></tr><tr><td/><td/><td/><td>sis (2), ovarian cyst, pelvic pain, asthmatic crisis, pneumonia as-</td></tr><tr><td/><td/><td/><td>piration, pneumothorax, respiratory failure, vocal cord polyp,</td></tr><tr><td/><td/><td/><td>abortion induced (79), deep vein thrombosis, hypovolaemic</td></tr><tr><td/><td/><td/><td>shock (2)</td></tr><tr><td/><td>Vaccine (quadriva-</td><td>184/7078</td><td>184 participants with 197 events: Anaemia, cle lip and palate,</td></tr><tr><td/><td>lent)</td><td/><td>Meckel's diverticulum, abdominal pain (2), abdominal pain low-</td></tr><tr><td/><td/><td/><td>er, colitis ulcerative, enterocolitis, gastritis, inguinal hernia,</td></tr><tr><td/><td/><td/><td>omental infarction, cholecystitis , cholelithiasis (2), appendici-</td></tr><tr><td/><td/><td/><td>tis (16), bronchitis (2), cellulitis, conjunctivitis, gastroenteritis</td></tr><tr><td/><td/><td/><td>(2), influenza, pelvic inflammatory disease, post abortion infec-</td></tr><tr><td/><td/><td/><td>tion, pyelonephritis, pyelonephritis acute (2), urinary tract in-</td></tr><tr><td/><td/><td/><td>fection (2), viral pharyngitis, foreign body in eye, fracture dis-</td></tr></table>",
                "type_str": "table"
            },
            "TABREF110": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF111": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF112": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF113": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Serious adverse events</td><td>Females and males</td><td>160 per</td><td>115 per 1000</td><td>OR 0.68</td><td>575</td><td>\u2295\u229d\u229d\u229d</td></tr><tr><td>at 4-year follow-up (adults) or 7-month fol-</td><td>with HIV (\u2265 27 years)</td><td>1000</td><td>(74 to 174)</td><td>(0.42 to 1.10)</td><td>(1 study)</td><td>VERY LOW 1,4,6,7</td></tr><tr><td>low-up (MSM)</td><td>MSM with HIV (\u2265 18</td><td>0 per 1000</td><td>0 per 1000</td><td>Not estimable,</td><td>129</td><td>\u2295\u229d\u229d\u229d</td></tr><tr><td/><td>years)</td><td/><td>(0 to 0)</td><td>no events were</td><td>(1 study)</td><td>VERY</td></tr><tr><td/><td/><td/><td/><td>reported</td><td/><td>LOW 5,6,7</td></tr><tr><td>Mortality</td><td>Females and males</td><td colspan=\"2\">21 per 1000 10 per 1000</td><td>OR 0.49</td><td>575</td><td>\u2295\u229d\u229d\u229d</td></tr><tr><td>at 4-year follow-up (adults) or 7-month fol-</td><td>with HIV (\u2265 27 years)</td><td/><td>(3 to 41)</td><td>(0.12 to 1.99)</td><td>(1 study)</td><td>VERY LOW 1,2</td></tr><tr><td>low-up (MSM)</td><td>MSM with HIV (\u2265 18</td><td>0 per 1000</td><td>0 per 1000</td><td>Not estimable,</td><td>129</td><td>\u2295\u2295\u229d\u229d</td></tr><tr><td/><td>years)</td><td/><td>(0 to 0)</td><td>no events were</td><td>(1 study)</td><td>LOW 5</td></tr><tr><td/><td/><td/><td/><td>reported</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF114": {
                "text": "We are very uncertain about the estimate.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF115": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF117": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF118": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF119": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td colspan=\"2\">5, and 6 months)</td><td/><td/><td/></tr><tr><td>Outcomes</td><td>Population</td><td colspan=\"2\">Anticipated absolute effects*</td><td>Relative effect</td><td>No of Par-</td><td>Quality of</td></tr><tr><td/><td/><td>(95% CI)</td><td/><td>(95% CI)</td><td>ticipants</td><td>the evi-</td></tr><tr><td/><td/><td/><td/><td/><td>(studies)</td><td>dence</td></tr><tr><td/><td/><td>Risk with</td><td>Risk with biva-</td><td/><td/><td>(GRADE)</td></tr><tr><td/><td/><td>quadriva-</td><td>lent HPV vaccine</td><td/><td/><td/></tr><tr><td/><td/><td>lent HPV</td><td/><td/><td/><td/></tr><tr><td/><td/><td>vaccine</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">High-grade neoplasia, cancer</td><td colspan=\"3\">No studies were identified that reported on this outcome.</td><td/><td/></tr><tr><td>Overall local/injec-</td><td>Females and</td><td>696 per 1000</td><td>911 per 1000</td><td>RR 1.31</td><td>92</td><td>\u2295\u2295\u229d\u229d</td></tr><tr><td>tion site adverse events at 4-day</td><td>males with HIV (\u2265 18 years)</td><td/><td>(737 to 1000)</td><td>(1.06 to 1.62)</td><td>(1 study)</td><td>LOW 1</td></tr><tr><td>follow-up</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Overall systemic events and general symp-</td><td colspan=\"3\">No studies were identified that reported on this outcome.</td><td/><td/></tr><tr><td>toms</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Serious adverse</td><td>Females and</td><td>0 per 1000</td><td>0 per 1000</td><td>Not estimable,</td><td>92</td><td>\u2295\u229d\u229d\u229d</td></tr><tr><td>events at 6-month follow-up (adults) and 7-month fol-</td><td>males with HIV (\u2265 18 years)</td><td/><td>(0 to 0)</td><td>no events were reported</td><td>(1 study)</td><td>VERY LOW 2,5,6</td></tr><tr><td>low-up (females)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>Females with HIV</td><td>55 per 1000</td><td>54 per 1000</td><td>OR 0.99</td><td>332</td><td>\u2295\u229d\u229d\u229d</td></tr><tr><td/><td>(15-25 years)</td><td/><td>(21 to 128)</td><td>(0.38 to 2.55)</td><td>(1 study)</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF121": {
                "text": "Table for Grading the Severity of Adverse Events\".",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"3\">Cochrane Database of Systematic Reviews</td></tr><tr><td>(Continued) (Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">were screened for</td><td/><td/><td>by arm, and</td><td/><td>only report-</td></tr><tr><td/><td colspan=\"2\">adverse events\".</td><td/><td/><td>after each</td><td/><td>ed narra-</td></tr><tr><td/><td/><td/><td/><td/><td>dose admin-</td><td/><td>tively as</td></tr><tr><td/><td/><td/><td/><td/><td>istration.</td><td/><td>propor-</td></tr><tr><td/><td/><td/><td/><td/><td>Attribution was not re-ported.</td><td/><td>tions. P-val-ue only re-ported for overall oc-</td></tr><tr><td/><td/><td/><td/><td/><td>No informa-tion on how withdrawals were han-dled in the No informa-tion on how withdrawals were han-dled in the analysis.</td><td>Unclear. \"A clinic visit was required within</td><td>No filter used currence of AEs. Specif-ic AEs were not report-ed sepa-rately by group.</td></tr><tr><td/><td/><td/><td/><td/><td>analysis.</td><td>24 hours</td></tr><tr><td>NCT00941889</td><td colspan=\"2\">Not applicable, se-</td><td>Not applica-</td><td>Not applicable</td><td>Not applica-</td><td>whenever Not applic-</td><td>Not applic-</td></tr><tr><td>2016</td><td colspan=\"2\">rious and/or oth-</td><td>ble</td><td/><td>ble</td><td>the study able</td><td>able</td></tr><tr><td/><td colspan=\"2\">er non-serious ad-</td><td/><td/><td/><td>coordina-</td></tr><tr><td/><td colspan=\"2\">verse events were</td><td/><td/><td/><td>tor consid-</td></tr><tr><td/><td colspan=\"2\">not collected or as-</td><td/><td/><td/><td>ered that</td></tr><tr><td/><td>sessed.</td><td/><td/><td/><td/><td>a reaction</td></tr><tr><td/><td/><td/><td/><td/><td/><td>might be</td></tr><tr><td>NCT01031069</td><td colspan=\"2\">Mode of data col-</td><td>Solicited lo-</td><td>Attribution, blinding or defini-</td><td>Reasons for</td><td>\u2265 grade 3\". Stopping</td><td>No filter</td></tr><tr><td>2017</td><td colspan=\"2\">lection was not re-</td><td>cal and gen-</td><td>tions were not reported.</td><td>discontinu-</td><td>However, rules not</td><td>used</td></tr><tr><td/><td>ported.</td><td/><td>eral symp-</td><td/><td>ation were</td><td>clear rules reported</td></tr><tr><td/><td/><td/><td>toms within</td><td/><td>separated by</td><td>regarding</td></tr><tr><td/><td/><td/><td>7 days after</td><td/><td>arm.</td><td>termina-</td></tr><tr><td/><td/><td/><td>each and any vaccination; unsolicited symptoms within 30 days (days 0-29) after any vaccina-tion; SAEs,</td><td/><td>All vaccinat-ed subjects for whom data were available were includ-ed in the analysis.</td><td>tion of the study were not report-ed.</td></tr><tr><td/><td/><td/><td>medically significant conditions, pregnancy</td><td/><td>Attribution was not re-ported.</td><td/></tr><tr><td/><td/><td/><td>outcomes,</td><td/><td/><td/></tr><tr><td/><td/><td/><td>clinically rel-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>evant abnor-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>malities in</td><td/><td/><td/></tr><tr><td/><td/><td/><td>haematolog-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>ical and bio-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>chemical pa-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>rameters up</td><td/><td/><td/></tr><tr><td/><td/><td/><td>to 30 days af-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>ter the last</td><td/><td/><td/></tr><tr><td/><td/><td/><td>dose of vac-</td><td/><td/><td/></tr><tr><td/><td/><td/><td>cine.</td><td/><td/><td/></tr><tr><td>NCT01862874</td><td colspan=\"2\">Mode of data col-</td><td>Serious and</td><td>Attribution, blinding or defini-</td><td>Reasons for</td><td>Stopping</td><td>Thresh-</td></tr><tr><td>2018</td><td colspan=\"2\">lection was not re-</td><td>other ad-</td><td>tions were not reported.</td><td>discontinu-</td><td>rules not</td><td>old above</td></tr><tr><td>Lin 2014</td><td colspan=\"2\">Unclear: \"Following ported, except that</td><td>Time frame verse events</td><td>Not reported</td><td>Reasons for ation were</td><td>Stopping reported</td><td>No filter which oth-</td></tr><tr><td/><td colspan=\"2\">each vaccination a vaccination re-</td><td>is unclear. followed</td><td/><td>discontinu-separated by</td><td>rules not</td><td>used. How-er adverse</td></tr><tr><td/><td colspan=\"2\">visit, participants port card was used.</td><td>up for 36</td><td/><td>ation were arm.</td><td>reported</td><td>ever, re-events are</td></tr><tr><td/><td/><td/><td>months; in-</td><td/><td>separated</td><td/><td>sults were</td></tr></table>",
                "type_str": "table"
            },
            "TABREF122": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"3\">Cochrane Database of Systematic Reviews</td></tr><tr><td/><td/><td>jection-site</td><td/><td>All vaccinat-</td><td/><td>reported:</td></tr><tr><td/><td/><td>AEs were re-</td><td/><td>ed subjects</td><td/><td>5%</td></tr><tr><td/><td/><td>ported up</td><td/><td>for whom</td><td/></tr><tr><td/><td/><td>to 5 days af-</td><td/><td>data were</td><td/></tr><tr><td/><td/><td>ter any vac-</td><td/><td>available</td><td/></tr><tr><td/><td/><td>cination; sys-</td><td/><td>were includ-</td><td/></tr><tr><td/><td/><td>temic AEs</td><td/><td>ed in the</td><td/></tr><tr><td/><td/><td>were report-</td><td/><td>analysis.</td><td/></tr><tr><td/><td/><td>ed up to 15 days after any vaccina-tion.</td><td/><td>Attribution was not re-ported.</td><td/></tr><tr><td colspan=\"2\">Wilkin 2018 Mode of data col-</td><td>Grade 3 or</td><td>Attribution determined by the</td><td>Reasons for</td><td>Stopping</td><td>No filter</td></tr><tr><td colspan=\"2\">lection was not re-</td><td>4 AEs that</td><td>local investigator, blinding not</td><td>discontinu-</td><td>rules not</td><td>used</td></tr><tr><td>ported.</td><td/><td>were possi-</td><td>reported.</td><td>ation were</td><td>reported</td></tr><tr><td/><td/><td>bly, proba-bly, or defi-nitely related to the vac-cine: to par-ticipant's last study visit, for up to 4 years.</td><td>Grade 3 or 4 adverse events were defined using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.</td><td>separated by arm. All vaccinat-ed subjects for whom data were available were includ-ed in the</td><td/></tr><tr><td/><td/><td/><td/><td>analysis.</td><td/></tr><tr><td/><td/><td/><td/><td>Attribution</td><td/></tr><tr><td/><td/><td/><td/><td>was made by</td><td/></tr><tr><td/><td/><td/><td/><td>the local in-</td><td/></tr><tr><td/><td/><td/><td/><td>vestigator.</td><td/></tr><tr><td colspan=\"2\">Petaja 2009 Proactive and pas-</td><td>Time frame</td><td/><td/><td/></tr><tr><td>sive:</td><td/><td>was</td><td/><td/><td/></tr><tr><td colspan=\"2\">\"Participants used</td><td>specified:</td><td/><td/><td/></tr><tr><td colspan=\"2\">diary cards to re-</td><td>7-day fol-</td><td/><td/><td/></tr><tr><td colspan=\"2\">port solicited local</td><td>low-up for</td><td/><td/><td/></tr><tr><td colspan=\"2\">and general symp-</td><td>local and</td><td/><td/><td/></tr><tr><td colspan=\"2\">toms during a 7-day</td><td>general</td><td/><td/><td/></tr><tr><td colspan=\"2\">follow-up period</td><td>symptoms;</td><td/><td/><td/></tr><tr><td colspan=\"2\">after each vaccine</td><td>30 days for</td><td/><td/><td/></tr><tr><td>dose\";</td><td/><td>unsolicited</td><td/><td/><td/></tr><tr><td colspan=\"2\">\"Unsolicited signs and symptoms were reported with-in 30 days after each dose\".</td><td>signs and symptoms; SAEs, NOCDs and other medically significant</td><td/><td/><td/></tr><tr><td colspan=\"2\">Data collection forms available from GSK report.</td><td>conditions (MSCs) were reported throughout</td><td/><td/><td/></tr><tr><td/><td/><td>the study pe-</td><td/><td/><td/></tr><tr><td/><td/><td>riod (up to</td><td/><td/><td/></tr><tr><td/><td/><td>month 12).</td><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF124": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td colspan=\"3\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>(Continued) (Continued) (Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">reported through-signs of illness and/</td><td/><td>by the primary investigator and</td><td/><td/><td>with 1 or</td></tr><tr><td/><td colspan=\"2\">out the study\". or changes in med-</td><td/><td>graded as \"unlikely\" or \"prob-</td><td/><td/><td>multiple</td></tr><tr><td/><td colspan=\"2\">ication occurring</td><td/><td>ably\" related to the study vac-</td><td/><td/><td>AEs.</td></tr><tr><td>Ro-</td><td colspan=\"2\">Proactive and pas-within 15 days after</td><td>Time frame</td><td>Attribution and blinding not re-cines\").</td><td>Attribution</td><td>Stopping</td><td>No filter</td></tr><tr><td>manowski</td><td colspan=\"2\">sive: \"Solicited immunization were</td><td>was spec-</td><td>ported.</td><td>was not re-</td><td>rules not</td><td>used. How-</td></tr><tr><td>Puthanakit 2016 2011 van Damme 2016 To 2014 Vesikari 2015</td><td colspan=\"2\">Proactive and pas-sive: \"Solicited lo-cal and general symptoms were recorded on diary cards for 7 days af-ter each vaccina-tion. Unsolicited symptoms were recorded for 30 days after each vac-cination. Pregnan-cies and outcomes, serious adverse events, medically significant adverse events, and poten-tial immune-medi-ated diseases were local symptoms (pain, redness or swelling at injection site) and general symptoms (fever, headache, fatigue, gastrointestinal symptoms, arthral-gia, myalgia, rash or urticaria) occur-ring within 7 d af-ter each vaccina-tion were record-ed by the subject or her parent/legal-ly acceptable rep-resentative using a diary card. Investi-gators document-ed the presence or absence of ur-ticaria/rash within 30 min after each vaccine. dose. Un-solicited AEs oc-curring within one month of each vac-cine dose were doc-umented by the in-vestigator. \"SAEs and other medically signif-icant conditions recorded on diary cards\". Proactive and pas-sive: \"Following each vaccination, participants were observed for 30 min for any unto-ward effects, in-cluding allergic re-actions. All par-ticipants received a vaccination re-port card (VRC) at each vaccination visit. They were asked to record their oral temper-ature on the VRC from day 1 to day 5 after each vaccina-tion (starting on the evening after vac-cination), and any injection-site and systemic AEs) for a total of 15 days in-cluding the day of vaccination \u2026 SAEs were collected for the entire duration of the study irre-spective of cause\". were reported in all subjects regardless of causal relation-ship to vaccination and intensity.\" Proactive and pas-sive: \"Participants were observed for 30 minutes after each immunization to evaluate imme-diate AEs. Solicited AEs occurring dur-ing the first 4 days after each immu-nization (injection site pain, swelling, erythema, fever, headache, nausea, myalgia, arthralgia and rash) and other Proactive and pas-sive: \"Participants were observed for 30 mins after each</td><td>Time frame was spec-ified (see methods of data collec-tion). ified (see methods of data collec-tion). Time frame was spec-ified (see methods of data collec-tion). Time frame was spec-ified (see methods of data collec-tion). Time frame was spec-ified (see methods of</td><td>\u2022 \"An SAE was defined as any untoward medical oc-currence that resulted in death, was life-threatening, required hospitalization, re-sulted in disability or in-capacity, was an important medical event or was a con-genital anomaly/birth defect in the offspring of a study sub-ject\" \u2022 \"MSCs were defined as non-serious AEs prompting either emergency room or physician visits not related to either common diseases or routine visits for physical examina-tion or vaccination, or SAEs not related to common dis-eases\" \u2022 \"Common diseases includ-ed upper respiratory infec-tions, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, and injury\" Attribution and blinding not re-ported. Grade 3 symptoms were defined Outcome definition reported (\"Medically significant condi-tion = AE prompting emergency room or physician visits that was not related to common dis-eases. New onset autoimmune diseases (which excluded aller-gy-related events or isolated signs and symptoms) were iden-tified by comparing all report-ed AEs with a pre-defined list of potential chronic autoimmune events derived from the Medical Dictionary for Regulatory Activi-ties\"). Attribution was made by inves-tigators based on the informa-tion provided by the patients (\"The study site personnel re-viewed the VRC for complete-ness and could not alter the original information recorded by the participants on the VRC. The investigator determined the causality of systemic AEs report-ed on the VRC, and classified each AE reported on the VRC as a serious or non-serious AE\"). Blinding was not reported. Outcome definition was report-ed (\"An oral temperature 37.8 C during the follow-up period was considered an elevated temper-ature (fever). For each AE, par-ticipants were asked to rate the symptom as mild (awareness of signor symptom but easily tol-erated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity); in-jection-site AEs of swelling and erythema were rated by size. In-vestigators were instructed to assign causality to AEs on the basis of exposure, time course, likely cause, and consistency with the vaccine's known pro-file. Serious AEs (SAEs) were (\"as redness or swelling &gt;50 mm in diameter, fever &gt;39\u00b0C, ur-ticaria distributed on \u22654 body areas, and, for other symptoms, as preventing normal activity\"). Attribution was unclear (see be-low). Blinding was not reported. Outcome definition was report-ed (\"Solicited and unsolicited AEs, as well as laboratory tests, were graded according to the common toxicity criteria ver-sion 2.0. All solicited local (in-predefined as any AE that re-sulted in death, deemed by the investigator to be life-threaten-ing, or that resulted in a persis-tent or significant disability or incapacity, resulted in or pro-longed an existing in-patient hospitalization, or was a con-genital anomaly, a cancer, or an 'other important medical event\"). jection site) and influenza-like (fever, arthralgia, chills, and fa-tigue) reactions were consid-ered causally related to vaccina-tion. Other AEs were evaluated Attribution was made by the in-vestigator (\"Investigators as-signed causality to AEs based on exposure, time course, like-</td><td>Reasons for discontinu-ation were separated ported. No informa-tion on how Reasons for withdrawals discontinu-would have ation were been han-separated by dled in the arm. analysis, however \"no subject was withdrawn Attribution was not re-ported. from the study due to an AE or a SAE\" No informa-tion provid-ed about how with-drawals were han-dled in the analysis. by arm, and after each dose admin-istration. Attribution was not re-ported. No informa-tion on how withdrawals were han-dled in the analysis. Withdrawals were not re-ported by group. No informa-tion on how withdrawals were han-dled in the analysis was provided. Attribution was not re-ported. Reasons for discontinu-ation were separated</td><td>Stopping rules not reported reported Stopping rules not reported Stopping rules not reported Stopping rules not reported</td><td>No filter used, how-ever, re-sults were ever, for many of the AEs, re-sults were Filter not provided used. AEs as number were re-of partici-ported as pants with n/N. Study at least 1 event, therefore did not dis-also report-ed number of partici-pants with tinguish be-tween par-ticipants with 1 or multiple AEs. no event, and num-ber with at least 1 event, but did not dis-tinguish be-tween par-ticipants with 1 or multiple AEs. provided as number of partici-pants with at least 1 event, therefore did not dis-tinguish be-tween par-ticipants with 1 or multiple AEs. Filter not used. Solicited AEs report-ed as n/N. Study al-so report-ed number of partici-pants with at least 1 event, but Filter not did not dis-used. AEs tinguish be-were re-tween par-ticipants ported as</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>123</td></tr></table>",
                "type_str": "table"
            },
            "TABREF125": {
                "text": "Results were stratified into subgroups by type of HPV vaccine and time point.GMTs and seropositivity to HPV 31, 33, 45, 52, and 58 are only measured in nonavalent vaccine trials (Iversen 2016).1 GRADE rating applies to specific vaccine type and outcome 2 Downgraded one level for inconsistency: moderate heterogeneity (I 2 > 30%)3 Downgraded one level for risk of bias: high loss to follow up 4 Downgraded one level for imprecision: small sample size",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"2\">Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>(Continued) (Continued) (Continued) (Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">vaccination for any immediate reac-tion. All subjects re-ceived a vaccina-tion report card at the day 1, month 2 and month 6 study vaccination vis-its. Oral tempera-ture was reported from day 1 to day 5 after any vacci-nation, and injec-tion-site reactions and systemic AEs were recorded on the vaccination re-port card from day 1 to day 15 after any vaccination. SAEs were moni-tored throughout the study regard-less of cause\". 1 month after last dose last dose 1.16 Seroconver-1.3.1 Bivalent vaccine lent vaccine 1 month after lent vaccine first dose 1.10.1 Quadriva-1 month after 1.22.2 Quadriva-60 months after 1.10 Seroconver-sion to HPV 6 1 month after last dose sion to HPV 31 last dose 1.15 Seroconver-sion to HPV 33 1 month after last dose 1.22 1 Bivalent vaccine 60 months after first dose vaccine first dose 1.30.1 Bivalent 60 months after lent vaccine last dose 1.14 Seroconver-1 month after ty to HPV 16 18 (mMU/mL) 1.30 Seropositivi-1.22 GMT of HPV 1.3 GMT of HPV 16 1.9 GMT of HPV 58 (mMU/mL) 1 month after last dose 1.13.3 Nonava-1 month after lent vaccine first dose lent vaccine first dose 1.29.2 Nonava-36 months after 1.2.2 Nonavalent vaccine 1 month after last dose 1.8 GMT of HPV 52 (mMU/mL) 1 month after last dose 1.13.1 Bivalent vaccine 1 month after last dose 1.13.2 Quadriva-lent vaccine 1 month after last dose 1.21.3 Nonava-36 months after 1.21.2 Quadriva-lent vaccine 60 months after first dose lent vaccine first dose 1.29.1 Quadriva-60 months after 1.1.1 Quadriva-1 month after 1.4.3 Nonavalent 1 month after 1.12.2 Quadriva-1 month after 1.20.1 Quadriva-60 months after 1.33 Seropositivi-36 months after lent vaccine last dose vaccine last dose lent vaccine last dose lent vaccine first dose ty to HPV 33 first dose 1.28 Seropositivi-ty to HPV 6 1.34 Seropositivi-36 months after 1.1.2 Nonavalent 1 month after 1.5 GMT of HPV 1 month after 1.12.3 Nonava-1 month after 1.20.2 Nonava-36 months after ty to HPV 45 first dose vaccine last dose 31 (mMU/mL) last dose lent vaccine last dose lent vaccine first dose 1.28.1 Quadriva-60 months after lent vaccine first dose 1.35 Seropositivi-36 months after 1.13 Seroconver-1 month after ty to HPV 52 first dose 1.2.1 Quadriva-lent vaccine 1 month after last dose 1.7 GMT of HPV 45 (mMU/mL) 1 month after last dose 1.21.1 bivalent vaccine 60 months after first dose ty to HPV 11 1.29 Seropositivi-1.2 GMT of HPV 11 (mMU/mL) 1 month after last dose 1.6 GMT of HPV 33 (mMU/mL) 1 month after last dose sion to HPV 18 last dose 1.21 GMT of HPV 1.28.2 Nonava-36 months after 16 (mMU/mL) lent vaccine first dose 1.36 Seropositivi-36 months after ty to HPV 58 first dose</td><td>data collec-tion). 1 (Ro-manowski 2011) 2013) 1 (Iversen 2013) 1 (Dobson 1 (Dobson 2 (Dobson 2013; Iversen 2016) 2016) 1 (Iversen 2016) 1 (Ro-manowski 2011) 2011) manowski 1 (Ro-2016) 1 (Iversen 1 (Iversen 2016) 2015) 1 (Iversen 2016) 2016) 1 (Iversen 1 (Iversen 2016) 1 (Iversen 2016) 1 (Ro-manowski 2011) 2 (Dobson 2013; Leung 1 (Iversen 1 (Dobson 2013) 2013) 1 (Dobson 1 (Dobson 1 (Iversen 2 (Dobson 1 (Dobson 1 (Iversen 2013) 2016) 2013; Leung 2013) 2016) 2015) 1 (Iversen 1 (Iversen 1 (Iversen 1 (Iversen 1 (Iversen 2016) 2016) 2016) 2016) 2016) 1 (Dobson 2013) 1 (Iversen 4 (Ro-2016) 1 (Dobson 2013) 1 (Iversen 2016) Leung 2015) 1 (Ro-manowski 2011) Iversen 2016; 2 (Dobson 2013; Iversen 2016) 1 (Iversen 2016) manowski 2011; Dob-1 (Iversen 2016) 1 (Iversen son 2013; 2016)</td><td colspan=\"3\">ly cause and consistency with the vaccine's known profile. Vaccine-related AEs were deter-mined by the investigator to be possibly, probably or definitely vaccine-related\"). Blinding was not reported. Outcome definition was report-ed (\"An elevated temperature (fever) was defined as maxi-mum temperature \u226537.8\u00b0C. For each AE, participants rated the symptom as mild (awareness of symptom but easily tolerated), moderate (discomfort enough to cause interference with usu-al activities) or severe (incapac-itating with inability to work or do usual activity); injection-site were rated by size. SAEs were predefined as any AE that re-by the investigator to be life-threatening, resulted in a per-ty or incapacity, resulted in or prolonged an existing in-pa-tient hospitalization or was a congenital anomaly, a cancer or an \"other important medical event\". 132 Ratio of GMTs (IV, ran-dom-effects, 95% CI) 95% CI) 549 RR (M-H, random-effects, dom-effects, 95% CI) 489 RR (M-H, random-effects, 101 Ratio of GMTs (IV, ran-1001 RR (M-H, random-effects, 95% CI) 95% CI) 548 RR (M-H, random-effects, 95% CI) 92 Ratio of GMTs (IV, ran-dom-effects, 95% CI) 95% CI) 490 RR (M-H, random-effects, sistent or significant disabili-95% CI) 543 RR (M-H, random-effects, sulted in death, were deemed 543 Ratio of GMTs (IV, ran-dom-effects, 95% CI) 542 RR (M-H, random-effects, dom-effects, 95% CI) 95% CI) 476 RR (M-H, random-effects, AEs of swelling and erythema by arm, and Ratio of GMTs 0.50 (0.38 to 0.66) 1.01) RR 1.00 (0.99 to 0.57 (0.34 to RR 1.00 (0.99 to Ratio of GMTs tive) RR 1.00 (0.99 to 1.01) 1.01) RR 1.00 (0.99 to 1.01) were seroposi-Ratio of GMTs 0.69 (0.47 to all participants 1.02) not estimable, RR 1.00 (95% CI 1.01) RR 1.00 (0.99 to Ratio of GMTs 1.02 (0.87 to 1.19) RR 1.00 (0.99 to 0.85 (0.69 to 0.99) 1.04) RR 0.95 (0.92 to after each dose admin-istration. Attribution was not re-ported. No informa-tion provid-ed about how with-drawals were han-analysis. 1.32) 512 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 1.06 (0.91 to 1.25) 0.65) 547 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 0.64 (0.55 to 0.74) 132 RR (M-H, random-effects, 95% CI) RR 1.00 (0.97 to 1.03) 1159 RR (M-H, random-effects, 95% CI) 503 Ratio of GMTs (IV, ran-Ratio of GMTs 1.00) tive) RR 1.00 (1.00 to 101 Ratio of GMTs (IV, ran-dom-effects, 95% CI) 1.14 (0.76 to were seroposi-1.73) all participants 95% CI) not estimable, Ratio of GMTs 101 RR (M-H, random-effects, RR 1.00 (95% CI dled in the 489 Ratio of GMTs (IV, ran-Ratio of GMTs 542 Ratio of GMTs (IV, ran-Ratio of GMTs 1143 RR (M-H, random-effects, RR 1.00 (1.00 to 101 Ratio of GMTs (IV, ran-Ratio of GMTs 510 RR (M-H, random-effects, RR 0.96 (0.92 to dom-effects, 95% CI) 1.18 (0.93 to dom-effects, 95% CI) 0.91 (0.76 to 95% CI) 1.00) dom-effects, 95% CI) 0.99 (0.68 to 95% CI) 0.99) 1.49) 1.09) 1.44) 511 RR (M-H, random-effects, RR 0.92 (0.86 to 512 Ratio of GMTs (IV, ran-Ratio of GMTs 543 Ratio of GMTs (IV, ran-Ratio of GMTs 541 RR (M-H, random-effects, RR 1.00 (0.99 to 476 Ratio of GMTs (IV, ran-Ratio of GMTs 95% CI) 0.98) dom-effects, 95% CI) 1.11 (0.94 to dom-effects, 95% CI) 0.82 (0.69 to 95% CI) 1.01) dom-effects, 95% CI) 0.84 (0.70 to 101 RR (M-H, random-effects, RR 0.98 (0.91 to 1.30) 0.98) 1.01) 95% CI) 1.05) 509 RR (M-H, random-effects, RR 0.96 (0.92 to 1833 RR (M-H, random-effects, RR 1.00 (1.00 to 95% CI) 0.99) 494 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 1.12 (0.95 to 549 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 0.54 (0.45 to 93 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 0.51 (0.36 to 0.72) 1006 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 1.09 (0.97 to 1.22) 548 Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs 1.29 (1.10 to 1.52) 95% CI) 1.00) 476 RR (M-H, random-effects, RR 0.97 (0.94 to 95% CI) 1.01) 505 RR (M-H, random-effects, RR 0.99 (0.97 to 95% CI) 1.01)</td><td>studies (I 2 = 89%) \u2295\u2295\u2295\u229d \u2295\u2295\u2295\u2295 LOW 3,4 ATE 1,4 \u2295\u2295\u229d\u229d MODER-\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u229d\u229d HIGH LOW 3,4 \u2295\u2295\u2295\u2295 HIGH able het-erogene-ity across \u2295\u2295\u2295\u2295 Not pooled due to consider-\u2295\u2295\u2295\u2295 HIGH HIGH HIGH \u2295\u2295\u2295\u2295 multiple AEs. \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u229d\u229d LOW 3,4 LOW 3,4 \u2295\u2295\u229d\u229d n/N. Study \u2295\u2295\u229d\u229d \u2295\u2295\u2295\u2295 also report-LOW 2,3 HIGH ed number of partici-\u2295\u2295\u2295\u2295 pants with \u2295\u2295\u2295\u2295 \u2295\u2295\u2295\u2295 HIGH no event, HIGH HIGH \u2295\u2295\u229d\u229d and num-LOW 3,4 \u2295\u2295\u2295\u2295 ber with \u2295\u2295\u2295\u2295 HIGH at least 1 event, but did not dis-tween par-ticipants with 1 or \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u229d\u229d LOW 3,4 tinguish be-\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 HIGH HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u2295\u2295 HIGH HIGH</td></tr><tr><td>sion to HPV 45 1.30.2 Quadriva-</td><td colspan=\"2\">last dose 60 months after</td><td>2016) 1 (Dobson</td><td>101</td><td>95% CI) RR (M-H, random-effects,</td><td>1.01) 0.96) RR 1.00 (95% CI</td><td>HIGH \u2295\u2295\u229d\u229d</td></tr><tr><td>1.3.2 Quadriva-lent vaccine 1.10.2 Nonava-lent vaccine 1.17 Seroconver-1.22.3 Nonava-lent vaccine</td><td colspan=\"2\">1 month after last dose 1 month after last dose 1 month after 36 months after first dose</td><td>2 (Dobson 2013; Leung 1 (Iversen 2016) 1 (Iversen 1 (Iversen 2013)</td><td>1143 512 547 504</td><td>Ratio of GMTs (IV, ran-dom-effects, 95% CI) RR (M-H, random-effects, 95% CI) RR (M-H, random-effects, Ratio of GMTs (IV, ran-95% CI)</td><td>Ratio of GMTs 1.03 (0.92 to RR 1.00 (0.99 to 1.02) RR 1.00 (0.99 to all participants Ratio of GMTs not estimable,</td><td>\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u2295\u2295 LOW 3,4</td></tr><tr><td>sion to HPV 52 lent vaccine</td><td colspan=\"2\">last dose first dose</td><td>2015) 2016) 2016)</td><td/><td>95% CI) dom-effects, 95% CI)</td><td>1.15) 1.01) 0.77 (0.65 to were seroposi-</td><td>HIGH HIGH</td></tr><tr><td>1.11 Seroconver-</td><td colspan=\"2\">1 month after</td><td>2 (Dobson</td><td>1006</td><td>RR (M-H, random-effects,</td><td>RR 1.00 (0.99 to 0.91) tive)</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>1.3.3 Nonavalent sion to HPV 11 1.18 Seroconver-</td><td colspan=\"2\">1 month after last dose 1 month after</td><td>1 (Iversen 2013; Iversen 1 (Iversen</td><td>541 543</td><td>Ratio of GMTs (IV, ran-95% CI) RR (M-H, random-effects,</td><td>Ratio of GMTs 1.01) RR 1.00 (0.99 to</td><td>\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295</td></tr><tr><td>vaccine sion to HPV 58 1.23 GMT of HPV 1.30.3 Nonava-</td><td colspan=\"2\">last dose last dose 36 months after 36 months after</td><td>2016) 2016) 2016) 1 (Iversen 1 (Iversen</td><td>506 503</td><td>dom-effects, 95% CI) 95% CI) Ratio of GMTs (IV, ran-RR (M-H, random-effects,</td><td>1.14 (0.98 to 1.01) Ratio of GMTs RR 0.98 (0.96 to</td><td>HIGH HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u2295\u2295</td></tr><tr><td>31 (mMU/mL) lent vaccine</td><td colspan=\"2\">first dose first dose</td><td>2016) 2016)</td><td/><td>dom-effects, 95% CI) 95% CI)</td><td>1.34) 0.62 (0.51 to 1.00)</td><td>HIGH HIGH</td></tr><tr><td>1.11.1 Quadriva-</td><td colspan=\"2\">1 month after</td><td>1 (Dobson</td><td>494</td><td>RR (M-H, random-effects,</td><td>RR 1.00 (0.99 to 0.75)</td></tr><tr><td>1.4 GMT of HPV lent vaccine 1.31 Seropositivi-</td><td colspan=\"2\">1 month after last dose</td><td>4 (Ro-2013)</td><td>1833</td><td>Ratio of GMTs (IV, ran-95% CI)</td><td>Ratio of GMTs 1.01)</td><td>\u2295\u2295\u2295\u229d</td></tr><tr><td>18 1.24 GMT of HPV ty to HPV 18 1.19 GMT of HPV 1.11.2 Nonava-33 (mMU/mL) 6 (mMU/mL) lent vaccine 1.31.1 Bivalent 1.19.1 Quadriva-vaccine 1.4.1 Bivalent vaccine 1.12 Seroconver-sion to HPV 16 lent vaccine 1.25 GMT of HPV 45 (mMU/mL) 1.31.2 Quadriva-1.19.2 Nonava-lent vaccine 1.26 GMT of HPV lent vaccine</td><td colspan=\"2\">last dose 36 months after 1 month after first dose last dose 60 months after 60 months after first dose 1 month after last dose 1 month after last dose first dose 36 months after first dose 60 months after 36 months after first dose 36 months after first dose</td><td>manowski 2011; Dob-1 (Iversen 1 (Iversen 2016) son 2013; 2016) 1 (Ro-Iversen 2016; 1 (Dobson manowski Leung 2015) 1 (Ro-manowski 2011) 4 (Ro-manowski 2013) 1 (Iversen 2011) 2016) 2011; Dob-1 (Dobson son 2013; Iversen 2016; 1 (Iversen 2016) 1 (Iversen 2013)</td><td>510 512 480 101 132 1816 511 101 476 509</td><td>dom-effects, 95% CI) Ratio of GMTs (IV, ran-RR (M-H, random-effects, dom-effects, 95% CI) 95% CI) RR (M-H, random-effects, Ratio of GMTs (IV, ran-95% CI) Ratio of GMTs (IV, ran-dom-effects, 95% CI) RR (M-H, random-effects, 95% CI) dom-effects, 95% CI) Ratio of GMTs (IV, ran-dom-effects, 95% CI) RR (M-H, random-effects, Ratio of GMTs (IV, ran-dom-effects, 95% CI) Ratio of GMTs (IV, ran-95% CI)</td><td>0.77 (0.69 to 0.87) Ratio of GMTs RR 1.00 (0.99 to 1.11 (0.94 to 1.01) 1.31) RR 1.00 (0.99 to Ratio of GMTs 1.01) RR 1.00 (1.00 to 1.00) 0.73 (0.50 to Ratio of GMTs 0.46 (0.39 to 1.06) Ratio of GMTs 0.56) RR 0.89 (0.78 to 0.74 (0.57 to 0.97) Ratio of GMTs 0.90 (0.76 to Ratio of GMTs 1.03)</td><td>MODER-\u2295\u2295\u2295\u2295 ATE 2 HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u229d\u229d HIGH \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 LOW 3,4 HIGH \u2295\u2295\u229d\u229d \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 LOW 3,4</td></tr><tr><td>1.4.2 Quadriva-lent vaccine 1.12.1 Bivalent 52 (mMU/mL) 1.31.3 Nonava-lent vaccine 1.20 GMT of HPV vaccine 11 (mMU/mL) 1.27 GMT of HPV 58 (mMU/mL) 1.32 Seropositivi-ty to HPV 31</td><td colspan=\"2\">1 month after last dose 1 month after first dose 36 months after first dose last dose 36 months after first dose 36 months after first dose</td><td>2 (Dobson 2013; Leung 2015) Leung 2015) 1 (Ro-2016) 1 (Iversen 2016) manowski 2011) 1 (Iversen 2016) 1 (Iversen 2016)</td><td>1159 132 504 505 506</td><td>Ratio of GMTs (IV, ran-dom-effects, 95% CI) RR (M-H, random-effects, dom-effects, 95% CI) RR (M-H, random-effects, 95% CI) 95% CI) Ratio of GMTs (IV, ran-dom-effects, 95% CI) RR (M-H, random-effects, 95% CI)</td><td>Ratio of GMTs 0.72 (0.64 to 1.08) 0.57 (0.49 to RR 0.98 (0.95 to 0.67) 1.02) RR 1.00 (0.97 to 0.81) 1.03) Ratio of GMTs 0.88 (0.74 to 1.05) RR 0.96 (0.93 to 1.00)</td><td>HIGH \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 \u2295\u2295\u2295\u2295 HIGH HIGH</td></tr></table>",
                "type_str": "table"
            },
            "TABREF126": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Outcome or subgroup*</td><td>Population</td><td>Follow-up</td><td>Studies</td><td>Participants</td><td>Statistical</td><td>Effect estimate</td><td>Certainty of</td></tr><tr><td/><td/><td/><td/><td/><td>method</td><td>(95% CI)</td><td>the evidence</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>(GRADE)</td></tr><tr><td>3.1 GMT of HPV 6 (mMU/mL)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>3.1.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Iversen</td><td>381</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td>males</td><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.62 (1.32 to 1.98)</td><td>HIGH</td></tr><tr><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.1.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>397</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.72 (1.41 to 2.09)</td><td>HIGH</td></tr><tr><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.2 GMT of HPV 11 (mMU/mL)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>3.2.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Iversen</td><td>381</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td>males</td><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>2.10 (1.82 to 2.40)</td><td>HIGH</td></tr><tr><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.2.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>398</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>2.08 (1.71 to 2.53)</td><td>HIGH</td></tr><tr><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.3</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF127": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Library</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr><tr><td>3.3.1 Bivalent vaccine (0 and 2</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Romanows-</td><td>136</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u229d</td><td/></tr><tr><td>months) vs (0 and 6 months 3.3.2 Bivalent vaccine (0 and 6 months) vs (0 and 12 months) 3.3.3 Nonavalent vaccine (0 and 6 months) vs (0 and 12 months)</td><td>males 9-to 14-year-old fe-males 9-to 14-year-old fe-males</td><td>last dose 1 month after last dose 1 month after last dose</td><td>ki 2011) 1 (Puthanakit 2016) 1 (Iversen 2016)</td><td>835 401</td><td>(IV, random-ef-fects, 95% CI) Ratio of GMTs (IV, random-ef-fects, 95% CI) Ratio of GMTs (IV, random-ef-fects, 95% CI)</td><td>2.06 (1.60 to 2.64) Ratio of GMTs 1.22 (1.10 to 1.34) Ratio of GMTs 1.73 (1.42 to 2.10)</td><td>MODERATE 1 \u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 HIGH</td><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF128": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>(Continued)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>3.3.4 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>408</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months) 3.4 GMT of HPV 18 (EU/mL or mMU/mL)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-fects, 95% CI)</td><td>1.75 (1.44 to 2.12)</td><td>HIGH</td><td colspan=\"3\">Cochrane Library</td></tr><tr><td/><td>3.4.1 Bivalent vaccine (0 and 2</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Romanows-</td><td>132</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u229d</td><td/><td/></tr><tr><td/><td>months) vs (0 and 6 months 3.4.2 Bivalent vaccine (0 and 6 months) vs (0 and 12 months)</td><td>males 9-to 14-year-old fe-males</td><td>last dose 1 month after last dose</td><td>ki 2011) 1 (Puthanakit 2016)</td><td>854</td><td>(IV, random-ef-fects, 95% CI) Ratio of GMTs (IV, random-ef-fects, 95% CI)</td><td>1.60 (1.22 to 2.10) Ratio of GMTs 1.12 (1.01 to 1.25)</td><td>MODERATE 1 \u2295\u2295\u2295\u2295 HIGH</td><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr><tr><td/><td>3.4.3 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Iversen</td><td>401</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td>males</td><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.44 (1.16 to 1.79)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.4.4 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>409</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.57 (1.27 to 1.95)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.5 GMT of HPV 31 (mMU/mL)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>3.5.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Iversen</td><td>404</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td>males</td><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.45 (1.18 to 1.79)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.5.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>407</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.43 (1.17 to 1.76)</td><td>HIGH</td><td/><td/></tr><tr><td>133</td><td>3.6 GMT of HPV 33 (mMU/mL) 3.6.1 Nonavalent vaccine (0 and 6 months) vs (0 and 12 months) 3.6.2 Nonavalent vaccine (0 and 6 months) vs (0 and 12 months)</td><td colspan=\"2\">9-to 14-year-old fe-males 9-to 14-year-old males 1 month after 1 month after last dose last dose</td><td>1 (Iversen 2016) 1 (Iversen 2016)</td><td>405 408</td><td>fects, 95% CI) Ratio of GMTs (IV, random-ef-fects, 95% CI) Ratio of GMTs (IV, random-ef-fects, 95% CI)</td><td>Ratio of GMTs 1.98 (1.63 to 2.40) Ratio of GMTs 2.27 (1.87 to 2.76)</td><td>\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295 HIGH</td><td>Cochrane Database of Systematic Reviews</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF129": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>(Continued)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>3.7 GMT of HPV 45 (mMU/mL)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>3.7.1 Nonavalent vaccine (0 and 6 months) vs (0 and 12 months) 3.7.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old fe-males 9-to 14-year-old males 1 month after 1 month after last dose</td><td>1 (Iversen 2016) 1 (Iversen</td><td>406 409</td><td>Ratio of GMTs (IV, random-ef-fects, 95% CI) Ratio of GMTs</td><td>Ratio of GMTs 1.23 (0.98 to 1.54) Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295 HIGH \u2295\u2295\u2295\u2295</td><td colspan=\"3\">Cochrane Library</td></tr><tr><td/><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.13 (0.90 to 1.41)</td><td>HIGH</td><td/><td/></tr><tr><td/><td>3.8 GMT of HPV 52 (mMU/mL) 3.8.1 Nonavalent vaccine (0 and 6 months) vs (0 and 12 months)</td><td>9-to 14-year-old fe-males</td><td>1 month after last dose</td><td>1 (Iversen 2016)</td><td>403</td><td>fects, 95% CI) Ratio of GMTs (IV, random-ef-</td><td>Ratio of GMTs 1.77 (1.47 to 2.13)</td><td>\u2295\u2295\u2295\u2295 HIGH</td><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.8.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>410</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.91 (1.59 to 2.29)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.9 GMT of HPV 58 (mMU/mL)</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>3.9.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Iversen</td><td>399</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td>males</td><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.79 (1.48 to 2.17)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td/><td>3.9.2 Nonavalent vaccine (0 and 6</td><td colspan=\"2\">9-to 14-year-old males 1 month after</td><td>1 (Iversen</td><td>406</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td><td/><td/></tr><tr><td/><td>months) vs (0 and 12 months)</td><td/><td>last dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>2.00 (1.66 to 2.41)</td><td>HIGH</td><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/><td/><td/></tr><tr><td>134</td><td>3.10 Seroconversion to HPV16 3.10.1 Bivalent vaccine (0 and 6 months) vs (0 and 12 months) 3.11 Seroconversion to HPV 18</td><td>9-to 14-year-old fe-males 9-to 14-year-old fe-males 9-to 14-year-old fe-males</td><td>1 month after last dose 1 month after last dose 1 month after last dose</td><td>1 (Puthanakit 2016) 1 (Puthanakit 2016) 1 (Puthanakit 2016)</td><td>835 835 854</td><td>RR (M-H, ran-dom-effects, 95% CI) RR (M-H, ran-dom-effects, 95% CI) RR (M-H, ran-dom-effects, 95% CI)</td><td>RR 1.00 (1.00 to 1.00) RR 1.00 (1.00 to 1.00) RR 1.00 (1.00 to 1.00)</td><td>\u2295\u2295\u2295\u2295 HIGH</td><td>Cochrane Database of Systematic Reviews</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF130": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>(Continued)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>3.11.1 Bivalent vaccine (0 and 6</td><td>9-to 14-year-old fe-9-to 14-year-old fe-</td><td>1 month after</td><td>1 (Puthanakit</td><td>854 263</td><td>RR (M-H, ran-</td><td>RR 1.00 (1.00 to Mean 673.8 (582.8</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td>males males short interval (0,</td><td>last dose</td><td>2016)</td><td/><td>dom-effects,</td><td>1.00) to 779.1)</td><td>HIGH</td></tr><tr><td/><td>6 months)</td><td/><td/><td/><td>95% CI)</td><td/><td/></tr><tr><td>3.12 GMT of HPV 6 (mMU/mL) \u2020</td><td>9-to 14-year-old males</td><td/><td/><td>248</td><td/><td>Mean 592.6 (514.7</td><td/></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 682.4)</td><td/></tr><tr><td>3.12.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males months)</td><td>36 months af-</td><td>1 (Iversen</td><td>246</td><td>Mean GMT (95%</td><td>Mean 401.2 (354.8</td><td/></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 453.7)</td><td/></tr><tr><td>3.15 GMT of HPV 18 (mMU/mL) \u2020</td><td>val (0, 12 months)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.15.1 Bivalent vaccine (0 and 6</td><td>9-to 14-year-old fe-9-to 14-year-old fe-</td><td>36 months af-</td><td>1 (Puthanakit</td><td>236 794</td><td>Ratio of GMTs</td><td>Mean 209.6 (184.9 Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td>males short interval (0, males</td><td>ter first dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>to 237.6) 1.43 (1.26 to 1.62)</td><td>HIGH</td></tr><tr><td/><td>6 months)</td><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.15.3 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males 9-14 year old males</td><td>36 months af-</td><td>1 (Iversen</td><td>254 255</td><td>Mean GMT (95%</td><td>Mean 160.1 (141.9 Mean 276.4 (245.3</td><td/></tr><tr><td>months) vs (0 and 12 months)</td><td>short interval (0, 6 and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 180.7) to 311.6)</td><td/></tr><tr><td/><td>months) val (0, 12 months)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.13 GMT of HPV 11 (mMU/mL) \u2020</td><td>9-to 14-year-old fe-</td><td/><td/><td>248</td><td/><td>Mean 158.9 (140.8</td><td/></tr><tr><td/><td>males short interval (0,</td><td/><td/><td/><td/><td>to 179.4)</td><td/></tr><tr><td>3.13.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males 6 months)</td><td>36 months af-</td><td>1 (Iversen</td><td>246</td><td>Mean GMT (95%</td><td>Mean 308.2 (271.8</td><td/></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 349.6)</td><td/></tr><tr><td/><td>val (0, 12 months) 9-to 14-year-old males</td><td/><td/><td>262</td><td/><td>Mean 141.7 (125.9</td><td/></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 159.4)</td><td/></tr><tr><td/><td>9-to 14-year-old fe-months)</td><td/><td/><td>236</td><td/><td>Mean 133.7 (117.6</td><td/></tr><tr><td/><td>males short interval (0,</td><td/><td/><td/><td/><td>to 152.1)</td><td/></tr><tr><td>3</td><td>6 months)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old males</td><td/><td/><td>255</td><td/><td>Mean 115.2 (101.8</td><td/></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 130.3)</td><td/></tr><tr><td/><td>months)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.14 GMT of HPV 16 (mMU/mL) \u2020</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>3.14.1 Bivalent vaccine (0 and 6</td><td>9-to 14-year-old fe-</td><td>36 months af-</td><td>1 (Puthanakit</td><td>817</td><td>Ratio of GMTs</td><td>Ratio of GMTs</td><td>\u2295\u2295\u2295\u2295</td></tr><tr><td>months) vs (0 and 12 months)</td><td>males</td><td>ter first dose</td><td>2016)</td><td/><td>(IV, random-ef-</td><td>1.29 (1.15 to 1.44)</td><td>HIGH</td></tr><tr><td/><td/><td/><td/><td/><td>fects, 95% CI)</td><td/><td/></tr><tr><td>3.14.3 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>253</td><td>Mean GMT (95%</td><td>Mean 1534.3</td><td/></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>(1328.8 to 1771.5)</td><td/></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>135</td><td/><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF131": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>(Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Library</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr><tr><td>3.16.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>257</td><td>Mean GMT (95%</td><td>Mean 218.0 (190.6</td></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 249.4)</td></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/></tr><tr><td>3.17 GMT of HPV 33 (mMU/mL) \u2020</td><td>9-to 14-year-old fe-males short interval (0, 6 months) 9-to 14-year-old males short interval (0, 6 months)</td><td/><td/><td>248 261</td><td/><td>Mean 127.8 (111.4 to 146.5) Mean 106.9 (93.5 to 122.1)</td><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF132": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>3.17.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>258</td><td>Mean GMT (95%</td><td>Mean 240.4 (213.8</td></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 270.3)</td></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old fe-</td><td/><td/><td>249</td><td/><td>Mean 106.0 (94.1</td></tr><tr><td/><td>males short interval (0,</td><td/><td/><td/><td/><td>to 119.5)</td></tr><tr><td/><td>6 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old males</td><td/><td/><td>261</td><td/><td>Mean 95.7 (85.1</td></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 107.5)</td></tr><tr><td/><td>months)</td><td/><td/><td/><td/><td/></tr><tr><td>3.18 GMT of HPV 45 (mMU/mL) \u2020</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.18.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>257</td><td>Mean GMT (95%</td><td>Mean 43.6 (38.3</td></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 49.7)</td></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old fe-</td><td/><td/><td>250</td><td/><td>Mean 30.6 (26.9</td></tr><tr><td/><td>males short interval (0,</td><td/><td/><td/><td/><td>to 35.0)</td></tr><tr><td/><td>6 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old males</td><td/><td/><td>263</td><td/><td>Mean 26.8 (23.6</td></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 30.4)</td></tr><tr><td/><td>months)</td><td/><td/><td/><td/><td/></tr><tr><td>3</td><td/><td/><td/><td/><td/><td/></tr><tr><td>137</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF133": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>(Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Library</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>Better health.</td><td>Informed decisions.</td><td>Trusted evidence.</td></tr><tr><td>3.19.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>257</td><td>Mean GMT (95%</td><td>Mean 143.2 (128.3</td></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 159.9)</td></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/></tr><tr><td>3.20 GMT of HPV 58 (mMU/mL) \u2020</td><td>9-to 14-year-old fe-males short interval (0, 6 months) 9-to 14-year-old males short interval (0, 6 months)</td><td/><td/><td>248 263</td><td/><td>Mean 66.2 (59.1 to 74.0) Mean 63.4 (56.8 to 70.7)</td><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF134": {
                "text": "Copyright \u00a9 2019 The Authors.Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>(Continued)</td><td/><td/><td/><td/><td/><td/></tr><tr><td>3.20.1 Nonavalent vaccine (0 and 6</td><td>9-to 14-year-old males</td><td>36 months af-</td><td>1 (Iversen</td><td>255</td><td>Mean GMT (95%</td><td>Mean 265.3 (234.8</td></tr><tr><td>months) vs (0 and 12 months)</td><td>and females long inter-</td><td>ter first dose</td><td>2016)</td><td/><td>CI)</td><td>to 299.8)</td></tr><tr><td/><td>val (0, 12 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old fe-</td><td/><td/><td>246</td><td/><td>Mean 125.8 (111.1</td></tr><tr><td/><td>males short interval (0,</td><td/><td/><td/><td/><td>to 142.5)</td></tr><tr><td/><td>6 months)</td><td/><td/><td/><td/><td/></tr><tr><td/><td>9-to 14-year-old males</td><td/><td/><td>261</td><td/><td>Mean 119.2 (105.6</td></tr><tr><td/><td>short interval (0, 6</td><td/><td/><td/><td/><td>to 134.5)</td></tr><tr><td/><td>months)</td><td/><td/><td/><td/><td/></tr><tr><td>138</td><td/><td/><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF135": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td/><td/><td/><td/><td colspan=\"2\">Cochrane Database of Systematic Reviews</td></tr><tr><td>8.1 GMT of</td><td>1 month after</td><td>1 (Levin</td><td>114 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td>\u2295\u2295\u229d\u229d</td></tr><tr><td>HPV 6</td><td>last dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>123.8 (89.0 to</td><td>LOW 1,2</td></tr><tr><td/><td/><td>quadriva-</td><td/><td/><td>172.1)</td><td/></tr><tr><td/><td/><td>lent</td><td/><td/><td/><td/></tr><tr><td/><td>24 months af-</td><td>1 (Levin</td><td>116 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td/></tr><tr><td/><td>ter first dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>50.44 (34.21 to</td><td/></tr><tr><td/><td/><td/><td/><td/><td>74.38)</td><td/></tr><tr><td>8.2 GMT of</td><td>1 month after</td><td>1 (Levin</td><td>117 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td>\u2295\u2295\u229d\u229d</td></tr><tr><td>HPV 11</td><td>last dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>330.4 (261.6 to</td><td>LOW 1,2</td></tr><tr><td/><td/><td/><td/><td/><td>417.2)</td><td/></tr><tr><td/><td>24 months af-</td><td>1 (Levin</td><td>116 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td/></tr><tr><td/><td>ter first dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>68.75 (49.33 to</td><td/></tr><tr><td/><td/><td/><td/><td/><td>95.81)</td><td/></tr><tr><td>8.3 GMT of</td><td>1 month after</td><td>1 (Levin</td><td>117 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td>\u2295\u2295\u229d\u229d</td></tr><tr><td>HPV 16</td><td>last dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>935.8 (724.5 to</td><td>LOW 1,2</td></tr><tr><td/><td/><td/><td/><td/><td>1208.7)</td><td/></tr><tr><td/><td>24 months af-</td><td>1 (Levin</td><td>116 children with HIV</td><td>Ratio of GMTs (IV, ran-</td><td>Ratio of GMTs</td><td/></tr><tr><td/><td>ter first dose</td><td>2010)</td><td>(7 to 12 years old)</td><td>dom-effects, 95% CI)</td><td>189.44 (129.29 to</td><td/></tr><tr><td/><td/><td/><td/><td/><td>277.59)</td><td/></tr><tr><td/><td>1 month after</td><td>1 (Levin</td><td/><td/><td/><td/></tr><tr><td/><td>last dose</td><td>2010)</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            }
        }
    }
}